,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,421,1,3,,17389805,89594,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
1,426,1,2,,17389805,89594,Inactive,,,,,Cell Viability - Jurkat,Confirmatory,,
2,427,1,1,,17389805,89594,Inactive,,,,,Cell Viability - Hek293,Confirmatory,,
3,433,1,1,,17389805,89594,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
4,434,1,2,,17389805,89594,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
5,435,1,2,,17389805,89594,Inactive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
6,445,3,1,,17389805,89594,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
7,530,1,1,,17389805,89594,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
8,540,1,1,,17389805,89594,Inactive,,,,,Cell Viability - N2a,Confirmatory,,
9,541,1,1,,17389805,89594,Inactive,,,,,Cell Viability - NIH 3T3,Confirmatory,,
10,542,1,1,,17389805,89594,Inactive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
11,543,1,1,,17389805,89594,Inactive,,,,,Cell Viability - H-4-II-E,Confirmatory,,
12,544,2,1,,17389805,89594,Inactive,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
13,545,1,1,,17389805,89594,Inactive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
14,546,1,1,,17389805,89594,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
15,584,1,3,,17389805,89594,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
16,585,1,4,,17389805,89594,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
17,595,1,3,,17389805,89594,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
18,596,1,2,,17389805,89594,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
19,603,1,2,,17389805,89594,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
20,605,1,2,,17389805,89594,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
21,608,1,6,,11537938,89594,Inactive,17149836.0,2280.0,,,NMR Based Screening Assay for FKBP12,Other,,
22,654,1,1,,17389805,89594,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
23,655,1,1,,17389805,89594,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
24,656,1,1,,17389805,89594,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
25,657,1,1,,17389805,89594,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
26,658,1,1,,17389805,89594,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
27,659,1,1,,17389805,89594,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
28,660,1,1,,17389805,89594,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
29,661,1,1,,17389805,89594,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
30,662,1,1,,17389805,89594,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
31,663,1,1,,17389805,89594,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
32,664,1,1,,17389805,89594,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
33,665,1,1,,17389805,89594,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
34,666,1,1,,17389805,89594,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
35,667,1,1,,17389805,89594,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
36,875,1,2,,17389805,89594,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
37,880,2,1,,17389805,89594,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
38,880,2,1,,17389805,89594,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
39,880,2,1,,26752744,89594,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
40,880,2,1,,26752744,89594,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
41,880,2,1,,26752745,89594,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
42,880,2,1,,26752745,89594,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
43,880,2,1,,50105392,89594,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
44,880,2,1,,50105392,89594,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
45,881,2,2,,17389805,89594,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
46,884,1,2,,17389805,89594,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
47,885,1,2,,17389805,89594,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
48,886,1,2,,17389805,89594,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
49,886,1,2,,17389805,89594,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
50,887,1,2,,17389805,89594,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
51,889,1,3,,17389805,89594,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
52,892,1,2,,17389805,89594,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
53,893,1,2,,17389805,89594,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
54,893,1,2,,17389805,89594,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
55,894,2,1,,17389805,89594,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
56,894,2,1,,50105392,89594,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
57,900,1,3,,17389805,89594,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
58,901,1,2,,17389805,89594,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
59,902,1,2,,17389805,89594,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
60,912,1,2,,17389805,89594,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
61,921,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-001,Confirmatory,,
62,923,1,2,,17389805,89594,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
63,924,1,2,,17389805,89594,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
64,925,1,2,,17389805,89594,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
65,926,1,2,,17389805,89594,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
66,938,1,2,,17389805,89594,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
67,946,1,2,,17389805,89594,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
68,947,1,2,,17389805,89594,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
69,948,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
70,955,1,2,,17389805,89594,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
71,960,1,2,,17389805,89594,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
72,961,1,2,,17389805,89594,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
73,962,1,2,,17389805,89594,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
74,963,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
75,964,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
76,965,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-003,Confirmatory,,
77,966,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-004,Confirmatory,,
78,967,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-005,Confirmatory,,
79,968,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-009,Confirmatory,,
80,969,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-011,Confirmatory,,
81,970,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-013,Confirmatory,,
82,971,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-015,Confirmatory,,
83,972,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-017,Confirmatory,,
84,973,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-019,Confirmatory,,
85,974,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-021,Confirmatory,,
86,975,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-023,Confirmatory,,
87,976,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-025,Confirmatory,,
88,977,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-002,Confirmatory,,
89,978,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-006,Confirmatory,,
90,979,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-007,Confirmatory,,
91,980,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-008,Confirmatory,,
92,981,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-010,Confirmatory,,
93,982,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-012,Confirmatory,,
94,983,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-014,Confirmatory,,
95,984,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-016,Confirmatory,,
96,985,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-018,Confirmatory,,
97,986,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-020,Confirmatory,,
98,987,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-022,Confirmatory,,
99,988,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-024,Confirmatory,,
100,989,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP2-026,Confirmatory,,
101,993,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
102,994,1,2,,17389805,89594,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
103,995,1,2,,17389805,89594,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
104,1030,2,1,,17389805,89594,Inconclusive,30582681.0,216.0,39.8107,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
105,1030,2,1,,26752744,89594,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
106,1030,2,1,,26752745,89594,Inconclusive,30582681.0,216.0,28.1838,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
107,1030,2,1,,50105392,89594,Inactive,30582681.0,216.0,15.8489,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
108,1033,2,2,,11537938,89594,Inactive,216546.0,,,,NMR Based Screening Assay for the substrate binding domain of the chaperone DnaK,Screening,,
109,1189,1,5,,48414101,89594,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
110,1194,1,3,,48414101,89594,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
111,1205,1,4,,48414101,89594,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,Other,,
112,1208,1,3,,48414101,89594,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
113,1379,1,2,,50105392,89594,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
114,1452,1,1,,17389805,89594,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
115,1454,1,1,,50105392,89594,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
116,1457,1,1,,17389805,89594,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
117,1457,1,1,,26752744,89594,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
118,1457,1,1,,26752745,89594,Inconclusive,44888968.0,83523.0,28.1838,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
119,1457,1,1,,50105392,89594,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
120,1458,1,1,,17389805,89594,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
121,1458,1,1,,26752744,89594,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
122,1458,1,1,,26752745,89594,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
123,1460,1,3,,26752744,89594,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
124,1460,1,3,,26752745,89594,Inconclusive,92096784.0,4137.0,22.3872,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
125,1460,1,3,,50105392,89594,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
126,1463,1,1,,26752744,89594,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
127,1463,1,1,,26752745,89594,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
128,1463,1,1,,50105392,89594,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
129,1467,1,3,,50105392,89594,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
130,1468,1,1,,26752744,89594,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
131,1468,1,1,,26752745,89594,Inconclusive,92096784.0,4137.0,22.3872,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
132,1468,1,1,,50105392,89594,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
133,1469,1,1,,17389805,89594,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
134,1469,1,1,,26752744,89594,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
135,1469,1,1,,26752745,89594,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
136,1469,1,1,,26752746,89594,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
137,1469,1,1,,50105392,89594,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
138,1471,2,1,,17389805,89594,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
139,1471,2,1,,26752744,89594,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
140,1471,2,1,,26752745,89594,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
141,1471,2,1,,50105392,89594,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
142,1476,2,1,,17389805,89594,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
143,1476,2,1,,50105392,89594,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
144,1477,1,1,,17389805,89594,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
145,1477,1,1,,26752744,89594,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
146,1477,1,1,,26752745,89594,Inconclusive,,,10.0,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
147,1477,1,1,,50105392,89594,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
148,1478,2,1,,17389805,89594,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
149,1478,2,1,,50105392,89594,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
150,1479,1,2,,17389805,89594,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
151,1479,1,2,,26752744,89594,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
152,1479,1,2,,26752745,89594,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
153,1479,1,2,,26752746,89594,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
154,1479,1,2,,50105392,89594,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
155,1490,2,1,,26752744,89594,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
156,1490,2,1,,26752745,89594,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
157,1490,2,1,,50105392,89594,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
158,1511,1,3,,56314824,89594,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
159,1519,1,3,,50105392,89594,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
160,1549,1,2,,11537938,89594,Inactive,89033149.0,,,,NMR Based Screening Assay for Novel Chemotypes against influenza A virus,Other,,
161,1552,1,3,,11537938,89594,Inactive,4507793.0,7334.0,,,NMR assay targeting the ubiquitin-proteasome system to modulate protein folding and degradation,Other,,
162,1554,1,1,,56314824,89594,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
163,1637,1,2,,11537938,89594,Inactive,,,,,NMR Based Screening Assay for Influenza A RNA Promoter,Other,,
164,1648,1,2,,11537938,89594,Inactive,159164579.0,,,,NMR Based Screening Assay For Novel Chemical Probes Targeting The FRB Domain of mTOR,Other,,
165,1662,1,2,,56314824,89594,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
166,1663,1,2,,56314824,89594,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
167,1672,1,3,,56314824,89594,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
168,1766,1,1,,50105392,89594,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
169,1766,1,1,,50105392,89594,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
170,1768,1,1,,50105392,89594,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
171,1768,1,1,,50105392,89594,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
172,1811,3,2,,46393352,89594,Active,47169320.0,,,,Experimentally measured binding affinity data derived from PDB,Other,,
173,1813,1,2,,56314824,89594,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
174,1814,1,2,,56314824,89594,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
175,1832,2,1,,56314824,89594,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
176,1850,2,1,,56314824,89594,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
177,1863,2,1,,56314824,89594,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
178,1865,1,1,,26752744,89594,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
179,1865,1,1,,26752745,89594,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
180,1865,1,1,,50105392,89594,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
181,1875,2,1,,56314824,89594,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
182,1885,2,1,,56314824,89594,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
183,1899,1,3,,56314824,89594,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
184,1903,2,3,,56314824,89594,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
185,1906,1,3,,56314824,89594,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
186,1910,1,2,,56314824,89594,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
187,1947,1,2,,56314824,89594,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
188,1948,1,1,,17389805,89594,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
189,1948,1,1,,50105392,89594,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
190,1950,1,3,,56314824,89594,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
191,1962,1,2,,56314824,89594,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
192,1974,1,2,,56314824,89594,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
193,1979,1,1,,56314824,89594,Inactive,994798.0,,,,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,Screening,,
194,1987,1,2,,56314824,89594,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
195,2016,1,3,,56314824,89594,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
196,2023,1,3,,56314824,89594,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
197,2025,1,3,,56314824,89594,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
198,2029,1,3,,56314824,89594,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
199,2052,2,1,,56314824,89594,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
200,2057,1,2,,56314824,89594,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
201,2066,1,4,,56314824,89594,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
202,2094,1,2,,56314824,89594,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
203,2094,1,2,,56314824,89594,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
204,2094,1,2,,56314824,89594,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
205,2097,1,2,,56314824,89594,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
206,2098,1,1,,56314824,89594,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
207,2099,1,1,,56314824,89594,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
208,2101,1,1,,17389805,89594,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
209,2101,1,1,,26752744,89594,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
210,2101,1,1,,26752745,89594,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
211,2101,1,1,,50105392,89594,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
212,2101,1,1,,56314824,89594,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
213,2107,1,1,,17389805,89594,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
214,2107,1,1,,26752744,89594,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
215,2107,1,1,,26752745,89594,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
216,2107,1,1,,50105392,89594,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
217,2112,1,1,,17389805,89594,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
218,2112,1,1,,26752744,89594,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
219,2112,1,1,,26752745,89594,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
220,2112,1,1,,50105392,89594,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
221,2120,1,1,,17389805,89594,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
222,2129,1,2,,56314824,89594,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
223,2130,1,3,,56314824,89594,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
224,2147,1,1,,50105392,89594,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
225,2156,2,2,,56314824,89594,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
226,2174,1,3,,56314824,89594,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
227,2177,1,3,,56314824,89594,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
228,2216,1,3,,56314824,89594,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
229,2221,1,2,,56314824,89594,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
230,2227,1,2,,56314824,89594,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
231,2234,1,2,,56314824,89594,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
232,2235,1,2,,56314824,89594,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
233,2237,1,2,,56314824,89594,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
234,2239,1,2,,56314824,89594,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
235,2240,1,1,,85788514,89594,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
236,2241,1,1,,85788514,89594,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
237,2247,1,2,,56314824,89594,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
238,2275,1,1,,85788514,89594,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
239,2280,2,3,,56314824,89594,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
240,2300,1,3,,56314824,89594,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
241,2313,1,1,,85788514,89594,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
242,2322,1,1,,85788514,89594,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
243,2330,1,1,,85788514,89594,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
244,2380,1,2,,56314824,89594,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
245,2391,1,1,,56314824,89594,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
246,2435,1,2,,56314824,89594,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
247,2445,1,2,,56314824,89594,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
248,2451,1,2,,50105392,89594,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
249,2462,1,1,,56314824,89594,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
250,2462,1,1,,56314824,89594,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
251,2472,1,2,,50105392,89594,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
252,2517,2,1,,17389805,89594,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
253,2517,2,1,,26752744,89594,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
254,2517,2,1,,26752745,89594,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
255,2517,2,1,,50105392,89594,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
256,2517,2,1,,56314824,89594,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
257,2520,1,4,,56314824,89594,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
258,2521,1,3,,56314824,89594,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
259,2524,1,2,,56314824,89594,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
260,2528,1,2,,50105392,89594,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
261,2540,1,2,,56314824,89594,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
262,2544,1,2,,56314824,89594,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
263,2546,1,1,,17389805,89594,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
264,2546,1,1,,50105392,89594,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
265,2549,1,1,,17389805,89594,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
266,2549,1,1,,26752744,89594,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
267,2549,1,1,,26752745,89594,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
268,2549,1,1,,50105392,89594,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
269,2550,1,3,,56314824,89594,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
270,2551,1,1,,17389805,89594,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
271,2551,1,1,,50105392,89594,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
272,2553,1,2,,56314824,89594,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
273,2557,1,3,,56314824,89594,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
274,2563,1,1,,56314824,89594,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
275,2599,1,2,,56314824,89594,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
276,2606,1,2,,56314824,89594,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
277,2629,1,1,,56314824,89594,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
278,2642,1,2,,56314824,89594,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
279,2648,1,2,,56314824,89594,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
280,2650,2,1,,56314824,89594,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
281,2660,1,1,,90341453,89594,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
282,2661,1,1,,56314824,89594,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
283,2666,1,1,,90341453,89594,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
284,2667,1,1,,90341453,89594,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
285,2668,1,1,,90341453,89594,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
286,2676,1,2,,56314824,89594,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
287,2685,1,1,,56314824,89594,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
288,2690,1,2,,56314824,89594,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
289,2716,1,1,,56314824,89594,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
290,2717,1,2,,56314824,89594,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
291,2718,1,1,,56314824,89594,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
292,2751,2,2,,56314824,89594,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
293,2796,1,4,,56314824,89594,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
294,2797,1,2,,56314824,89594,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
295,2805,2,2,,56314824,89594,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
296,2806,2,2,,56314824,89594,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
297,2825,1,2,,56314824,89594,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
298,6344,7,4,,103163782,89594,Unspecified,,,71.0,Ki,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,Confirmatory,11212100.0,
299,7783,3,4,,103163782,89594,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
300,8002,5,2,,103163782,89594,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
301,19424,3,4,,103163782,89594,Unspecified,,,,,Partition coefficient (logD7.4),Other,11448232.0,
302,19737,6,1,,103163782,89594,Unspecified,,,,,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",Other,10377231.0,
303,19738,6,1,,103163782,89594,Unspecified,,,,,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",Other,10377231.0,
304,19739,6,1,,103163782,89594,Unspecified,,,,,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",Other,10377231.0,
305,26362,4,3,,103163782,89594,Unspecified,,,,,Ionization constant (pKa),Other,14971904.0,
306,27167,3,4,,103163782,89594,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
307,28233,3,3,,103163782,89594,Unspecified,,,,,Fraction ionized (pH 7.4),Other,12061889.0,
308,28235,3,3,,103163782,89594,Unspecified,,,,,Unbound fraction (plasma),Other,12061889.0,
309,28236,3,3,,103163782,89594,Unspecified,,,,,Unbound fraction (tissues),Other,12061889.0,
310,28681,3,4,,103163782,89594,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
311,29337,3,3,,103163782,89594,Unspecified,,,,,Ionisation constant (pKa),Other,12061889.0,
312,29359,3,3,,103163782,89594,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
313,29423,3,4,,103163782,89594,Unspecified,,,,,HPLC capacity factor (k'),Other,12061889.0,
314,29812,3,3,,103163782,89594,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
315,29925,5,2,,103163782,89594,Unspecified,,,,,Volume of distribution in man (IV dose),Other,12061889.0,
316,30377,4,10,,103163782,89594,Unspecified,,,,,Maximum percent of enhancement of binding.,Other,4032427.0,
317,30378,5,7,,103163782,89594,Unspecified,,,,,Maximum percent of inhibition of binding was determined,Other,4032427.0,
318,30379,9,3,,103163782,89594,Active,,,4.9e-09,Kd,Compound was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1,Confirmatory,4032427.0,
319,30389,9,3,,103163782,89594,Active,,,1e-05,Kd,Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 2,Confirmatory,4032427.0,
320,30391,9,3,,103163782,89594,Active,,,0.43,Kd,Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 3.,Confirmatory,4032427.0,
321,30392,11,2,,103163782,89594,Active,,,11.0,Kd,Compounds was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 4,Confirmatory,4032427.0,
322,30394,11,2,,103163782,89594,Active,,,45.0,Kd,Compounds was evaluated in vitro for ability to enhance and inhibit the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 4,Confirmatory,4032427.0,
323,30514,6,5,,103163782,89594,Unspecified,,,43000.0,Kd,Compounds was evaluated in vitro for ability to enhance and inhibit the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 5,Confirmatory,4032427.0,
324,30515,3,10,,103163782,89594,Unspecified,,,,,Compound was evaluate for its ability to enhance (+/-)-[3H]nicotine binding at a dose range 10e-11 M to 10E-8 M was reported,Other,4032427.0,
325,35535,4,4,,103163782,89594,Active,,,0.0015,Ki,Inhibition of [3H]epibatidine binding at the alpha beta nicotinic AChR in male rat cerebral cortex,Confirmatory,11708907.0,
326,52134,4,3,,103163782,89594,Unspecified,,,20.0,Ki,Binding affinity at CCR was determined by displacement of [125I]- alpha-BgT from Torpedo californica electroplax,Confirmatory,7909335.0,
327,52135,4,3,,103163782,89594,Active,,,4.0,Ki,Binding affinity at CCR was determined by displacement of [125I]- alpha-BgT from rat brain,Confirmatory,7909335.0,
328,52136,4,4,,103163782,89594,Unspecified,,,20.0,Ki,Binding affinity at CCR was determined by displacement of [3H]OXO-M from rat brain,Confirmatory,7909335.0,
329,52137,4,4,,103163782,89594,Active,,,0.0011,Ki,Binding affinity at CCR was determined by displacement of [3H]cytisine from rat brain,Confirmatory,7909335.0,
330,52138,4,4,,103163782,89594,Active,,,0.0014,Ki,Binding affinity at CCR was determined by displacement of [3H]nicotine from rat brain,Confirmatory,7909335.0,
331,71786,7,1,,103163782,89594,Active,,,,,Agonist efficacy was evaluated as concentration that produces 10-m V depolarization in frog sartorius muscle.,Other,4032432.0,
332,91525,6,2,,103163782,89594,Active,,,21.0,EC50,Ability to stimulate Rb+ efflux from human IMR-32 cell preparations containing human alpha3-betaX receptors,Confirmatory,8632405.0,
333,91527,6,2,,103163782,89594,Active,,,21.0,EC50,Concentration required to elicit ganglionic receptors measured using [86Rb+] flux functional assay in a human neuroblastoma-derived IMR-32 cell line,Confirmatory,9022806.0,
334,91534,4,4,,103163782,89594,Unspecified,,,,,Maximum efficacy relative to 100(uM) (S)-nicotine for cell preparations containing alpha3-betaX IMR32 cells,Other,8632405.0,
335,91535,3,4,,103163782,89594,Unspecified,,,,,The maximal efficacy relative to 100 uM nicotine,Other,9022806.0,
336,94460,6,2,,103163782,89594,Active,,,5.0,EC50,Ability to stimulate Rb+ efflux from human K177 cell preparations containing human alpha4-beta2 receptors,Confirmatory,8632405.0,
337,94462,3,4,,103163782,89594,Unspecified,,,,,Ability to stimulate Rb+ efflux from human IMR-32 cell preparations containing human alpha3-betaX receptors,Other,8632405.0,
338,111824,3,3,,103163782,89594,Unspecified,,,,,"Ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 0.31 mg/kg",Other,6716406.0,
339,111825,3,3,,103163782,89594,Unspecified,,,,,"Ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 0.63 mg/kg",Other,6716406.0,
340,111826,3,3,,103163782,89594,Unspecified,,,,,"Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 1.25 mg/kg",Other,6716406.0,
341,111830,3,3,,103163782,89594,Unspecified,,,,,"Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 2.5 mg/kg",Other,6716406.0,
342,111841,3,3,,103163782,89594,Unspecified,,,,,"Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 5 mg/kg",Other,6716406.0,
343,113134,5,3,,103163782,89594,Unspecified,,,,,Compound was tested in vivo for exploratory locomotor activity in mice after peroral administration,Other,,
344,113137,5,3,,103163782,89594,Unspecified,,,,,Compound was tested in vivo for exploratory locomotor activity in mice after subcutaneous administration,Other,,
345,114185,6,2,,103163782,89594,Unspecified,,,,,Effective dose for antinociception in mice was determined by hotplate assay,Other,11708907.0,
346,114186,6,2,,103163782,89594,Unspecified,,,,,Effective dose for antinociception in mice was determined by tail-flick assay,Other,11708907.0,
347,114187,6,2,,103163782,89594,Unspecified,,,,,Effective dose for hypomotility in mice was determined,Other,11708907.0,
348,114188,6,2,,103163782,89594,Unspecified,,,,,Effective dose for hypothermia in mice was determined,Other,11708907.0,
349,114298,6,2,,103163782,89594,Unspecified,,,,,Antinociceptive action was determined by hotplate assay in mouse administered subcutaneously,Other,15203136.0,
350,114300,6,2,,103163782,89594,Unspecified,,,,,Antinociceptive action was determined by tail-flick assay in mouse administered intrathecally,Other,15203136.0,
351,114302,6,2,,103163782,89594,Unspecified,,,,,Antinociceptive action was determined by tail-flick assay in mouse administered subcutaneously,Other,15203136.0,
352,114320,6,2,,103163782,89594,Unspecified,,,,,Antinociceptive effect upon subcutaneous administration in mice using tail-flick assay; 0.9-1.7,Other,14611857.0,
353,118784,3,3,,103163782,89594,Unspecified,,,,,Compound was tested for cognitive activity by measuring retention for passive avoidance learning in mice at dose 0.32 mg/kg,Other,7265121.0,
354,118785,3,3,,103163782,89594,Unspecified,,,,,Compound was tested for cognitive activity by measuring retention for passive avoidance learning in mice at dose 0.63 mg/kg,Other,7265121.0,
355,118789,3,3,,103163782,89594,Unspecified,,,,,Retention for passive avoidance learning in mice at dose 2.5 mg/kg,Other,7265121.0,
356,118796,3,3,,103163782,89594,Unspecified,,,,,Compound was tested for cognitive activity by measuring retention for passive avoidance learning in mice at dose 1.25 mg/kg,Other,7265121.0,
357,118802,5,2,,103163782,89594,Unspecified,,,,,Compound was tested for lethality in mice at a dose 5.0 mg/kg intraperitoneally; L denotes lethal at this dose,Other,7265121.0,
358,129065,5,4,,103163782,89594,Unspecified,,,,,Maximal number of operative binding sites(Bmax) per mg protein was evaluated,Other,8230128.0,
359,129297,5,2,,103163782,89594,Unspecified,,,,,Antinociception by tail-flick test in male ICR mice after intrathecal (i.t.) injection,Other,11405659.0,
360,129326,4,2,,103163782,89594,Unspecified,,,,,Antinociceptive effect upon intrathecal administration in mouse using tail-flick assay; 10-18,Other,14611857.0,
361,130403,3,3,,103163782,89594,Unspecified,,,,,Minimum dose of the drug (intraperitoneal) required elicited a statistically significant response in locomotor activity assay,Other,9022806.0,
362,130405,3,3,,103163782,89594,Unspecified,,,,,Minimum dose of the drug (intraperitoneal) required for elicited a statistically significant response in hypothermia assay,Other,9022806.0,
363,130406,3,3,,103163782,89594,Unspecified,,,,,Minimum dose of the drug (intraperitoneal) required for elicited a statistically significant response in seizure assay,Other,9022806.0,
364,130407,3,3,,103163782,89594,Unspecified,,,,,Minimum dose of the drug (intraperitoneal) required that elicited a statistically significant response in mouse inhibitory avoidance assay,Other,9022806.0,
365,130905,7,2,,103163782,89594,Unspecified,,,,,Inhibition of spontaneous activity in mice,Other,8230128.0,
366,131047,7,2,,103163782,89594,Unspecified,,,,,Inhibition of tail-flick response (antinociception) in mice,Other,8230128.0,
367,131534,7,2,,103163782,89594,Unspecified,,,,,Effective dose for Antinociceptive activity expressed as Spontaneous activity was determined in mice antagonized by 1 mg/Kg of Mecamylamine.,Other,12270194.0,
368,131720,7,2,,103163782,89594,Unspecified,,,,,Effective dose for Antinociceptive activity was determined in mice using Tail -Flick Assay,Other,12270194.0,
369,132272,4,2,,103163782,89594,Unspecified,,,,,The compound was evaluated for its antinociceptive potency (indicate 95% confidence limit) after intrathecal route in mouse,Other,11128647.0,
370,134061,4,4,,103163782,89594,Active,,,0.00141,Kd,Equilibrium dissociation constant (Kd) was determined,Confirmatory,8230128.0,
371,140967,7,2,,103163782,89594,Active,,,28.0,IC50,Inhibitory concentration required for in vitro binding affinity to cholinergic central muscarinic receptor on rat brain cortex by using [3H]OXO-M,Confirmatory,,
372,140972,7,2,,103163782,89594,Unspecified,,,5.0,Ki,Binding affinity for muscarinic receptor site in rat hippocampus was determined using competitive radioligand binding assays employing [3H]OXO-M,Confirmatory,,
373,141666,7,1,,103163782,89594,Active,,,32.0,IC50,In vitro displacement of [3H]oxotremorine-M from muscarinic acetylcholine receptor in rat brain cortex,Confirmatory,10585207.0,
374,141677,8,1,,103163782,89594,Unspecified,,,360.0,IC50,Muscarinic acetylcholine receptor binding (rat cortical membranes) was determined by displacement of [3H]quinuclidinyl benzylate [3H]QNB),Confirmatory,8765504.0,
375,145345,6,2,,103163782,89594,Active,,,2.0,Ki,Potency to displace [3H]IMI binding to Nicotinic acetylcholine receptor from Drosophila head membranes,Confirmatory,12061885.0,
376,145356,10,1,,103163782,89594,Active,2506129.0,1143.0,21.0,EC50,Compound was evaluated for functional potencies and efficacies at human Nicotinic acetylcholine receptor subtype IMR-32 (ganglionic),Confirmatory,9435889.0,
377,145356,10,1,,103163782,89594,Active,254763435.0,1136.0,21.0,EC50,Compound was evaluated for functional potencies and efficacies at human Nicotinic acetylcholine receptor subtype IMR-32 (ganglionic),Confirmatory,9435889.0,
378,145357,9,3,,103163782,89594,Unspecified,,,160.0,EC50,Compound was evaluated for functional potencies and efficacies at human Nicotinic acetylcholine receptor subtype TE671 (muscle),Confirmatory,9435889.0,
379,145361,6,6,,103163782,89594,Unspecified,113071.0,1134.0,65.0,EC50,The compound was tested on recombinant human alpha-1-beta-1-gamma-delta cell lines of human embryonic kidney for nicotinic acetylcholine receptor agonist functional potency,Confirmatory,8765504.0,
380,145361,6,6,,103163782,89594,Unspecified,543759.0,1144.0,65.0,EC50,The compound was tested on recombinant human alpha-1-beta-1-gamma-delta cell lines of human embryonic kidney for nicotinic acetylcholine receptor agonist functional potency,Confirmatory,8765504.0,
381,145361,6,6,,103163782,89594,Unspecified,1168301.0,1145.0,65.0,EC50,The compound was tested on recombinant human alpha-1-beta-1-gamma-delta cell lines of human embryonic kidney for nicotinic acetylcholine receptor agonist functional potency,Confirmatory,8765504.0,
382,145361,6,6,,103163782,89594,Unspecified,21903373.0,1140.0,65.0,EC50,The compound was tested on recombinant human alpha-1-beta-1-gamma-delta cell lines of human embryonic kidney for nicotinic acetylcholine receptor agonist functional potency,Confirmatory,8765504.0,
383,145361,6,6,,103163782,89594,Unspecified,126302510.0,1146.0,65.0,EC50,The compound was tested on recombinant human alpha-1-beta-1-gamma-delta cell lines of human embryonic kidney for nicotinic acetylcholine receptor agonist functional potency,Confirmatory,8765504.0,
384,145496,7,1,,103163782,89594,Active,113071.0,1134.0,10.0,EC50,The compound was tested on recombinant human alpha2-beta4 cell lines of Human embryonic kidney for nicotinic acetylcholine receptor agonist functional potency,Confirmatory,8765504.0,
385,145496,7,1,,103163782,89594,Active,2506129.0,1143.0,10.0,EC50,The compound was tested on recombinant human alpha2-beta4 cell lines of Human embryonic kidney for nicotinic acetylcholine receptor agonist functional potency,Confirmatory,8765504.0,
386,145498,7,1,,103163782,89594,Unspecified,2506129.0,1143.0,51.0,EC50,The compound was tested on recombinant human alpha3-beta4 cell lines of Human embryonic kidney for nicotinic acetylcholine receptor agonist functional potency,Confirmatory,8765504.0,
387,145498,7,1,,103163782,89594,Unspecified,254763435.0,1136.0,51.0,EC50,The compound was tested on recombinant human alpha3-beta4 cell lines of Human embryonic kidney for nicotinic acetylcholine receptor agonist functional potency,Confirmatory,8765504.0,
388,145499,7,1,,103163782,89594,Active,113105.0,1141.0,2.1,EC50,The compound was tested on recombinant human alpha4-beta2 cell lines of Human embryonic kidney for nicotinic acetylcholine receptor agonist functional potency,Confirmatory,8765504.0,
389,145499,7,1,,103163782,89594,Active,1351848.0,1137.0,2.1,EC50,The compound was tested on recombinant human alpha4-beta2 cell lines of Human embryonic kidney for nicotinic acetylcholine receptor agonist functional potency,Confirmatory,8765504.0,
390,145502,7,1,,103163782,89594,Active,1351848.0,1137.0,7.1,EC50,The compound was tested on recombinant human alpha4-beta4 cell lines of Human embryonic kidney for nicotinic acetylcholine receptor agonist functional potency,Confirmatory,8765504.0,
391,145502,7,1,,103163782,89594,Active,2506129.0,1143.0,7.1,EC50,The compound was tested on recombinant human alpha4-beta4 cell lines of Human embryonic kidney for nicotinic acetylcholine receptor agonist functional potency,Confirmatory,8765504.0,
392,145522,7,2,,103163782,89594,Active,,,0.0024,IC50,Binding affinity towards Nicotinic acetylcholine receptor by the displacement of [3H]-nicotine from rat cortical membranes,Confirmatory,10346920.0,
393,145656,6,1,,103163782,89594,Active,,,0.005,Kd,The compound was tested for the inhibition of binding of [3H]epibatidine to central nicotinic acetylcholine receptor (nAChR) in rat brain.,Confirmatory,9784094.0,
394,145657,9,5,,103163782,89594,Active,113061.0,25101.0,20.0,EC50,Compound was evaluated for functional potencies and efficacies at rat Nicotinic acetylcholine receptor subtype PC12 (ganglionic),Confirmatory,9435889.0,
395,145657,9,5,,103163782,89594,Active,113066.0,25102.0,20.0,EC50,Compound was evaluated for functional potencies and efficacies at rat Nicotinic acetylcholine receptor subtype PC12 (ganglionic),Confirmatory,9435889.0,
396,145657,9,5,,103163782,89594,Active,113108.0,171131.0,20.0,EC50,Compound was evaluated for functional potencies and efficacies at rat Nicotinic acetylcholine receptor subtype PC12 (ganglionic),Confirmatory,9435889.0,
397,145657,9,5,,103163782,89594,Active,113111.0,25103.0,20.0,EC50,Compound was evaluated for functional potencies and efficacies at rat Nicotinic acetylcholine receptor subtype PC12 (ganglionic),Confirmatory,9435889.0,
398,145657,9,5,,103163782,89594,Active,1168297.0,81721.0,20.0,EC50,Compound was evaluated for functional potencies and efficacies at rat Nicotinic acetylcholine receptor subtype PC12 (ganglionic),Confirmatory,9435889.0,
399,145657,9,5,,103163782,89594,Active,2851491.0,170945.0,20.0,EC50,Compound was evaluated for functional potencies and efficacies at rat Nicotinic acetylcholine receptor subtype PC12 (ganglionic),Confirmatory,9435889.0,
400,145657,9,5,,103163782,89594,Active,6226548.0,54239.0,20.0,EC50,Compound was evaluated for functional potencies and efficacies at rat Nicotinic acetylcholine receptor subtype PC12 (ganglionic),Confirmatory,9435889.0,
401,145657,9,5,,103163782,89594,Active,8469182.0,25590.0,20.0,EC50,Compound was evaluated for functional potencies and efficacies at rat Nicotinic acetylcholine receptor subtype PC12 (ganglionic),Confirmatory,9435889.0,
402,145657,9,5,,103163782,89594,Active,68051992.0,64574.0,20.0,EC50,Compound was evaluated for functional potencies and efficacies at rat Nicotinic acetylcholine receptor subtype PC12 (ganglionic),Confirmatory,9435889.0,
403,145657,9,5,,103163782,89594,Active,68067466.0,65024.0,20.0,EC50,Compound was evaluated for functional potencies and efficacies at rat Nicotinic acetylcholine receptor subtype PC12 (ganglionic),Confirmatory,9435889.0,
404,145657,9,5,,103163782,89594,Active,146345356.0,25302.0,20.0,EC50,Compound was evaluated for functional potencies and efficacies at rat Nicotinic acetylcholine receptor subtype PC12 (ganglionic),Confirmatory,9435889.0,
405,145661,7,5,,103163782,89594,Active,,,0.004,IC50,Binding affinity at NAChRs was determined by measuring the displacement of ([3H]Nic) from a preparation of rat cortical membranes.,Confirmatory,8765504.0,
406,145668,7,2,,103163782,89594,Active,,,0.0066,IC50,In vitro displacement of [3H]methylcarbamylcholine from nicotinic acetylcholine receptor in rat brain cortex,Confirmatory,10585207.0,
407,145669,9,5,,103163782,89594,Active,113061.0,25101.0,0.006999999999999999,IC50,Inhibition of (-)-[3H]nicotine binding to rat brain membranes,Confirmatory,3346870.0,
408,145669,9,5,,103163782,89594,Active,113066.0,25102.0,0.006999999999999999,IC50,Inhibition of (-)-[3H]nicotine binding to rat brain membranes,Confirmatory,3346870.0,
409,145669,9,5,,103163782,89594,Active,113108.0,171131.0,0.006999999999999999,IC50,Inhibition of (-)-[3H]nicotine binding to rat brain membranes,Confirmatory,3346870.0,
410,145669,9,5,,103163782,89594,Active,113111.0,25103.0,0.006999999999999999,IC50,Inhibition of (-)-[3H]nicotine binding to rat brain membranes,Confirmatory,3346870.0,
411,145669,9,5,,103163782,89594,Active,1168297.0,81721.0,0.006999999999999999,IC50,Inhibition of (-)-[3H]nicotine binding to rat brain membranes,Confirmatory,3346870.0,
412,145669,9,5,,103163782,89594,Active,2851491.0,170945.0,0.006999999999999999,IC50,Inhibition of (-)-[3H]nicotine binding to rat brain membranes,Confirmatory,3346870.0,
413,145669,9,5,,103163782,89594,Active,6226548.0,54239.0,0.006999999999999999,IC50,Inhibition of (-)-[3H]nicotine binding to rat brain membranes,Confirmatory,3346870.0,
414,145669,9,5,,103163782,89594,Active,8469182.0,25590.0,0.006999999999999999,IC50,Inhibition of (-)-[3H]nicotine binding to rat brain membranes,Confirmatory,3346870.0,
415,145669,9,5,,103163782,89594,Active,68051992.0,64574.0,0.006999999999999999,IC50,Inhibition of (-)-[3H]nicotine binding to rat brain membranes,Confirmatory,3346870.0,
416,145669,9,5,,103163782,89594,Active,68067466.0,65024.0,0.006999999999999999,IC50,Inhibition of (-)-[3H]nicotine binding to rat brain membranes,Confirmatory,3346870.0,
417,145669,9,5,,103163782,89594,Active,146345356.0,25302.0,0.006999999999999999,IC50,Inhibition of (-)-[3H]nicotine binding to rat brain membranes,Confirmatory,3346870.0,
418,145670,9,5,,103163782,89594,Active,113061.0,25101.0,0.003,IC50,Inhibition of [3H]MCC binding to rat brain membranes,Confirmatory,3346870.0,
419,145670,9,5,,103163782,89594,Active,113066.0,25102.0,0.003,IC50,Inhibition of [3H]MCC binding to rat brain membranes,Confirmatory,3346870.0,
420,145670,9,5,,103163782,89594,Active,113108.0,171131.0,0.003,IC50,Inhibition of [3H]MCC binding to rat brain membranes,Confirmatory,3346870.0,
421,145670,9,5,,103163782,89594,Active,113111.0,25103.0,0.003,IC50,Inhibition of [3H]MCC binding to rat brain membranes,Confirmatory,3346870.0,
422,145670,9,5,,103163782,89594,Active,1168297.0,81721.0,0.003,IC50,Inhibition of [3H]MCC binding to rat brain membranes,Confirmatory,3346870.0,
423,145670,9,5,,103163782,89594,Active,2851491.0,170945.0,0.003,IC50,Inhibition of [3H]MCC binding to rat brain membranes,Confirmatory,3346870.0,
424,145670,9,5,,103163782,89594,Active,6226548.0,54239.0,0.003,IC50,Inhibition of [3H]MCC binding to rat brain membranes,Confirmatory,3346870.0,
425,145670,9,5,,103163782,89594,Active,8469182.0,25590.0,0.003,IC50,Inhibition of [3H]MCC binding to rat brain membranes,Confirmatory,3346870.0,
426,145670,9,5,,103163782,89594,Active,68051992.0,64574.0,0.003,IC50,Inhibition of [3H]MCC binding to rat brain membranes,Confirmatory,3346870.0,
427,145670,9,5,,103163782,89594,Active,68067466.0,65024.0,0.003,IC50,Inhibition of [3H]MCC binding to rat brain membranes,Confirmatory,3346870.0,
428,145670,9,5,,103163782,89594,Active,146345356.0,25302.0,0.003,IC50,Inhibition of [3H]MCC binding to rat brain membranes,Confirmatory,3346870.0,
429,145672,7,4,,103163782,89594,Active,113061.0,25101.0,0.004,IC50,Inhibitory concentration required for in vitro binding affinity to cholinergic central Nicotinic acetylcholine receptor on rat brain cortex by using [3H]MCC,Confirmatory,,
430,145672,7,4,,103163782,89594,Active,113066.0,25102.0,0.004,IC50,Inhibitory concentration required for in vitro binding affinity to cholinergic central Nicotinic acetylcholine receptor on rat brain cortex by using [3H]MCC,Confirmatory,,
431,145672,7,4,,103163782,89594,Active,113108.0,171131.0,0.004,IC50,Inhibitory concentration required for in vitro binding affinity to cholinergic central Nicotinic acetylcholine receptor on rat brain cortex by using [3H]MCC,Confirmatory,,
432,145672,7,4,,103163782,89594,Active,113111.0,25103.0,0.004,IC50,Inhibitory concentration required for in vitro binding affinity to cholinergic central Nicotinic acetylcholine receptor on rat brain cortex by using [3H]MCC,Confirmatory,,
433,145672,7,4,,103163782,89594,Active,1168297.0,81721.0,0.004,IC50,Inhibitory concentration required for in vitro binding affinity to cholinergic central Nicotinic acetylcholine receptor on rat brain cortex by using [3H]MCC,Confirmatory,,
434,145672,7,4,,103163782,89594,Active,2851491.0,170945.0,0.004,IC50,Inhibitory concentration required for in vitro binding affinity to cholinergic central Nicotinic acetylcholine receptor on rat brain cortex by using [3H]MCC,Confirmatory,,
435,145672,7,4,,103163782,89594,Active,6226548.0,54239.0,0.004,IC50,Inhibitory concentration required for in vitro binding affinity to cholinergic central Nicotinic acetylcholine receptor on rat brain cortex by using [3H]MCC,Confirmatory,,
436,145672,7,4,,103163782,89594,Active,8469182.0,25590.0,0.004,IC50,Inhibitory concentration required for in vitro binding affinity to cholinergic central Nicotinic acetylcholine receptor on rat brain cortex by using [3H]MCC,Confirmatory,,
437,145672,7,4,,103163782,89594,Active,68051992.0,64574.0,0.004,IC50,Inhibitory concentration required for in vitro binding affinity to cholinergic central Nicotinic acetylcholine receptor on rat brain cortex by using [3H]MCC,Confirmatory,,
438,145672,7,4,,103163782,89594,Active,68067466.0,65024.0,0.004,IC50,Inhibitory concentration required for in vitro binding affinity to cholinergic central Nicotinic acetylcholine receptor on rat brain cortex by using [3H]MCC,Confirmatory,,
439,145672,7,4,,103163782,89594,Active,146345356.0,25302.0,0.004,IC50,Inhibitory concentration required for in vitro binding affinity to cholinergic central Nicotinic acetylcholine receptor on rat brain cortex by using [3H]MCC,Confirmatory,,
440,145677,3,10,,103163782,89594,Active,113061.0,25101.0,,,Kapp value towards nicotinic acetylcholine receptor was obtained from three to four independent competition binding experiments using [3H]-NCEPB,Other,9240344.0,
441,145677,3,10,,103163782,89594,Active,113066.0,25102.0,,,Kapp value towards nicotinic acetylcholine receptor was obtained from three to four independent competition binding experiments using [3H]-NCEPB,Other,9240344.0,
442,145677,3,10,,103163782,89594,Active,113108.0,171131.0,,,Kapp value towards nicotinic acetylcholine receptor was obtained from three to four independent competition binding experiments using [3H]-NCEPB,Other,9240344.0,
443,145677,3,10,,103163782,89594,Active,113111.0,25103.0,,,Kapp value towards nicotinic acetylcholine receptor was obtained from three to four independent competition binding experiments using [3H]-NCEPB,Other,9240344.0,
444,145677,3,10,,103163782,89594,Active,1168297.0,81721.0,,,Kapp value towards nicotinic acetylcholine receptor was obtained from three to four independent competition binding experiments using [3H]-NCEPB,Other,9240344.0,
445,145677,3,10,,103163782,89594,Active,2851491.0,170945.0,,,Kapp value towards nicotinic acetylcholine receptor was obtained from three to four independent competition binding experiments using [3H]-NCEPB,Other,9240344.0,
446,145677,3,10,,103163782,89594,Active,6226548.0,54239.0,,,Kapp value towards nicotinic acetylcholine receptor was obtained from three to four independent competition binding experiments using [3H]-NCEPB,Other,9240344.0,
447,145677,3,10,,103163782,89594,Active,8469182.0,25590.0,,,Kapp value towards nicotinic acetylcholine receptor was obtained from three to four independent competition binding experiments using [3H]-NCEPB,Other,9240344.0,
448,145677,3,10,,103163782,89594,Active,68051992.0,64574.0,,,Kapp value towards nicotinic acetylcholine receptor was obtained from three to four independent competition binding experiments using [3H]-NCEPB,Other,9240344.0,
449,145677,3,10,,103163782,89594,Active,68067466.0,65024.0,,,Kapp value towards nicotinic acetylcholine receptor was obtained from three to four independent competition binding experiments using [3H]-NCEPB,Other,9240344.0,
450,145677,3,10,,103163782,89594,Active,146345356.0,25302.0,,,Kapp value towards nicotinic acetylcholine receptor was obtained from three to four independent competition binding experiments using [3H]-NCEPB,Other,9240344.0,
451,145682,7,4,,103163782,89594,Active,113061.0,25101.0,0.001,Ki,Binding affinity against Nicotinic Acetylcholine Receptor was determined by measuring the displacement of [3H]cytisine from a preparation of whole rat brain.,Confirmatory,8632405.0,
452,145682,7,4,,103163782,89594,Active,113066.0,25102.0,0.001,Ki,Binding affinity against Nicotinic Acetylcholine Receptor was determined by measuring the displacement of [3H]cytisine from a preparation of whole rat brain.,Confirmatory,8632405.0,
453,145682,7,4,,103163782,89594,Active,113108.0,171131.0,0.001,Ki,Binding affinity against Nicotinic Acetylcholine Receptor was determined by measuring the displacement of [3H]cytisine from a preparation of whole rat brain.,Confirmatory,8632405.0,
454,145682,7,4,,103163782,89594,Active,113111.0,25103.0,0.001,Ki,Binding affinity against Nicotinic Acetylcholine Receptor was determined by measuring the displacement of [3H]cytisine from a preparation of whole rat brain.,Confirmatory,8632405.0,
455,145682,7,4,,103163782,89594,Active,1168297.0,81721.0,0.001,Ki,Binding affinity against Nicotinic Acetylcholine Receptor was determined by measuring the displacement of [3H]cytisine from a preparation of whole rat brain.,Confirmatory,8632405.0,
456,145682,7,4,,103163782,89594,Active,2851491.0,170945.0,0.001,Ki,Binding affinity against Nicotinic Acetylcholine Receptor was determined by measuring the displacement of [3H]cytisine from a preparation of whole rat brain.,Confirmatory,8632405.0,
457,145682,7,4,,103163782,89594,Active,6226548.0,54239.0,0.001,Ki,Binding affinity against Nicotinic Acetylcholine Receptor was determined by measuring the displacement of [3H]cytisine from a preparation of whole rat brain.,Confirmatory,8632405.0,
458,145682,7,4,,103163782,89594,Active,8469182.0,25590.0,0.001,Ki,Binding affinity against Nicotinic Acetylcholine Receptor was determined by measuring the displacement of [3H]cytisine from a preparation of whole rat brain.,Confirmatory,8632405.0,
459,145682,7,4,,103163782,89594,Active,68051992.0,64574.0,0.001,Ki,Binding affinity against Nicotinic Acetylcholine Receptor was determined by measuring the displacement of [3H]cytisine from a preparation of whole rat brain.,Confirmatory,8632405.0,
460,145682,7,4,,103163782,89594,Active,68067466.0,65024.0,0.001,Ki,Binding affinity against Nicotinic Acetylcholine Receptor was determined by measuring the displacement of [3H]cytisine from a preparation of whole rat brain.,Confirmatory,8632405.0,
461,145682,7,4,,103163782,89594,Active,146345356.0,25302.0,0.001,Ki,Binding affinity against Nicotinic Acetylcholine Receptor was determined by measuring the displacement of [3H]cytisine from a preparation of whole rat brain.,Confirmatory,8632405.0,
462,145683,7,4,,103163782,89594,Active,,,0.0084,Ki,Binding affinity for Nicotinic acetylcholine receptor site in rat cortex was determined using [3H]MCC as radioligand,Confirmatory,,
463,145684,7,4,,103163782,89594,Active,113061.0,25101.0,0.0024,Ki,Binding affinity towards nicotinic acetylcholine receptor (nACh) using [3H](-)-nicotine as radioligand in rat brain,Confirmatory,14611857.0,
464,145684,7,4,,103163782,89594,Active,113066.0,25102.0,0.0024,Ki,Binding affinity towards nicotinic acetylcholine receptor (nACh) using [3H](-)-nicotine as radioligand in rat brain,Confirmatory,14611857.0,
465,145684,7,4,,103163782,89594,Active,113108.0,171131.0,0.0024,Ki,Binding affinity towards nicotinic acetylcholine receptor (nACh) using [3H](-)-nicotine as radioligand in rat brain,Confirmatory,14611857.0,
466,145684,7,4,,103163782,89594,Active,113111.0,25103.0,0.0024,Ki,Binding affinity towards nicotinic acetylcholine receptor (nACh) using [3H](-)-nicotine as radioligand in rat brain,Confirmatory,14611857.0,
467,145684,7,4,,103163782,89594,Active,1168297.0,81721.0,0.0024,Ki,Binding affinity towards nicotinic acetylcholine receptor (nACh) using [3H](-)-nicotine as radioligand in rat brain,Confirmatory,14611857.0,
468,145684,7,4,,103163782,89594,Active,2851491.0,170945.0,0.0024,Ki,Binding affinity towards nicotinic acetylcholine receptor (nACh) using [3H](-)-nicotine as radioligand in rat brain,Confirmatory,14611857.0,
469,145684,7,4,,103163782,89594,Active,6226548.0,54239.0,0.0024,Ki,Binding affinity towards nicotinic acetylcholine receptor (nACh) using [3H](-)-nicotine as radioligand in rat brain,Confirmatory,14611857.0,
470,145684,7,4,,103163782,89594,Active,8469182.0,25590.0,0.0024,Ki,Binding affinity towards nicotinic acetylcholine receptor (nACh) using [3H](-)-nicotine as radioligand in rat brain,Confirmatory,14611857.0,
471,145684,7,4,,103163782,89594,Active,68051992.0,64574.0,0.0024,Ki,Binding affinity towards nicotinic acetylcholine receptor (nACh) using [3H](-)-nicotine as radioligand in rat brain,Confirmatory,14611857.0,
472,145684,7,4,,103163782,89594,Active,68067466.0,65024.0,0.0024,Ki,Binding affinity towards nicotinic acetylcholine receptor (nACh) using [3H](-)-nicotine as radioligand in rat brain,Confirmatory,14611857.0,
473,145684,7,4,,103163782,89594,Active,146345356.0,25302.0,0.0024,Ki,Binding affinity towards nicotinic acetylcholine receptor (nACh) using [3H](-)-nicotine as radioligand in rat brain,Confirmatory,14611857.0,
474,145685,7,4,,103163782,89594,Active,113061.0,25101.0,0.013000000000000001,Ki,Binding affinity towards rat forebrain nicotinic acetylcholine receptor using [3H]EB as radioligand,Confirmatory,15050613.0,
475,145685,7,4,,103163782,89594,Active,113066.0,25102.0,0.013000000000000001,Ki,Binding affinity towards rat forebrain nicotinic acetylcholine receptor using [3H]EB as radioligand,Confirmatory,15050613.0,
476,145685,7,4,,103163782,89594,Active,113108.0,171131.0,0.013000000000000001,Ki,Binding affinity towards rat forebrain nicotinic acetylcholine receptor using [3H]EB as radioligand,Confirmatory,15050613.0,
477,145685,7,4,,103163782,89594,Active,113111.0,25103.0,0.013000000000000001,Ki,Binding affinity towards rat forebrain nicotinic acetylcholine receptor using [3H]EB as radioligand,Confirmatory,15050613.0,
478,145685,7,4,,103163782,89594,Active,1168297.0,81721.0,0.013000000000000001,Ki,Binding affinity towards rat forebrain nicotinic acetylcholine receptor using [3H]EB as radioligand,Confirmatory,15050613.0,
479,145685,7,4,,103163782,89594,Active,2851491.0,170945.0,0.013000000000000001,Ki,Binding affinity towards rat forebrain nicotinic acetylcholine receptor using [3H]EB as radioligand,Confirmatory,15050613.0,
480,145685,7,4,,103163782,89594,Active,6226548.0,54239.0,0.013000000000000001,Ki,Binding affinity towards rat forebrain nicotinic acetylcholine receptor using [3H]EB as radioligand,Confirmatory,15050613.0,
481,145685,7,4,,103163782,89594,Active,8469182.0,25590.0,0.013000000000000001,Ki,Binding affinity towards rat forebrain nicotinic acetylcholine receptor using [3H]EB as radioligand,Confirmatory,15050613.0,
482,145685,7,4,,103163782,89594,Active,68051992.0,64574.0,0.013000000000000001,Ki,Binding affinity towards rat forebrain nicotinic acetylcholine receptor using [3H]EB as radioligand,Confirmatory,15050613.0,
483,145685,7,4,,103163782,89594,Active,68067466.0,65024.0,0.013000000000000001,Ki,Binding affinity towards rat forebrain nicotinic acetylcholine receptor using [3H]EB as radioligand,Confirmatory,15050613.0,
484,145685,7,4,,103163782,89594,Active,146345356.0,25302.0,0.013000000000000001,Ki,Binding affinity towards rat forebrain nicotinic acetylcholine receptor using [3H]EB as radioligand,Confirmatory,15050613.0,
485,145688,7,2,,103163782,89594,Active,,,0.0013,Ki,Binding affinity towards nicotinic acetylcholine receptor using [3H]nicotine as radioligand in rat brain homogenates,Confirmatory,12113825.0,
486,145690,7,3,,103163782,89594,Active,,,0.00115,Ki,Ability to displace [3H](-)-cytisine from nicotinic acetylcholine receptor (nAChR) in a whole rat brain preparation,Confirmatory,,
487,145828,3,10,,103163782,89594,Unspecified,113061.0,25101.0,,,Potency relative to PHT in rat brain membranes ([3H]MCC binding),Other,3346870.0,
488,145828,3,10,,103163782,89594,Unspecified,113066.0,25102.0,,,Potency relative to PHT in rat brain membranes ([3H]MCC binding),Other,3346870.0,
489,145828,3,10,,103163782,89594,Unspecified,113108.0,171131.0,,,Potency relative to PHT in rat brain membranes ([3H]MCC binding),Other,3346870.0,
490,145828,3,10,,103163782,89594,Unspecified,113111.0,25103.0,,,Potency relative to PHT in rat brain membranes ([3H]MCC binding),Other,3346870.0,
491,145828,3,10,,103163782,89594,Unspecified,1168297.0,81721.0,,,Potency relative to PHT in rat brain membranes ([3H]MCC binding),Other,3346870.0,
492,145828,3,10,,103163782,89594,Unspecified,2851491.0,170945.0,,,Potency relative to PHT in rat brain membranes ([3H]MCC binding),Other,3346870.0,
493,145828,3,10,,103163782,89594,Unspecified,6226548.0,54239.0,,,Potency relative to PHT in rat brain membranes ([3H]MCC binding),Other,3346870.0,
494,145828,3,10,,103163782,89594,Unspecified,8469182.0,25590.0,,,Potency relative to PHT in rat brain membranes ([3H]MCC binding),Other,3346870.0,
495,145828,3,10,,103163782,89594,Unspecified,68051992.0,64574.0,,,Potency relative to PHT in rat brain membranes ([3H]MCC binding),Other,3346870.0,
496,145828,3,10,,103163782,89594,Unspecified,68067466.0,65024.0,,,Potency relative to PHT in rat brain membranes ([3H]MCC binding),Other,3346870.0,
497,145828,3,10,,103163782,89594,Unspecified,146345356.0,25302.0,,,Potency relative to PHT in rat brain membranes ([3H]MCC binding),Other,3346870.0,
498,145829,3,10,,103163782,89594,Unspecified,113061.0,25101.0,,,Potency relative to PHT in rat brain membranes ([3H]nicotine binding),Other,3346870.0,
499,145829,3,10,,103163782,89594,Unspecified,113066.0,25102.0,,,Potency relative to PHT in rat brain membranes ([3H]nicotine binding),Other,3346870.0,
500,145829,3,10,,103163782,89594,Unspecified,113108.0,171131.0,,,Potency relative to PHT in rat brain membranes ([3H]nicotine binding),Other,3346870.0,
501,145829,3,10,,103163782,89594,Unspecified,113111.0,25103.0,,,Potency relative to PHT in rat brain membranes ([3H]nicotine binding),Other,3346870.0,
502,145829,3,10,,103163782,89594,Unspecified,1168297.0,81721.0,,,Potency relative to PHT in rat brain membranes ([3H]nicotine binding),Other,3346870.0,
503,145829,3,10,,103163782,89594,Unspecified,2851491.0,170945.0,,,Potency relative to PHT in rat brain membranes ([3H]nicotine binding),Other,3346870.0,
504,145829,3,10,,103163782,89594,Unspecified,6226548.0,54239.0,,,Potency relative to PHT in rat brain membranes ([3H]nicotine binding),Other,3346870.0,
505,145829,3,10,,103163782,89594,Unspecified,8469182.0,25590.0,,,Potency relative to PHT in rat brain membranes ([3H]nicotine binding),Other,3346870.0,
506,145829,3,10,,103163782,89594,Unspecified,68051992.0,64574.0,,,Potency relative to PHT in rat brain membranes ([3H]nicotine binding),Other,3346870.0,
507,145829,3,10,,103163782,89594,Unspecified,68067466.0,65024.0,,,Potency relative to PHT in rat brain membranes ([3H]nicotine binding),Other,3346870.0,
508,145829,3,10,,103163782,89594,Unspecified,146345356.0,25302.0,,,Potency relative to PHT in rat brain membranes ([3H]nicotine binding),Other,3346870.0,
509,145837,9,2,,103163782,89594,Active,,,0.001,IC50,Inhibition of [3H]MCC binding to torpedo electroplax membranes,Confirmatory,3346870.0,
510,145838,9,2,,103163782,89594,Active,,,0.004,IC50,inhibition of (-)-[3H]nicotine binding to torpedo electroplax membranes,Confirmatory,3346870.0,
511,145839,3,7,,103163782,89594,Unspecified,,,,,Potency relative to PHT in torpedo electroplax membranes ([3H]MCC binding),Other,3346870.0,
512,145840,3,7,,103163782,89594,Unspecified,,,,,Potency relative to PHT in torpedo electroplax membranes ([3H]nicotine binding),Other,3346870.0,
513,145846,7,4,,103163782,89594,Active,,,0.027000000000000003,Ki,Binding affinity against nicotinic acetylcholine receptor using [3H]epibatidine as radioligand in rat brain tissue,Confirmatory,14684341.0,
514,145848,3,10,,103163782,89594,Unspecified,,,,,Selectivity ratio of Ki of Nicotinic acetylcholine receptor of Drosophila to Nicotinic acetylcholine receptor alpha4-beta2,Other,12061885.0,
515,145854,9,1,,103163782,89594,Active,,,5.5,Ki,In vitro Binding affinity towards alpha-1-beta-1-gamma delta nAChR was determined,Confirmatory,11212100.0,
516,145859,7,2,,103163782,89594,Active,,,0.012,Ki,Tested for binding affinity against Nicotinic acetylcholine receptor alpha2-beta2,Confirmatory,12620069.0,
517,145975,6,2,,103163782,89594,Active,,,0.004,IC50,"In vitro ability to displace tritiated nicotine from rat brain binding sites, and calcium flux (c.f)",Confirmatory,9873508.0,
518,145981,8,5,,103163782,89594,Active,2851491.0,170945.0,0.012,Ki,Binding affinity towards nicotinic acetylcholine receptor alpha2-beta2 using [3H]epibatidine,Confirmatory,15050615.0,
519,145981,8,5,,103163782,89594,Active,6226548.0,54239.0,0.012,Ki,Binding affinity towards nicotinic acetylcholine receptor alpha2-beta2 using [3H]epibatidine,Confirmatory,15050615.0,
520,145983,8,5,,103163782,89594,Active,2851491.0,170945.0,0.015,Ki,Binding affinity towards rat nicotinic acetylcholine receptor alpha2-beta2 expressed in HEK293 cells using [3H]EB as radioligand,Confirmatory,15050613.0,
521,145983,8,5,,103163782,89594,Active,6226548.0,54239.0,0.015,Ki,Binding affinity towards rat nicotinic acetylcholine receptor alpha2-beta2 expressed in HEK293 cells using [3H]EB as radioligand,Confirmatory,15050613.0,
522,145987,7,2,,103163782,89594,Active,,,0.11199999999999999,Ki,Tested for binding affinity against Nicotinic acetylcholine receptor alpha2-beta4,Confirmatory,12620069.0,
523,145988,8,5,,103163782,89594,Active,113111.0,25103.0,0.11199999999999999,Ki,Binding affinity towards Nicotinic acetylcholine receptor alpha2-beta4 using [3H]epibatidine,Confirmatory,15050615.0,
524,145988,8,5,,103163782,89594,Active,2851491.0,170945.0,0.11199999999999999,Ki,Binding affinity towards Nicotinic acetylcholine receptor alpha2-beta4 using [3H]epibatidine,Confirmatory,15050615.0,
525,145990,7,1,,103163782,89594,Active,,,0.10300000000000001,Ki,Binding affinity against nicotinic acetylcholine receptor alpha2-beta4 using [3H]epibatidine as radioligand expressed in HEK293 cells or tsA cells,Confirmatory,14684341.0,
526,145991,7,2,,103163782,89594,Active,,,0.22,Ki,In vitro Binding affinity towards alpha-3 (PC12) nAChR was determined,Confirmatory,11212100.0,
527,146001,7,2,,103163782,89594,Active,,,0.047,Ki,Tested for binding affinity against Nicotinic acetylcholine receptor alpha3-beta2,Confirmatory,12620069.0,
528,146003,7,2,,103163782,89594,Active,,,0.0038,IC50,Inhibitory concentration required for in vitro binding affinity to Nicotinic acetylcholine receptor alpha3-beta2 expressed on cell line sf 9 by using [3H]-MCC,Confirmatory,,
529,146005,8,5,,103163782,89594,Active,113061.0,25101.0,0.047,Ki,Binding affinity towards Nicotinic acetylcholine receptor alpha3-beta2 using [3H]epibatidine,Confirmatory,15050615.0,
530,146005,8,5,,103163782,89594,Active,6226548.0,54239.0,0.047,Ki,Binding affinity towards Nicotinic acetylcholine receptor alpha3-beta2 using [3H]epibatidine,Confirmatory,15050615.0,
531,146006,8,5,,103163782,89594,Active,113061.0,25101.0,0.043,Ki,Binding affinity towards rat Nicotinic acetylcholine receptor alpha3-beta2 expressed in HEK293 cells using [3H]EB as radioligand,Confirmatory,15050613.0,
532,146006,8,5,,103163782,89594,Active,6226548.0,54239.0,0.043,Ki,Binding affinity towards rat Nicotinic acetylcholine receptor alpha3-beta2 expressed in HEK293 cells using [3H]EB as radioligand,Confirmatory,15050613.0,
533,146149,7,3,,103163782,89594,Active,,,0.073,Ki,Binding affinity to Nicotinic acetylcholine receptor alpha3-beta4 using +/-[3H]epibatidine as radioligand in pig adrenal gland,Confirmatory,11855986.0,
534,146151,7,2,,103163782,89594,Active,,,0.44299999999999995,Ki,Tested for binding affinity against Nicotinic acetylcholine receptor alpha3-beta4,Confirmatory,12620069.0,
535,146161,8,5,,103163782,89594,Active,113061.0,25101.0,0.44299999999999995,Ki,Binding affinity towards Nicotinic acetylcholine receptor alpha3-beta4 using [3H]epibatidine,Confirmatory,15050615.0,
536,146161,8,5,,103163782,89594,Active,113111.0,25103.0,0.44299999999999995,Ki,Binding affinity towards Nicotinic acetylcholine receptor alpha3-beta4 using [3H]epibatidine,Confirmatory,15050615.0,
537,146162,8,5,,103163782,89594,Active,113061.0,25101.0,0.53,Ki,Binding affinity towards rat Nicotinic acetylcholine receptor alpha3-beta4 expressed in HEK293 cells using [3H]EB as radioligand,Confirmatory,15050613.0,
538,146162,8,5,,103163782,89594,Active,113111.0,25103.0,0.53,Ki,Binding affinity towards rat Nicotinic acetylcholine receptor alpha3-beta4 expressed in HEK293 cells using [3H]EB as radioligand,Confirmatory,15050613.0,
539,146165,6,3,,103163782,89594,Active,,,4.3,EC50,Agonistic potency against nicotinic acetylcholine receptor alpha3-beta4,Confirmatory,14684341.0,
540,146167,7,1,,103163782,89594,Active,,,0.32,Ki,Binding affinity against nicotinic acetylcholine receptor alpha3-beta4 using [3H]epibatidine as radioligand expressed in HEK293 cells or tsA cells,Confirmatory,14684341.0,
541,146171,7,1,,103163782,89594,Active,,,0.002,Ki,Potency to displace [3H]nicotine binding to Nicotinic acetylcholine receptor alpha4-beta2 immuno-isolated from M10 cells,Confirmatory,12061885.0,
542,146297,9,2,,103163782,89594,Active,,,4.0,EC50,Compound was evaluated for functional potencies and efficacies at human Nicotinic acetylcholine receptor alpha4-beta2,Confirmatory,9435889.0,
543,146311,6,3,,103163782,89594,Active,,,0.0042,IC50,Inhibitory concentration required for in vitro binding affinity to Nicotinic acetylcholine receptor alpha4-beta2 expressed on cell line sf 21 by using [3H]-MCC,Confirmatory,,
544,146314,7,2,,103163782,89594,Active,,,0.0013,Ki,Affinity at alpha4-beta2 nACh receptors in rat brain (minus cerebellum) homogenates.,Confirmatory,12639569.0,
545,146315,9,2,,103163782,89594,Active,,,0.001,Ki,Affinity for Nicotinic acetylcholine receptor alpha4-beta2 tested by analogue-induced inhibition of [3H]NIC binding to rat striatal membranes,Confirmatory,11354387.0,
546,146319,11,1,,103163782,89594,Active,,,0.59,EC50,Compound was evaluated for functional potencies and efficacies at ratNicotinic acetylcholine receptor alpha4-beta2,Confirmatory,9435889.0,
547,146321,7,1,,103163782,89594,Active,,,4.0,EC50,Functional potency for Nicotinic acetylcholine receptor alpha4-beta2 (rat brain),Confirmatory,9435889.0,
548,146453,8,5,,103163782,89594,Active,6226548.0,54239.0,0.0009400000000000001,Ki,Displacement of [3H]cytisine from Nicotinic acetylcholine receptor alpha4-beta2 in rat forebrain,Confirmatory,12190326.0,
549,146453,8,5,,103163782,89594,Active,8469182.0,25590.0,0.0009400000000000001,Ki,Displacement of [3H]cytisine from Nicotinic acetylcholine receptor alpha4-beta2 in rat forebrain,Confirmatory,12190326.0,
550,146456,7,1,,103163782,89594,Active,,,0.0023,Ki,Binding affinity in rat forebrain against Nicotinic acetylcholine receptor alpha4-beta2,Confirmatory,11063601.0,
551,146458,7,1,,103163782,89594,Active,,,0.00105,Ki,Binding potency for Nicotinic acetylcholine receptor alpha4-beta2 (rat brain),Confirmatory,9435889.0,
552,146460,9,2,,103163782,89594,Active,,,0.001,Ki,Inhibition of binding of [3H]nicotine to Nicotinic acetylcholine receptor alpha4-beta2 in rat cerebral cortical membranes,Confirmatory,9622546.0,
553,146462,7,2,,103163782,89594,Active,,,0.01,Ki,Tested for binding affinity against Nicotinic acetylcholine receptor alpha4-beta2,Confirmatory,12620069.0,
554,146463,9,2,,103163782,89594,Active,,,0.001,Ki,The compound was evaluated for percentage inhibition of binding of [3H]- nicotine to Nicotinic acetylcholine receptor alpha4-beta2 in Rat Cerebral Cortical Membranes,Confirmatory,9622546.0,
555,146468,10,5,,103163782,89594,Active,6226548.0,54239.0,0.0014,Ki,Binding affinity for nicotinic acetylcholine receptor alpha4-beta2 was evaluated by its ability to inhibit [3H]NIC binding to rat brain membranes,Confirmatory,12372503.0,
556,146468,10,5,,103163782,89594,Active,8469182.0,25590.0,0.0014,Ki,Binding affinity for nicotinic acetylcholine receptor alpha4-beta2 was evaluated by its ability to inhibit [3H]NIC binding to rat brain membranes,Confirmatory,12372503.0,
557,146473,8,5,,103163782,89594,Active,6226548.0,54239.0,0.0015,Ki,Inhibition of [3H]epibatidine binding at the nicotinic acetylcholine receptor alpha4-beta2 in male rat cerebral cortex,Confirmatory,11405659.0,
558,146473,8,5,,103163782,89594,Active,8469182.0,25590.0,0.0015,Ki,Inhibition of [3H]epibatidine binding at the nicotinic acetylcholine receptor alpha4-beta2 in male rat cerebral cortex,Confirmatory,11405659.0,
559,146476,8,5,,103163782,89594,Active,6226548.0,54239.0,0.00101,Ki,Non-specific binding in presence of 300 uM nicotine at nicotinic acetylcholine receptor alpha4-beta2 in rat cerebral cortex membranes,Confirmatory,11405659.0,
560,146476,8,5,,103163782,89594,Active,8469182.0,25590.0,0.00101,Ki,Non-specific binding in presence of 300 uM nicotine at nicotinic acetylcholine receptor alpha4-beta2 in rat cerebral cortex membranes,Confirmatory,11405659.0,
561,146478,5,6,,103163782,89594,Active,6226548.0,54239.0,0.0073,EC50,In vitro binding affinity by inhibiting [3H]dopamine release in rat brain tissue at Nicotinic acetylcholine receptor alpha4-beta2,Confirmatory,12086489.0,
562,146478,5,6,,103163782,89594,Active,8469182.0,25590.0,0.0073,EC50,In vitro binding affinity by inhibiting [3H]dopamine release in rat brain tissue at Nicotinic acetylcholine receptor alpha4-beta2,Confirmatory,12086489.0,
563,146483,9,5,,103163782,89594,Active,6226548.0,54239.0,0.00084,Ki,Binding affinity to Nicotinic acetylcholine receptor alpha4-beta2 using +/-[3H]epibatidine as radioligand in rat brain,Confirmatory,11855986.0,
564,146483,9,5,,103163782,89594,Active,8469182.0,25590.0,0.00084,Ki,Binding affinity to Nicotinic acetylcholine receptor alpha4-beta2 using +/-[3H]epibatidine as radioligand in rat brain,Confirmatory,11855986.0,
565,146484,8,5,,103163782,89594,Active,6226548.0,54239.0,0.01,Ki,Binding affinity towards Nicotinic acetylcholine receptor alpha4-beta2 using [3H]epibatidine,Confirmatory,15050615.0,
566,146484,8,5,,103163782,89594,Active,8469182.0,25590.0,0.01,Ki,Binding affinity towards Nicotinic acetylcholine receptor alpha4-beta2 using [3H]epibatidine,Confirmatory,15050615.0,
567,146485,8,1,,103163782,89594,Active,,,0.0021,Ki,Binding affinity towards nicotinic acetylcholine receptor alpha4-beta2 from rat brain homogenates,Confirmatory,14698195.0,
568,146486,8,5,,103163782,89594,Active,6226548.0,54239.0,0.012,Ki,Binding affinity towards rat Nicotinic acetylcholine receptor alpha4-beta2 expressed in HEK293 cells using [3H]EB as radioligand,Confirmatory,15050613.0,
569,146486,8,5,,103163782,89594,Active,8469182.0,25590.0,0.012,Ki,Binding affinity towards rat Nicotinic acetylcholine receptor alpha4-beta2 expressed in HEK293 cells using [3H]EB as radioligand,Confirmatory,15050613.0,
570,146612,8,5,,103163782,89594,Active,6226548.0,54239.0,0.008,Ki,In vitro binding affinity by inhibiting [3H]cytisine binding in rat brain tissue at Nicotinic acetylcholine receptor alpha4-beta2,Confirmatory,12086489.0,
571,146612,8,5,,103163782,89594,Active,8469182.0,25590.0,0.008,Ki,In vitro binding affinity by inhibiting [3H]cytisine binding in rat brain tissue at Nicotinic acetylcholine receptor alpha4-beta2,Confirmatory,12086489.0,
572,146613,8,5,,103163782,89594,Active,6226548.0,54239.0,0.001,Ki,In vitro binding affinity towards Nicotinic acetylcholine receptor alpha4-beta2 using [3H]cytisine in rat brain,Confirmatory,11741488.0,
573,146613,8,5,,103163782,89594,Active,8469182.0,25590.0,0.001,Ki,In vitro binding affinity towards Nicotinic acetylcholine receptor alpha4-beta2 using [3H]cytisine in rat brain,Confirmatory,11741488.0,
574,146620,8,5,,103163782,89594,Active,6226548.0,54239.0,0.001,Ki,Inhibition of [3H]nicotine binding to Nicotinic acetylcholine receptor alpha4-beta2 from rat membranes,Confirmatory,15050621.0,
575,146620,8,5,,103163782,89594,Active,8469182.0,25590.0,0.001,Ki,Inhibition of [3H]nicotine binding to Nicotinic acetylcholine receptor alpha4-beta2 from rat membranes,Confirmatory,15050621.0,
576,146633,7,2,,103163782,89594,Active,,,0.0012,Ki,Affinity for nicotinic acetylcholine receptor alpha4-beta2,Confirmatory,15203136.0,
577,146635,7,2,,103163782,89594,Active,,,0.004,Ki,Binding affinity at heteropentameric Nicotinic acetylcholine receptor alpha4-beta2 subtype using [3H]bungarotoxin as radioligand,Confirmatory,10447950.0,
578,146637,7,1,,103163782,89594,Active,,,0.0091,Ki,Binding affinity against nicotinic acetylcholine receptor alpha4-beta2 using [3H]epibatidine as radioligand expressed in HEK293 cells or tsA cells,Confirmatory,14684341.0,
579,146639,7,2,,103163782,89594,Active,,,0.002,Ki,Binding affinity towards nicotinic acetylcholine receptor alpha4-beta2,Confirmatory,15050612.0,
580,146640,7,2,,103163782,89594,Active,,,0.0023,Ki,In vitro Binding affinity towards Nicotinic acetylcholine receptor alpha4-beta2 was determined,Confirmatory,11212100.0,
581,146769,7,2,,103163782,89594,Active,,,0.04,Ki,Tested for binding affinity against Nicotinic acetylcholine receptor alpha4-beta4,Confirmatory,12620069.0,
582,146771,8,5,,103163782,89594,Active,113111.0,25103.0,0.04,Ki,Binding affinity towards Nicotinic acetylcholine receptor alpha4-beta4 using [3H]epibatidine,Confirmatory,15050615.0,
583,146771,8,5,,103163782,89594,Active,8469182.0,25590.0,0.04,Ki,Binding affinity towards Nicotinic acetylcholine receptor alpha4-beta4 using [3H]epibatidine,Confirmatory,15050615.0,
584,146772,8,5,,103163782,89594,Active,113111.0,25103.0,0.046,Ki,Binding affinity towards rat Nicotinic acetylcholine receptor alpha4-beta4 expressed in HEK293 cells using [3H]EB as radioligand,Confirmatory,15050613.0,
585,146772,8,5,,103163782,89594,Active,8469182.0,25590.0,0.046,Ki,Binding affinity towards rat Nicotinic acetylcholine receptor alpha4-beta4 expressed in HEK293 cells using [3H]EB as radioligand,Confirmatory,15050613.0,
586,146775,7,1,,103163782,89594,Active,,,0.129,Ki,Binding affinity against nicotinic acetylcholine receptor alpha4-beta4 using [3H]epibatidine as radioligand expressed in HEK293 cells or tsA cells,Confirmatory,14684341.0,
587,146779,9,2,,103163782,89594,Unspecified,,,83.0,EC50,Compound was evaluated for functional potencies and efficacies at human Nicotinic acetylcholine receptor alpha7,Confirmatory,9435889.0,
588,146785,7,1,,103163782,89594,Active,,,1.61,Ki,Bindind affinity value obtained by measuring the displacement of radioligand [125I]alpha-bungarotoxin from K-28 cells stably express human Nicotinic acetylcholine receptor alpha7,Confirmatory,9022806.0,
589,146789,7,2,,103163782,89594,Active,,,0.48,Ki,In vitro Binding affinity towards alpha-7 nAChR was determined,Confirmatory,11212100.0,
590,146797,9,1,,103163782,89594,Unspecified,,,54.0,EC50,Functional potency for Nicotinic acetylcholine receptor alpha-7 (rat brain),Confirmatory,9435889.0,
591,146799,6,4,,103163782,89594,Unspecified,,,43000.0,EC50,Potency was determined by measuring current activation in Xenopus oocytes expressing rat Nicotinic acetylcholine receptor alpha7,Confirmatory,11063601.0,
592,146926,9,2,,103163782,89594,Active,,,0.77,Ki,Affinity for alpha-7 neuronal nicotinic acetylcholine receptor subtype determined by inhibition of [3H]-MLA binding to rat brain membranes,Confirmatory,11354387.0,
593,146932,7,1,,103163782,89594,Active,,,0.48,Ki,Binding affinity in rat hippocampi against Nicotinic acetylcholine receptor alpha7,Confirmatory,11063601.0,
594,146934,9,1,,103163782,89594,Active,,,0.45,Ki,Binding affinity nicotinic acetylcholine receptor alpha-7 was evaluated by its ability to inhibit [3H]methyllycaconitine ([3H]-MLA) binding to rat brain membranes,Confirmatory,12372503.0,
595,146935,7,1,,103163782,89594,Active,,,0.13,Ki,Binding affinity to subtype Nicotinic acetylcholine receptor alpha-7 using [125I]-alpha-BTX as radioligand in rat brain,Confirmatory,11855986.0,
596,146938,9,1,,103163782,89594,Active,,,4.0,Ki,Binding potency for Nicotinic acetylcholine receptor alpha-7 (rat brain),Confirmatory,9435889.0,
597,146940,9,1,,103163782,89594,Active,,,4.0,Ki,In vitro binding affinity towards Nicotinic acetylcholine receptor alpha7 using [125I]alpha-bungarotoxin in rat brain,Confirmatory,11741488.0,
598,147077,3,7,,103163782,89594,Unspecified,,,,,Intrinsic activity was determined by measuring current activation in Xenopus oocytes expressing rat Nicotinic acetylcholine receptor alpha7,Other,11063601.0,
599,147083,7,2,,103163782,89594,Active,,,0.62,Ki,Binding affinity at homopentameric Nicotinic acetylcholine receptor alpha-7 subtype using [3H]S-(-)-nicotine as radioligand,Confirmatory,10447950.0,
600,147091,4,4,,103163782,89594,Active,,,0.0021,Ki,The compound was evaluated for its binding affinity towards nicotinic acetylcholinergic (n ACh) receptor using [3H]nicotine as the radioligand in rat brain,Confirmatory,11128647.0,
601,147094,8,5,,103163782,89594,Active,146345356.0,25302.0,0.016,IC50,Compound was tested for its binding affinity against nicotinic receptor in synaptic membrane fractions from rat cerebral cortices.,Confirmatory,10522693.0,
602,147716,7,5,,103163782,89594,Active,,,0.0012,Ki,Binding affinity against Nicotinic acetylcholine receptor using [3H](-)-nicotine radioligand,Confirmatory,12270194.0,
603,161281,10,5,,103163782,89594,Unspecified,7531135.0,3757.0,245.47099999999998,IC50,Inhibition of human Potassium channel HERG expressed in mammalian cells,Confirmatory,12873512.0,
604,168208,3,3,,103163782,89594,Unspecified,,,,,Acetylcholine release data in Square-Dawley rats when compound was administered subcutaneously at dose of 0.4(mg/Kg),Other,10346920.0,
605,171587,2,5,,103163782,89594,Unspecified,,,,,The compound was tested for inducing [3H]dopamine release from striatal slices at 10 uM nicotine,Other,,
606,171588,2,5,,103163782,89594,Unspecified,,,,,The compound was tested for inducing [3H]dopamine release from striatal slices at 1 uM nicotine,Other,,
607,171591,2,4,,103163782,89594,Unspecified,,,,,The compound was tested in vivo against effective nicotinic agonistic activity in rat,Other,,
608,174139,4,4,,103163782,89594,Unspecified,,,,,Effect of compound on accumulation of dopamine metabolite dihydroxyphenyl acetic acid (DOPAC) in nucleus accumbens,Other,,
609,174140,4,5,,103163782,89594,Unspecified,,,,,Effect of compound on accumulation of dopamine metabolite dihydroxyphenyl acetic acid (DOPAC) in rat striatum,Other,,
610,174141,4,4,,103163782,89594,Unspecified,,,,,Effect of compound on accumulation of homovanillic acid (HVA) in nucleus accumbens,Other,,
611,174142,4,5,,103163782,89594,Unspecified,,,,,Effect of compound on accumulation of homovanillic acid (HVA) in rat striatum,Other,,
612,175480,6,2,,103163782,89594,Active,,,0.04,EC50,Compound was evaluated for functional potencies and efficacies at rat nAChR subtype DA release,Confirmatory,9435889.0,
613,175537,2,4,,103163782,89594,Unspecified,,,,,Effect of compound on accumulation of dopamine metabolite dihydroxyphenyl acetic acid (DOPAC) in nucleus accumbens,Other,,
614,175538,2,5,,103163782,89594,Unspecified,,,,,Effect of compound on accumulation of dopamine metabolite dihydroxyphenyl acetic acid (DOPAC) in rat striatum,Other,,
615,175539,2,4,,103163782,89594,Unspecified,,,,,Effect of compound on accumulation of homovanillic acid (HVA) in nucleus accumbens,Other,,
616,175540,2,5,,103163782,89594,Unspecified,,,,,Effect of compound on accumulation of homovanillic acid (HVA) in rat striatum,Other,,
617,176019,6,3,,103163782,89594,Active,,,40.0,EC50,Tested for nAChR-mediated dopamine release from rat striatal slices.,Confirmatory,,
618,178015,7,2,,103163782,89594,Unspecified,,,,,Effective dose for Antinociceptive activity was determined in rat using drug discrimination assay,Other,12270194.0,
619,178953,5,1,,103163782,89594,Active,,,0.01,ED50,Effective dose required to produce prostration after injection into rat's fourth ventricle,Confirmatory,3346870.0,
620,179665,3,5,,103163782,89594,Unspecified,,,,,In vitro efficacy to stimulate [3H]NE in rat hippocampus,Other,10346920.0,
621,179667,3,5,,103163782,89594,Unspecified,,,,,In vitro efficacy to stimulate [3H]NE in rat prefrontal cortex membrane slice,Other,10346920.0,
622,179670,3,4,,103163782,89594,Unspecified,,,,,In vitro efficacy to stimulate the release of [3H]dopamine from rat striatal slices,Other,10346920.0,
623,180535,5,3,,103163782,89594,Unspecified,,,,,The compound was tested in vivo against effective nicotinic agonistic activity in rat when administered s.c.,Other,,
624,187463,4,3,,103163782,89594,Unspecified,,,,,Relative potency at [86Rb+] binding to modulate ion fluxes across the plasma membrane of rat cortex; 100% efficacy,Other,11741488.0,
625,187466,3,3,,103163782,89594,Unspecified,,,,,Relative potency at [3H]acetylcholine binding site to modulate ion fluxes across the plasma membrane of rat cortex; 100% efficacy,Other,11741488.0,
626,187469,4,4,,103163782,89594,Unspecified,,,,,Relative potency at [3H]DA binding site to modulate ion fluxes across the plasma membrane of rat striatal membranes; 100% efficacy,Other,11741488.0,
627,189548,3,3,,103163782,89594,Unspecified,,,,,"Potency for prostration assay, relative to PHT",Other,3346870.0,
628,192639,3,8,,103163782,89594,Unspecified,,,,,In vitro neuronal nAChRs evoked [3H]dopamine release was determined in rat striatal slices at concentration of 10e-6 M,Other,7799396.0,
629,193829,2,4,,103163782,89594,Unspecified,,,,,Percent intrinsic activity relative to 100 uM (S)-nicotine.,Other,,
630,195823,3,4,,103163782,89594,Unspecified,,,,,The efficiency of the compound (300 micro M) to stimulate [3H]-dopamine ([3H]DA) release,Other,8765504.0,
631,197118,3,4,,103163782,89594,Unspecified,,,,,Compound was evaluated for the binding affinity at crude mitochondrial fraction of rat whole brain at 13 fmol of binding sites/mg of protein,Other,7401120.0,
632,197119,3,4,,103163782,89594,Unspecified,,,,,Compound was evaluated for the binding affinity at crude mitochondrial fraction of rat whole brain at 7 nmol/mg of protein.,Other,7401120.0,
633,219639,9,1,,103163782,89594,Unspecified,,,60.0,EC50,Functional potency for nAChR subtype Alpha-1-beta-1-delta gamma(torpedo),Confirmatory,9435889.0,
634,219641,4,8,,103163782,89594,Unspecified,,,10.0,Ki,Binding potency for nAChR subtype Alpha-1-beta-1-delta-gamma (torpedo),Confirmatory,9435889.0,
635,219910,3,4,,103163782,89594,Unspecified,,,,,Compound was tested for inducing stimulation of current response in Xenopus oocytes (alpha3-beta2) at 30 uM,Other,,
636,219911,3,4,,103163782,89594,Unspecified,,,,,Compound was tested for inducing stimulation of current response in Xenopus oocytes (alpha4-beta2) at 1 uM,Other,,
637,219945,6,3,,103163782,89594,Active,,,21.0,EC50,Tested for functional activity against neuronal nicotinic acetylcholine receptor(nAChR) expressed in IMR-32 cells using isotopic rubidium efflux assay.,Confirmatory,,
638,219946,3,7,,103163782,89594,Unspecified,,,,,Percent intrinsic activity against IMR-32 cells relative to 100 uM (S)-nicotine.,Other,,
639,219962,7,6,,103163782,89594,Active,113105.0,1141.0,5.0,EC50,Tested for functional activity against neuronal nicotinic acetylcholine receptor(nAChR) expressed in K177 cells using isotopic rubidium efflux assay.,Confirmatory,,
640,219962,7,6,,103163782,89594,Active,1351848.0,1137.0,5.0,EC50,Tested for functional activity against neuronal nicotinic acetylcholine receptor(nAChR) expressed in K177 cells using isotopic rubidium efflux assay.,Confirmatory,,
641,219963,3,10,,103163782,89594,Unspecified,113105.0,1141.0,,,Percent intrinsic activity against K177 cells relative to 100 uM (S)-nicotine.,Other,,
642,219963,3,10,,103163782,89594,Unspecified,1351848.0,1137.0,,,Percent intrinsic activity against K177 cells relative to 100 uM (S)-nicotine.,Other,,
643,220121,8,2,,103163782,89594,Active,,,0.0038,IC50,Inhibition of [3H](-)-nicotine binding to recombinant rat alpha4-beta2 nAChR.,Confirmatory,10377228.0,
644,220126,9,1,,103163782,89594,Active,,,0.001,Ki,Binding affinity towards alpha4-beta2 measured by using the inhibition of [3H]NIC binding to rat striatal membrane,Confirmatory,12467625.0,
645,220450,3,7,,103163782,89594,Unspecified,,,,,Functional activity is expressed as percent efficacy for alpha-7 nAChR.,Other,11212100.0,
646,220452,4,8,,103163782,89594,Active,,,38.0,EC50,"Effective concentration that causes inhibition of alpha-7 nAChR, was determined. Values are expressed as EC50 +/- SEM.",Confirmatory,11212100.0,
647,220453,9,1,,103163782,89594,Active,,,0.34,Ki,Binding affinity towards alpha-7 neuronal nicotinic acetylcholine receptor (nAChRs) measured by using the inhibition of [3H]-MLA binding to whole brain membrane,Confirmatory,12467625.0,
648,225711,9,2,,103163782,89594,Active,113061.0,25101.0,0.001,Ki,Binding affinity values obtained by measuring the displacement of radioligand [3H](-)-cytisine from a preparation of whole rat brain,Confirmatory,9022806.0,
649,225711,9,2,,103163782,89594,Active,113066.0,25102.0,0.001,Ki,Binding affinity values obtained by measuring the displacement of radioligand [3H](-)-cytisine from a preparation of whole rat brain,Confirmatory,9022806.0,
650,225711,9,2,,103163782,89594,Active,113108.0,171131.0,0.001,Ki,Binding affinity values obtained by measuring the displacement of radioligand [3H](-)-cytisine from a preparation of whole rat brain,Confirmatory,9022806.0,
651,225711,9,2,,103163782,89594,Active,113111.0,25103.0,0.001,Ki,Binding affinity values obtained by measuring the displacement of radioligand [3H](-)-cytisine from a preparation of whole rat brain,Confirmatory,9022806.0,
652,225711,9,2,,103163782,89594,Active,1168297.0,81721.0,0.001,Ki,Binding affinity values obtained by measuring the displacement of radioligand [3H](-)-cytisine from a preparation of whole rat brain,Confirmatory,9022806.0,
653,225711,9,2,,103163782,89594,Active,2851491.0,170945.0,0.001,Ki,Binding affinity values obtained by measuring the displacement of radioligand [3H](-)-cytisine from a preparation of whole rat brain,Confirmatory,9022806.0,
654,225711,9,2,,103163782,89594,Active,6226548.0,54239.0,0.001,Ki,Binding affinity values obtained by measuring the displacement of radioligand [3H](-)-cytisine from a preparation of whole rat brain,Confirmatory,9022806.0,
655,225711,9,2,,103163782,89594,Active,8469182.0,25590.0,0.001,Ki,Binding affinity values obtained by measuring the displacement of radioligand [3H](-)-cytisine from a preparation of whole rat brain,Confirmatory,9022806.0,
656,225711,9,2,,103163782,89594,Active,68051992.0,64574.0,0.001,Ki,Binding affinity values obtained by measuring the displacement of radioligand [3H](-)-cytisine from a preparation of whole rat brain,Confirmatory,9022806.0,
657,225711,9,2,,103163782,89594,Active,68067466.0,65024.0,0.001,Ki,Binding affinity values obtained by measuring the displacement of radioligand [3H](-)-cytisine from a preparation of whole rat brain,Confirmatory,9022806.0,
658,225711,9,2,,103163782,89594,Active,146345356.0,25302.0,0.001,Ki,Binding affinity values obtained by measuring the displacement of radioligand [3H](-)-cytisine from a preparation of whole rat brain,Confirmatory,9022806.0,
659,225712,7,2,,103163782,89594,Active,,,0.0011,Ki,In vitro binding affinity to neuronal nAChRs was determined by measuring the displacement of [3H]cytisine in rat brain,Confirmatory,7799396.0,
660,225713,7,4,,103163782,89594,Active,113061.0,25101.0,0.001,Ki,Tested for neuronal nicotinic acetylcholine receptor (nAChR) binding in a whole rat brain preparation using [3H]cystine as the radioligand.,Confirmatory,,
661,225713,7,4,,103163782,89594,Active,113066.0,25102.0,0.001,Ki,Tested for neuronal nicotinic acetylcholine receptor (nAChR) binding in a whole rat brain preparation using [3H]cystine as the radioligand.,Confirmatory,,
662,225713,7,4,,103163782,89594,Active,113108.0,171131.0,0.001,Ki,Tested for neuronal nicotinic acetylcholine receptor (nAChR) binding in a whole rat brain preparation using [3H]cystine as the radioligand.,Confirmatory,,
663,225713,7,4,,103163782,89594,Active,113111.0,25103.0,0.001,Ki,Tested for neuronal nicotinic acetylcholine receptor (nAChR) binding in a whole rat brain preparation using [3H]cystine as the radioligand.,Confirmatory,,
664,225713,7,4,,103163782,89594,Active,1168297.0,81721.0,0.001,Ki,Tested for neuronal nicotinic acetylcholine receptor (nAChR) binding in a whole rat brain preparation using [3H]cystine as the radioligand.,Confirmatory,,
665,225713,7,4,,103163782,89594,Active,2851491.0,170945.0,0.001,Ki,Tested for neuronal nicotinic acetylcholine receptor (nAChR) binding in a whole rat brain preparation using [3H]cystine as the radioligand.,Confirmatory,,
666,225713,7,4,,103163782,89594,Active,6226548.0,54239.0,0.001,Ki,Tested for neuronal nicotinic acetylcholine receptor (nAChR) binding in a whole rat brain preparation using [3H]cystine as the radioligand.,Confirmatory,,
667,225713,7,4,,103163782,89594,Active,8469182.0,25590.0,0.001,Ki,Tested for neuronal nicotinic acetylcholine receptor (nAChR) binding in a whole rat brain preparation using [3H]cystine as the radioligand.,Confirmatory,,
668,225713,7,4,,103163782,89594,Active,68051992.0,64574.0,0.001,Ki,Tested for neuronal nicotinic acetylcholine receptor (nAChR) binding in a whole rat brain preparation using [3H]cystine as the radioligand.,Confirmatory,,
669,225713,7,4,,103163782,89594,Active,68067466.0,65024.0,0.001,Ki,Tested for neuronal nicotinic acetylcholine receptor (nAChR) binding in a whole rat brain preparation using [3H]cystine as the radioligand.,Confirmatory,,
670,225713,7,4,,103163782,89594,Active,146345356.0,25302.0,0.001,Ki,Tested for neuronal nicotinic acetylcholine receptor (nAChR) binding in a whole rat brain preparation using [3H]cystine as the radioligand.,Confirmatory,,
671,225714,7,2,,103163782,89594,Active,,,0.00115,Ki,Tested for the binding affinity against neuronal nicotinic acetylcholine receptors from whole rat brain,Confirmatory,7932582.0,
672,225716,6,4,,103163782,89594,Unspecified,,,180.0,EC50,Tested for functional activity against alpha-1 neuronal nicotinic acetylcholine receptor(nAChR) expressed in TE671 cells using isotopic rubidium efflux assay.,Confirmatory,,
673,225719,3,8,,103163782,89594,Unspecified,,,,,Percent intrinsic activity against TE671 cells relative to 100 uM (S)-nicotine.,Other,,
674,225720,6,2,,103163782,89594,Active,,,0.13,Ki,Binding affinity towards rat alpha2-beta4 nACh receptor expressed in HEK293 cells using [3H]EB as radioligand,Confirmatory,15050613.0,
675,225723,11,2,,103163782,89594,Active,113105.0,1141.0,21.0,EC50,Stimulation of cation efflux in human nAChR subtype alpha3-betaX expressing IMR-32 cells,Confirmatory,9871663.0,
676,225723,11,2,,103163782,89594,Active,2506128.0,1142.0,21.0,EC50,Stimulation of cation efflux in human nAChR subtype alpha3-betaX expressing IMR-32 cells,Confirmatory,9871663.0,
677,225723,11,2,,103163782,89594,Active,2506129.0,1143.0,21.0,EC50,Stimulation of cation efflux in human nAChR subtype alpha3-betaX expressing IMR-32 cells,Confirmatory,9871663.0,
678,225723,11,2,,103163782,89594,Active,21903373.0,1140.0,21.0,EC50,Stimulation of cation efflux in human nAChR subtype alpha3-betaX expressing IMR-32 cells,Confirmatory,9871663.0,
679,225723,11,2,,103163782,89594,Active,254763435.0,1136.0,21.0,EC50,Stimulation of cation efflux in human nAChR subtype alpha3-betaX expressing IMR-32 cells,Confirmatory,9871663.0,
680,225724,10,5,,103163782,89594,Active,113105.0,1141.0,5.0,EC50,Stimulation of cation efflux in human nAChR alpha4-beta2 expressing K177 cells,Confirmatory,9871663.0,
681,225724,10,5,,103163782,89594,Active,1351848.0,1137.0,5.0,EC50,Stimulation of cation efflux in human nAChR alpha4-beta2 expressing K177 cells,Confirmatory,9871663.0,
682,225730,3,11,,103163782,89594,Unspecified,113105.0,1141.0,,,"Maximal efficacy in nAChR subtype human alpha3betaX, expressed in IMR-32 cells",Other,9871663.0,
683,225730,3,11,,103163782,89594,Unspecified,1351848.0,1137.0,,,"Maximal efficacy in nAChR subtype human alpha3betaX, expressed in IMR-32 cells",Other,9871663.0,
684,225731,3,10,,103163782,89594,Unspecified,113105.0,1141.0,,,Maximal efficacy in human nAChR alpha4-beta2 expressing K177 cells,Other,9871663.0,
685,225731,3,10,,103163782,89594,Unspecified,1351848.0,1137.0,,,Maximal efficacy in human nAChR alpha4-beta2 expressing K177 cells,Other,9871663.0,
686,226266,3,4,,103163782,89594,Unspecified,,,,,Compound was evaluated for the functional selectivity for alpha4-beta2 (rat brain)/ vs alpha-7 (rat brain),Other,9435889.0,
687,226647,4,4,,103163782,89594,Unspecified,,,,,Hill slope value of the compound,Other,11405659.0,
688,227718,7,1,,103163782,89594,Unspecified,,,,,Binding energy by using the equation deltaG obsd = -RT ln KD,Other,6094812.0,
689,227721,3,4,,103163782,89594,Unspecified,,,,,Compound is evaluated for the binding selectivity for alpha4-beta2 (rat brain)/ vs alpha-7 (rat brain),Other,9435889.0,
690,229187,7,1,,103163782,89594,Unspecified,,,10.0,IC50,Inhibition of specific binding of [125I]PIPAG to sigma receptor in Guinea pig brain membranes,Confirmatory,1469697.0,
691,229709,3,3,,103163782,89594,Unspecified,,,,,Functional / binding potency ratio for nAChR subtype Alpha1-beta1 delta gamma(torpedo),Other,9435889.0,
692,229711,3,4,,103163782,89594,Unspecified,,,,,Functional / binding potency ratio for nAChR subtype Alpha4 beta-2 (rat brain),Other,9435889.0,
693,229713,3,3,,103163782,89594,Unspecified,,,,,Functional / binding potency ratio for nAChR subtype Alpha7 (rat brain),Other,9435889.0,
694,231911,3,3,,103163782,89594,Unspecified,,,,,Ratio between the binding affinities towards rat alpha2-beta4 and alpha2-beta2 nACh receptor using [3H]-EB as radioligand,Other,15050613.0,
695,231912,3,4,,103163782,89594,Unspecified,,,,,Ratio between the binding affinities towards rat alpha3-beta4 and alpha3-beta2 nACh receptor using [3H]EB as radioligand,Other,15050613.0,
696,231914,3,4,,103163782,89594,Unspecified,,,,,Ratio between the binding affinities towards rat alpha3-beta4 and forebrain nACh receptor using [3H]EB as radioligand,Other,15050613.0,
697,231915,3,4,,103163782,89594,Unspecified,,,,,Ratio between the binding affinities towards rat alpha4-beta4 and alpha4-beta2 nACh receptor using [3H]EB as radioligand,Other,15050613.0,
698,233593,3,6,,103163782,89594,Unspecified,,,,,Ratio of IC50 values for displacing [3H]-MCC to [3H]OXO-M,Other,10585207.0,
699,234087,3,7,,103163782,89594,Unspecified,,,,,Selectivity for nicotinic agonist activity was determined between Ki for [3H]-OXO-M and to that for [3H]MCC,Other,,
700,237685,4,3,,103163782,89594,Unspecified,,,,,Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system,Other,15857133.0,
701,238080,6,2,,103163782,89594,Active,,,0.0030800000000000003,Kd,Dissociation constant for nicotinic acetylcholine receptor alpha4-beta2 of mouse M10 cells; n=3,Confirmatory,15686879.0,
702,238082,8,5,,103163782,89594,Active,2506127.0,1139.0,0.00106,Kd,Dissociation constant for nicotinic acetylcholine receptor alpha 7 from human neuroblastoma SH-SY5Y cells; n=3,Confirmatory,15686879.0,
703,238615,6,7,,103163782,89594,Active,308153612.0,1548.0,4.4,Ki,Effect on coumarin 7-hydroxylation by human Cytochrome P-450 2A6,Confirmatory,15634016.0,
704,238996,6,4,,103163782,89594,Unspecified,,,10.0,Ki,Binding affinity towards Nicotinic acetylcholine receptor alpha4-beta2; Not significant,Confirmatory,15808471.0,
705,239232,10,1,,103163782,89594,Active,146345356.0,25302.0,0.77,Ki,Inhibition of [3H]-MLA binding to alpha-7 nicotinic acetylcholine receptor of rat brain membrane,Confirmatory,16005216.0,
706,239283,8,1,,103163782,89594,Active,2506127.0,1139.0,6.3,Ki,Inhibition of [3H]alpha-bungarotoxin binding to nicotinic acetylcholine receptor alpha7 of IMR32 cells,Confirmatory,15908213.0,
707,239291,12,2,,103163782,89594,Active,6226548.0,54239.0,0.001,Ki,Inhibition of [3H]MLA binding to alpha4-beta2 nicotinic acetylcholine receptor of rat brain membrane,Confirmatory,16005216.0,
708,239291,12,2,,103163782,89594,Active,8469182.0,25590.0,0.001,Ki,Inhibition of [3H]MLA binding to alpha4-beta2 nicotinic acetylcholine receptor of rat brain membrane,Confirmatory,16005216.0,
709,239302,6,2,,103163782,89594,Active,,,0.04,Ki,Inhibition of [3H]epibatidine binding to Nicotinic acetylcholine receptor alpha4-beta4,Confirmatory,15771418.0,
710,239312,8,5,,103163782,89594,Active,6226548.0,54239.0,0.00095,Ki,Inhibition of [3H]nicotine binding to nicotinic acetylcholine receptor alpha4-beta2 of rat cortex,Confirmatory,15887955.0,
711,239312,8,5,,103163782,89594,Active,8469182.0,25590.0,0.00095,Ki,Inhibition of [3H]nicotine binding to nicotinic acetylcholine receptor alpha4-beta2 of rat cortex,Confirmatory,15887955.0,
712,239319,9,5,,103163782,89594,Active,6226548.0,54239.0,0.0015,Ki,Inhibition of alpha beta[3H]epibatidine binding to Nicotinic acetylcholine receptor alpha4-beta2 of rat cerebral cortex,Confirmatory,15317468.0,
713,239319,9,5,,103163782,89594,Active,8469182.0,25590.0,0.0015,Ki,Inhibition of alpha beta[3H]epibatidine binding to Nicotinic acetylcholine receptor alpha4-beta2 of rat cerebral cortex,Confirmatory,15317468.0,
714,239324,6,2,,103163782,89594,Active,,,0.012,Ki,Inhibition of [3H]epibatidine binding to Nicotinic acetylcholine receptor alpha2-beta2,Confirmatory,15771418.0,
715,239325,6,2,,103163782,89594,Active,,,0.11199999999999999,Ki,Inhibition of [3H]epibatidine binding to Nicotinic acetylcholine receptor alpha2-beta4,Confirmatory,15771418.0,
716,239326,7,2,,103163782,89594,Active,,,0.047,Ki,Inhibition of [3H]epibatidine binding to Nicotinic acetylcholine receptor alpha3-beta2,Confirmatory,15771418.0,
717,239374,8,5,,103163782,89594,Active,2506129.0,1143.0,0.53,Ki,Inhibition of [3H]epibatidine binding to nicotinic acetylcholine receptor alpha3-beta4 of human IMR32 cells,Confirmatory,15887955.0,
718,239374,8,5,,103163782,89594,Active,254763435.0,1136.0,0.53,Ki,Inhibition of [3H]epibatidine binding to nicotinic acetylcholine receptor alpha3-beta4 of human IMR32 cells,Confirmatory,15887955.0,
719,239383,8,5,,103163782,89594,Active,113061.0,25101.0,0.44299999999999995,Ki,Inhibition of [3H]epibatidine binding to rat Nicotinic acetylcholine receptor alpha3-beta4,Confirmatory,15771418.0,
720,239383,8,5,,103163782,89594,Active,113111.0,25103.0,0.44299999999999995,Ki,Inhibition of [3H]epibatidine binding to rat Nicotinic acetylcholine receptor alpha3-beta4,Confirmatory,15771418.0,
721,239384,8,5,,103163782,89594,Active,6226548.0,54239.0,0.01,Ki,Inhibition of [3H]epibatidine binding to rat Nicotinic acetylcholine receptor alpha4-beta2,Confirmatory,15771418.0,
722,239384,8,5,,103163782,89594,Active,8469182.0,25590.0,0.01,Ki,Inhibition of [3H]epibatidine binding to rat Nicotinic acetylcholine receptor alpha4-beta2,Confirmatory,15771418.0,
723,239394,8,5,,103163782,89594,Active,113105.0,1141.0,0.0016,Ki,Binding affinity against nicotinic acetylcholine receptor alpha4-beta2 in human HEK293 cells using [3H]- nicotine as radioligand,Confirmatory,15908213.0,
724,239394,8,5,,103163782,89594,Active,1351848.0,1137.0,0.0016,Ki,Binding affinity against nicotinic acetylcholine receptor alpha4-beta2 in human HEK293 cells using [3H]- nicotine as radioligand,Confirmatory,15908213.0,
725,239410,10,2,,103163782,89594,Active,6226548.0,54239.0,0.00095,Ki,Inhibition of [3H]-nicotine binding to nicotinic acetylcholine receptor alpha4-beta2 in rat cortex,Confirmatory,15908213.0,
726,239410,10,2,,103163782,89594,Active,8469182.0,25590.0,0.00095,Ki,Inhibition of [3H]-nicotine binding to nicotinic acetylcholine receptor alpha4-beta2 in rat cortex,Confirmatory,15908213.0,
727,239419,6,2,,103163782,89594,Active,,,0.0025,Ki,Binding affinity for nicotinic acetylcholine receptor alpha4-beta2 from mouse M10 cells; n=3,Confirmatory,15686879.0,
728,239450,8,5,,103163782,89594,Active,2506129.0,1143.0,0.53,Ki,Inhibition of [3H]epibatidine binding to nicotinic acetylcholine receptor alpha3-beta4 of IMR32 cells,Confirmatory,15908213.0,
729,239450,8,5,,103163782,89594,Active,254763435.0,1136.0,0.53,Ki,Inhibition of [3H]epibatidine binding to nicotinic acetylcholine receptor alpha3-beta4 of IMR32 cells,Confirmatory,15908213.0,
730,239452,8,5,,103163782,89594,Active,6226548.0,54239.0,0.0015,Ki,Inhibition of [3H]epibatidine binding to Nicotinic acetylcholine receptor alpha4-beta2 in rat cerebral cortex,Confirmatory,15715488.0,
731,239452,8,5,,103163782,89594,Active,8469182.0,25590.0,0.0015,Ki,Inhibition of [3H]epibatidine binding to Nicotinic acetylcholine receptor alpha4-beta2 in rat cerebral cortex,Confirmatory,15715488.0,
732,239458,8,1,,103163782,89594,Active,146345356.0,25302.0,1.7480000000000002,Ki,Inhibitory constant against [3H]methyllycaconitine binding towards Nicotinic acetylcholine receptor alpha-7 of rat brain hippocampus,Confirmatory,15808471.0,
733,239475,6,2,,103163782,89594,Active,,,6.3,Ki,Inhibition of [3H]alpha-bungarotoxin binding to nicotinic acetylcholine receptor alpha-1-beta-1-delta-gamma of electroplax,Confirmatory,15908213.0,
734,239519,10,1,,103163782,89594,Active,146345356.0,25302.0,0.46,Ki,Inhibition of [125 I]-alpha Bungarotoxin binding to alpha 7 nicotinic acetylcholine receptor of rat cortex membranes,Confirmatory,15501049.0,
735,239537,7,3,,103163782,89594,Active,,,6.27,Ki,Inhibition of [125I]alpha-bungarotoxin binding to nicotinic acetylcholine receptor alpha1 beta gamma delta of electroplax,Confirmatory,15887955.0,
736,239590,8,1,,103163782,89594,Active,146345356.0,25302.0,6.29,Ki,Inhibition of [125I]alpha-bungarotoxin binding to nicotinic acetylcholine receptor alpha-7 subunit in rat GH4C1 cells,Confirmatory,15887955.0,
737,239596,8,5,,103163782,89594,Active,6226548.0,54239.0,0.035,Ki,Inhibition of [3H](-)-nicotine binding to rat brain (minus cerebellum) Nicotinic acetylcholine receptor alpha4-beta2,Confirmatory,15925512.0,
738,239596,8,5,,103163782,89594,Active,8469182.0,25590.0,0.035,Ki,Inhibition of [3H](-)-nicotine binding to rat brain (minus cerebellum) Nicotinic acetylcholine receptor alpha4-beta2,Confirmatory,15925512.0,
739,239598,10,5,,103163782,89594,Active,6226548.0,54239.0,0.002,Ki,Inhibition of [3H]epibatidine binding to alpha 4 beta 2 nicotinic acetylcholine receptor of rat cortex membranes,Confirmatory,15501049.0,
740,239598,10,5,,103163782,89594,Active,8469182.0,25590.0,0.002,Ki,Inhibition of [3H]epibatidine binding to alpha 4 beta 2 nicotinic acetylcholine receptor of rat cortex membranes,Confirmatory,15501049.0,
741,239605,8,8,,103163782,89594,Inconclusive,113121.0,25229.0,,,Inhibition of [3H]N-methylscopolamine binding to muscarinic receptor of rat cortex membranes; not determined,Other,15501049.0,
742,239605,8,8,,103163782,89594,Inconclusive,113127.0,24260.0,,,Inhibition of [3H]N-methylscopolamine binding to muscarinic receptor of rat cortex membranes; not determined,Other,15501049.0,
743,239605,8,8,,103163782,89594,Inconclusive,113130.0,25111.0,,,Inhibition of [3H]N-methylscopolamine binding to muscarinic receptor of rat cortex membranes; not determined,Other,15501049.0,
744,239605,8,8,,103163782,89594,Inconclusive,113132.0,53949.0,,,Inhibition of [3H]N-methylscopolamine binding to muscarinic receptor of rat cortex membranes; not determined,Other,15501049.0,
745,239605,8,8,,103163782,89594,Inconclusive,12643977.0,81645.0,,,Inhibition of [3H]N-methylscopolamine binding to muscarinic receptor of rat cortex membranes; not determined,Other,15501049.0,
746,239634,9,5,,103163782,89594,Active,2506127.0,1139.0,7.2,Ki,Binding affinity for nicotinic acetylcholine receptor alpha 7 from human neuroblastoma SH-SY5Y cells; n=3,Confirmatory,15686879.0,
747,240064,12,1,,103163782,89594,Active,146345356.0,25302.0,13.0,EC50,Effective concentration against rat alpha-7 nicotinic acetylcholine receptor,Confirmatory,16005216.0,
748,240073,10,5,,103163782,89594,Unspecified,2506127.0,1139.0,113.0,EC50,Effective concentration against Nicotinic acetylcholine receptor alpha 7,Confirmatory,16033252.0,
749,240077,12,2,,103163782,89594,Unspecified,113061.0,25101.0,86.0,EC50,Effective concentration against rat alpha3-beta4 nicotinic acetylcholine receptor,Confirmatory,16005216.0,
750,240077,12,2,,103163782,89594,Unspecified,113111.0,25103.0,86.0,EC50,Effective concentration against rat alpha3-beta4 nicotinic acetylcholine receptor,Confirmatory,16005216.0,
751,240078,12,2,,103163782,89594,Active,6226548.0,54239.0,1.0,EC50,Effective concentration against rat alpha4-beta2 nicotinic acetylcholine receptor,Confirmatory,16005216.0,
752,240078,12,2,,103163782,89594,Active,8469182.0,25590.0,1.0,EC50,Effective concentration against rat alpha4-beta2 nicotinic acetylcholine receptor,Confirmatory,16005216.0,
753,240234,8,3,,103163782,89594,Active,,,21.0,EC50,Effective concentration against Nicotinic acetylcholine receptor alpha2-beta4 expressed in xenopus oocytes,Confirmatory,16033252.0,
754,240235,10,5,,103163782,89594,Unspecified,113105.0,1141.0,132.0,EC50,Effective concentration against Nicotinic acetylcholine receptor alpha3-beta2 expressed in xenopus oocytes,Confirmatory,16033252.0,
755,240235,10,5,,103163782,89594,Unspecified,254763435.0,1136.0,132.0,EC50,Effective concentration against Nicotinic acetylcholine receptor alpha3-beta2 expressed in xenopus oocytes,Confirmatory,16033252.0,
756,240236,8,3,,103163782,89594,Unspecified,,,80.0,EC50,Effective concentration against Nicotinic acetylcholine receptor alpha3-beta4 expressed in xenopus oocytes,Confirmatory,16033252.0,
757,240237,8,3,,103163782,89594,Active,,,5.5,EC50,Effective concentration against Nicotinic acetylcholine receptor alpha4-beta2 expressed in xenopus oocytes,Confirmatory,16033252.0,
758,240238,8,3,,103163782,89594,Active,,,5.0,EC50,Effective concentration against Nicotinic acetylcholine receptor alpha4-beta4 expressed in xenopus oocytes,Confirmatory,16033252.0,
759,241334,6,7,,103163782,89594,Unspecified,117144.0,1544.0,4100.0,IC50,Inhibitory concentration against recombinant human cytochrome P450 1A2,Confirmatory,15916432.0,
760,242822,3,8,,103163782,89594,Unspecified,146345356.0,25302.0,,,Maximal response against rat alpha-7 nicotinic acetylcholine receptor,Other,16005216.0,
761,242824,3,10,,103163782,89594,Unspecified,113061.0,25101.0,,,Maximal response against rat alpha3-beta4 nicotinic acetylcholine receptor,Other,16005216.0,
762,242824,3,10,,103163782,89594,Unspecified,113111.0,25103.0,,,Maximal response against rat alpha3-beta4 nicotinic acetylcholine receptor,Other,16005216.0,
763,242825,3,10,,103163782,89594,Unspecified,6226548.0,54239.0,,,Maximal response against rat alpha4-beta2 nicotinic acetylcholine receptor,Other,16005216.0,
764,242825,3,10,,103163782,89594,Unspecified,8469182.0,25590.0,,,Maximal response against rat alpha4-beta2 nicotinic acetylcholine receptor,Other,16005216.0,
765,242871,3,11,,103163782,89594,Unspecified,2506129.0,1143.0,,,Maximal response against Nicotinic acetylcholine receptor,Other,16033252.0,
766,242871,3,11,,103163782,89594,Unspecified,308153405.0,1135.0,,,Maximal response against Nicotinic acetylcholine receptor,Other,16033252.0,
767,242872,9,1,,103163782,89594,Unspecified,146345356.0,25302.0,,,Maximal response against Nicotinic acetylcholine receptor alpha 7,Other,16033252.0,
768,242874,3,8,,103163782,89594,Unspecified,,,,,Maximal response against Nicotinic acetylcholine receptor alpha2-beta4,Other,16033252.0,
769,242876,4,7,,103163782,89594,Unspecified,,,,,Maximal response against Nicotinic acetylcholine receptor alpha3-beta4,Other,16033252.0,
770,242877,9,1,,103163782,89594,Unspecified,,,,,Maximal response against Nicotinic acetylcholine receptor alpha4-beta2,Other,16033252.0,
771,242878,4,7,,103163782,89594,Unspecified,,,,,Maximal response against Nicotinic acetylcholine receptor alpha4-beta4,Other,16033252.0,
772,242880,3,10,,103163782,89594,Unspecified,2506129.0,1143.0,,,Maximal response against Nicotinic acetylcholine receptor alpha3-beta4,Other,16033252.0,
773,242880,3,10,,103163782,89594,Unspecified,254763435.0,1136.0,,,Maximal response against Nicotinic acetylcholine receptor alpha3-beta4,Other,16033252.0,
774,242891,3,12,,103163782,89594,Unspecified,2506129.0,1143.0,,,Maximal response against Nicotinic acetylcholine receptor alpha2-beta4 expressed in HEK293 cells,Other,16033252.0,
775,242891,3,12,,103163782,89594,Unspecified,308153405.0,1135.0,,,Maximal response against Nicotinic acetylcholine receptor alpha2-beta4 expressed in HEK293 cells,Other,16033252.0,
776,242892,3,12,,103163782,89594,Unspecified,113105.0,1141.0,,,Maximal response against Nicotinic acetylcholine receptor alpha3-beta2 expressed in HEK293 cells,Other,16033252.0,
777,242892,3,12,,103163782,89594,Unspecified,254763435.0,1136.0,,,Maximal response against Nicotinic acetylcholine receptor alpha3-beta2 expressed in HEK293 cells,Other,16033252.0,
778,242894,3,11,,103163782,89594,Unspecified,113105.0,1141.0,,,Maximal response against Nicotinic acetylcholine receptor alpha4-beta2 expressed in HEK293 cells,Other,16033252.0,
779,242894,3,11,,103163782,89594,Unspecified,1351848.0,1137.0,,,Maximal response against Nicotinic acetylcholine receptor alpha4-beta2 expressed in HEK293 cells,Other,16033252.0,
780,242975,3,5,,103163782,89594,Unspecified,,,,,Ratio of IC50 for human CYP2A6 to that of mouse CYP2A5 was determined,Other,15658857.0,
781,243151,7,2,,103163782,89594,Unspecified,,,245.47099999999998,IC50,Inhibitory concentration against potassium channel HERG,Confirmatory,15911273.0,
782,243426,3,10,,103163782,89594,Unspecified,113105.0,1141.0,,,Percent agonist activity relative to 10 uM (-)-nicotine at human nicotinic acetylcholine receptor alpha4-beta2 at 10 uM,Other,15887955.0,
783,243426,3,10,,103163782,89594,Unspecified,1351848.0,1137.0,,,Percent agonist activity relative to 10 uM (-)-nicotine at human nicotinic acetylcholine receptor alpha4-beta2 at 10 uM,Other,15887955.0,
784,244249,3,6,,103163782,89594,Unspecified,,,,,Selectivity against Nicotinic acetylcholine receptor subtypes alpha3-beta4 and alpha4-beta2,Other,15771418.0,
785,246831,6,2,,103163782,89594,Unspecified,,,,,Antinociceptive response was determined in mice using tail flick method,Other,15317468.0,
786,246832,6,2,,103163782,89594,Unspecified,,,,,Antinociceptive response was determined in mice using hypothermia method,Other,15317468.0,
787,246838,6,2,,103163782,89594,Unspecified,,,,,Antinociceptive response was determined in mice using hot plate flick method,Other,15317468.0,
788,246840,7,2,,103163782,89594,Unspecified,,,,,Effective dose to induce hypothermia in mouse was determined,Other,15715488.0,
789,246852,6,2,,103163782,89594,Unspecified,,,,,Antinociceptive response was determined in mice using spontaneous activity method,Other,15317468.0,
790,246869,7,2,,103163782,89594,Unspecified,,,,,Effective dose to induce spontaneous activity in mouse was determined,Other,15715488.0,
791,246898,7,2,,103163782,89594,Unspecified,,,,,Effective dose to induce antinociception in mouse determined in hotplate test,Other,15715488.0,
792,246901,7,2,,103163782,89594,Unspecified,,,,,Effective dose to induce antinociception in mouse determined in tail-flick test,Other,15715488.0,
793,251221,3,10,,103163782,89594,Unspecified,113105.0,1141.0,,,Percent response relative to 10 uM nicotine in human Nicotinic acetylcholine receptor alpha4-beta2,Other,15908213.0,
794,251221,3,10,,103163782,89594,Unspecified,1351848.0,1137.0,,,Percent response relative to 10 uM nicotine in human Nicotinic acetylcholine receptor alpha4-beta2,Other,15908213.0,
795,252065,6,8,,103163782,89594,Inconclusive,113105.0,1141.0,,,Percent inhibition of 10 uM nicotine response by human Nicotinic acetylcholine receptor alpha4-beta2; (-)=not determined,Other,15908213.0,
796,252065,6,8,,103163782,89594,Inconclusive,1351848.0,1137.0,,,Percent inhibition of 10 uM nicotine response by human Nicotinic acetylcholine receptor alpha4-beta2; (-)=not determined,Other,15908213.0,
797,254461,8,5,,103163782,89594,Active,2851491.0,170945.0,0.012,Ki,In vitro binding affinity towards rat Nicotinic acetylcholine receptor alpha2-beta2 using 0.5 nM [3H]epibatidine,Confirmatory,16039849.0,
798,254461,8,5,,103163782,89594,Active,6226548.0,54239.0,0.012,Ki,In vitro binding affinity towards rat Nicotinic acetylcholine receptor alpha2-beta2 using 0.5 nM [3H]epibatidine,Confirmatory,16039849.0,
799,254462,8,5,,103163782,89594,Active,113111.0,25103.0,0.11,Ki,In vitro binding affinity towards rat Nicotinic acetylcholine receptor alpha2-beta4 using 0.5 nM [3H]epibatidine,Confirmatory,16039849.0,
800,254462,8,5,,103163782,89594,Active,2851491.0,170945.0,0.11,Ki,In vitro binding affinity towards rat Nicotinic acetylcholine receptor alpha2-beta4 using 0.5 nM [3H]epibatidine,Confirmatory,16039849.0,
801,254463,8,5,,103163782,89594,Active,113061.0,25101.0,0.047,Ki,In vitro binding affinity towards rat Nicotinic acetylcholine receptor alpha3-beta2 using 0.5 nM [3H]epibatidine,Confirmatory,16039849.0,
802,254463,8,5,,103163782,89594,Active,6226548.0,54239.0,0.047,Ki,In vitro binding affinity towards rat Nicotinic acetylcholine receptor alpha3-beta2 using 0.5 nM [3H]epibatidine,Confirmatory,16039849.0,
803,254464,8,5,,103163782,89594,Active,113061.0,25101.0,0.44,Ki,In vitro binding affinity towards rat Nicotinic acetylcholine receptor alpha3-beta4 using 0.5 nM [3H]epibatidine,Confirmatory,16039849.0,
804,254464,8,5,,103163782,89594,Active,113111.0,25103.0,0.44,Ki,In vitro binding affinity towards rat Nicotinic acetylcholine receptor alpha3-beta4 using 0.5 nM [3H]epibatidine,Confirmatory,16039849.0,
805,254465,8,5,,103163782,89594,Active,6226548.0,54239.0,0.01,Ki,In vitro binding affinity towards rat Nicotinic acetylcholine receptor alpha4-beta2 using 0.5 nM [3H]epibatidine,Confirmatory,16039849.0,
806,254465,8,5,,103163782,89594,Active,8469182.0,25590.0,0.01,Ki,In vitro binding affinity towards rat Nicotinic acetylcholine receptor alpha4-beta2 using 0.5 nM [3H]epibatidine,Confirmatory,16039849.0,
807,254466,8,5,,103163782,89594,Active,113111.0,25103.0,0.04,Ki,In vitro binding affinity towards rat Nicotinic acetylcholine receptor alpha4-beta4 using 0.5 nM [3H]epibatidine,Confirmatory,16039849.0,
808,254466,8,5,,103163782,89594,Active,8469182.0,25590.0,0.04,Ki,In vitro binding affinity towards rat Nicotinic acetylcholine receptor alpha4-beta4 using 0.5 nM [3H]epibatidine,Confirmatory,16039849.0,
809,254476,8,5,,103163782,89594,Active,113105.0,1141.0,0.0016,Ki,Binding affinity for human Nicotinic acetylcholine receptor alpha4-beta2 expressed in HEK 293 cells using [3H]nicotine,Confirmatory,16171993.0,
810,254476,8,5,,103163782,89594,Active,1351848.0,1137.0,0.0016,Ki,Binding affinity for human Nicotinic acetylcholine receptor alpha4-beta2 expressed in HEK 293 cells using [3H]nicotine,Confirmatory,16171993.0,
811,254478,8,5,,103163782,89594,Active,2506129.0,1143.0,0.53,Ki,Binding affinity to human Nicotinic acetylcholine receptor alpha3-beta4 expressed in IMR32 cells using [3H]epibatidine,Confirmatory,16171993.0,
812,254478,8,5,,103163782,89594,Active,254763435.0,1136.0,0.53,Ki,Binding affinity to human Nicotinic acetylcholine receptor alpha3-beta4 expressed in IMR32 cells using [3H]epibatidine,Confirmatory,16171993.0,
813,254483,8,5,,103163782,89594,Active,6226548.0,54239.0,0.0018,Ki,Binding affinity for rat brain Nicotinic acetylcholine receptor alpha4-beta2 using [3H]S-(-)-nicotine,Confirmatory,16039854.0,
814,254483,8,5,,103163782,89594,Active,8469182.0,25590.0,0.0018,Ki,Binding affinity for rat brain Nicotinic acetylcholine receptor alpha4-beta2 using [3H]S-(-)-nicotine,Confirmatory,16039854.0,
815,254485,8,5,,103163782,89594,Active,2506127.0,1139.0,0.63,Ki,Binding affinity to human Nicotinic acetylcholine receptor alpha7 expressed in IMR32 cells using [3H]alpha-bungarotoxin,Confirmatory,16171993.0,
816,254522,8,5,,103163782,89594,Active,113071.0,1134.0,6.27,Ki,Binding affinity to human Nicotinic acetylcholine receptor alpha-1-beta-gamma-delta expressed in HEK 293 cells using [3H]alpha-bungarotoxin,Confirmatory,16171993.0,
817,254522,8,5,,103163782,89594,Active,543759.0,1144.0,6.27,Ki,Binding affinity to human Nicotinic acetylcholine receptor alpha-1-beta-gamma-delta expressed in HEK 293 cells using [3H]alpha-bungarotoxin,Confirmatory,16171993.0,
818,254522,8,5,,103163782,89594,Active,21903373.0,1140.0,6.27,Ki,Binding affinity to human Nicotinic acetylcholine receptor alpha-1-beta-gamma-delta expressed in HEK 293 cells using [3H]alpha-bungarotoxin,Confirmatory,16171993.0,
819,254522,8,5,,103163782,89594,Active,126302510.0,1146.0,6.27,Ki,Binding affinity to human Nicotinic acetylcholine receptor alpha-1-beta-gamma-delta expressed in HEK 293 cells using [3H]alpha-bungarotoxin,Confirmatory,16171993.0,
820,256206,3,10,,103163782,89594,Unspecified,113105.0,1141.0,,,Efficacy against human Nicotinic acetylcholine receptor alpha4-beta2 expressed in Xenopus oocytes at 10 uM relative to 10 uM nicotine,Other,16171993.0,
821,256206,3,10,,103163782,89594,Unspecified,1351848.0,1137.0,,,Efficacy against human Nicotinic acetylcholine receptor alpha4-beta2 expressed in Xenopus oocytes at 10 uM relative to 10 uM nicotine,Other,16171993.0,
822,256400,6,8,,103163782,89594,Inconclusive,113105.0,1141.0,,,Percent inhibition against 10 uM nicotine binding to human Nicotinic acetylcholine receptor alpha4-beta2 expressed in Xenopus oocytes at 10 uM; - = not determined,Other,16171993.0,
823,256400,6,8,,103163782,89594,Inconclusive,1351848.0,1137.0,,,Percent inhibition against 10 uM nicotine binding to human Nicotinic acetylcholine receptor alpha4-beta2 expressed in Xenopus oocytes at 10 uM; - = not determined,Other,16171993.0,
824,256414,3,10,,103163782,89594,Unspecified,113061.0,25101.0,,,Agonistic activity as [86Rb+] efflux from KXalpha-3-beta-4R2 cells expressing rat Nicotinic acetylcholine receptor at 100 uM,Other,16039849.0,
825,256414,3,10,,103163782,89594,Unspecified,113111.0,25103.0,,,Agonistic activity as [86Rb+] efflux from KXalpha-3-beta-4R2 cells expressing rat Nicotinic acetylcholine receptor at 100 uM,Other,16039849.0,
826,263014,3,3,,103163782,89594,Unspecified,,,,,"Analgesic activity in mice at 10 mg/kg, sc by acetic acid writhing test",Other,16412637.0,
827,263015,3,3,,103163782,89594,Unspecified,,,,,"Analgesic activity in mice at 5 mg/kg, sc by acetic acid writhing test",Other,16412637.0,
828,263016,3,3,,103163782,89594,Unspecified,,,,,"Toxicity in rat at 20 mg/kg, sc assessed as rate of death",Other,16412637.0,
829,263017,3,3,,103163782,89594,Unspecified,,,,,"Toxicity in rat at 10 mg/kg, sc assessed as rate of death",Other,16412637.0,
830,263018,3,3,,103163782,89594,Unspecified,,,,,"Toxicity in rat at 5 mg/kg, sc assessed as rate of death",Other,16412637.0,
831,264242,7,6,,103163782,89594,Active,113061.0,25101.0,35.0,EC50,Agonist activity at rat alpha3beta4 nACHR expressed in human HEK293 cells by rubidium efflux assay,Confirmatory,16640326.0,
832,264242,7,6,,103163782,89594,Active,113111.0,25103.0,35.0,EC50,Agonist activity at rat alpha3beta4 nACHR expressed in human HEK293 cells by rubidium efflux assay,Confirmatory,16640326.0,
833,264243,3,11,,103163782,89594,Unspecified,113061.0,25101.0,,,Efficacy at rat alpha3beta4 nACHR expressed in human HEK293 cells by rubidium efflux assay relative to nicotine,Other,16640326.0,
834,264243,3,11,,103163782,89594,Unspecified,113111.0,25103.0,,,Efficacy at rat alpha3beta4 nACHR expressed in human HEK293 cells by rubidium efflux assay relative to nicotine,Other,16640326.0,
835,264244,7,6,,103163782,89594,Active,6226548.0,54239.0,10.0,EC50,Agonist activity at rat alpha-4-beta-2 nACHR by rubidium efflux assay,Confirmatory,16640326.0,
836,264244,7,6,,103163782,89594,Active,8469182.0,25590.0,10.0,EC50,Agonist activity at rat alpha-4-beta-2 nACHR by rubidium efflux assay,Confirmatory,16640326.0,
837,264245,3,10,,103163782,89594,Unspecified,6226548.0,54239.0,,,Efficacy at rat alpha4beta2 nACHR by rubidium efflux assay,Other,16640326.0,
838,264245,3,10,,103163782,89594,Unspecified,8469182.0,25590.0,,,Efficacy at rat alpha4beta2 nACHR by rubidium efflux assay,Other,16640326.0,
839,265641,8,5,,103163782,89594,Active,6226548.0,54239.0,0.0015,Ki,Displacement of [3H]epibatidine from alpha-4-beta-2 nACHR in rat cerebral cortex,Confirmatory,16722642.0,
840,265641,8,5,,103163782,89594,Active,8469182.0,25590.0,0.0015,Ki,Displacement of [3H]epibatidine from alpha-4-beta-2 nACHR in rat cerebral cortex,Confirmatory,16722642.0,
841,265642,7,2,,103163782,89594,Unspecified,,,,,Antinociceptive activity in mouse by tail flick assay,Other,16722642.0,
842,265646,7,2,,103163782,89594,Unspecified,,,,,Antinociceptive activity in sc dosed mouse by hot plate assay after 5 mins,Other,16722642.0,
843,265650,7,2,,103163782,89594,Unspecified,,,,,Hypothermia in mouse,Other,16722642.0,
844,265653,7,2,,103163782,89594,Unspecified,,,,,Spontaneous activity in mouse,Other,16722642.0,
845,265665,3,3,,103163782,89594,Unspecified,,,,,Agonist activity on nicotine discrimination in rat at 0.4 mg/kg by lever press assay,Other,16722642.0,
846,266760,6,1,,103163782,89594,Unspecified,,,,,Permeability coefficient in silicon membrane using diffusion cells,Other,16789751.0,
847,266761,7,1,,103163782,89594,Unspecified,,,,,Effective permeability coefficient in 100% silicon membrane,Other,16789751.0,
848,266762,6,1,,103163782,89594,Unspecified,,,,,Effective permeability coefficient in 100% IPM membrane,Other,16789751.0,
849,266763,4,1,,103163782,89594,Unspecified,,,,,Membrane retention in 70% silicon-30% IPM membrane,Other,16789751.0,
850,266764,3,3,,103163782,89594,Unspecified,,,,,"Membrane permeability, CA(t)/CD(0) in 70% silicon-30% IPM membrane",Other,16789751.0,
851,266765,6,1,,103163782,89594,Unspecified,,,,,Effective permeability coefficient in 70% silicon-30% IPM membrane,Other,16789751.0,
852,266766,3,3,,103163782,89594,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,16789751.0,
853,266767,3,3,,103163782,89594,Unspecified,,,,,Membrane retention in 100% silicon membrane,Other,16789751.0,
854,266768,3,3,,103163782,89594,Unspecified,,,,,"Membrane permeability, CA(t)/CD(0) in 100% silicon membrane",Other,16789751.0,
855,266769,3,3,,103163782,89594,Unspecified,,,,,Membrane retention in 100% IPM membrane,Other,16789751.0,
856,266770,3,3,,103163782,89594,Unspecified,,,,,"Membrane permeability, CA(t)/CD(0) in 100% IPM membrane",Other,16789751.0,
857,266771,6,1,,103163782,89594,Unspecified,,,,,Permeability in human skin,Other,16789751.0,
858,269973,9,5,,103163782,89594,Active,146345356.0,25302.0,0.75,Ki,Displacement of [125I]iodo-MLA from alpha-7 nAChR in rat cerebral cortex,Confirmatory,16765047.0,
859,276314,9,5,,103163782,89594,Active,146345356.0,25302.0,0.23399999999999999,Ki,Displacement of [3H]alpha-Bungarotoxin from alpha-7 nAChR in rat brain cortex membranes,Confirmatory,16942873.0,
860,276315,10,5,,103163782,89594,Active,6226548.0,54239.0,0.004,Ki,Displacement of [3H]epibatidine from alpha-4-beta-2 nAChR in rat brain cortex membrane,Confirmatory,16942873.0,
861,276315,10,5,,103163782,89594,Active,8469182.0,25590.0,0.004,Ki,Displacement of [3H]epibatidine from alpha-4-beta-2 nAChR in rat brain cortex membrane,Confirmatory,16942873.0,
862,282345,9,2,,103163782,89594,Active,2506129.0,1143.0,19.83,EC50,Agonist activity at alpha-3-beta-4 nAChR in KXalpha-3-beta-4R2 cells by rubidium efflux assay,Confirmatory,15615518.0,
863,282345,9,2,,103163782,89594,Active,254763435.0,1136.0,19.83,EC50,Agonist activity at alpha-3-beta-4 nAChR in KXalpha-3-beta-4R2 cells by rubidium efflux assay,Confirmatory,15615518.0,
864,282346,4,10,,103163782,89594,Unspecified,2506129.0,1143.0,,,Agonist activity at alpha-3-beta-4 nAChR in KXalpha-3-beta-4R2 cells by rubidium efflux assay relative to nicotine,Other,15615518.0,
865,282346,4,10,,103163782,89594,Unspecified,254763435.0,1136.0,,,Agonist activity at alpha-3-beta-4 nAChR in KXalpha-3-beta-4R2 cells by rubidium efflux assay relative to nicotine,Other,15615518.0,
866,282347,3,10,,103163782,89594,Unspecified,2506129.0,1143.0,,,Displacement of [3H]epibatidine from alpha-3-beta-4 nAChR immobilized on liquid chromatographic stationary phases,Other,15615518.0,
867,282347,3,10,,103163782,89594,Unspecified,254763435.0,1136.0,,,Displacement of [3H]epibatidine from alpha-3-beta-4 nAChR immobilized on liquid chromatographic stationary phases,Other,15615518.0,
868,282348,3,10,,103163782,89594,Unspecified,113105.0,1141.0,,,Displacement of [3H]epibatidine from alpha-4-beta-2 nAChR immobilized on liquid chromatographic stationary phases,Other,15615518.0,
869,282348,3,10,,103163782,89594,Unspecified,1351848.0,1137.0,,,Displacement of [3H]epibatidine from alpha-4-beta-2 nAChR immobilized on liquid chromatographic stationary phases,Other,15615518.0,
870,291933,9,1,,103163782,89594,Active,6226548.0,54239.0,0.000933,Ki,Displacement of [3H]cytisine from alpha-4-beta-2 in rat cerebral cortical membrane,Confirmatory,17585748.0,
871,291933,9,1,,103163782,89594,Active,8469182.0,25590.0,0.000933,Ki,Displacement of [3H]cytisine from alpha-4-beta-2 in rat cerebral cortical membrane,Confirmatory,17585748.0,
872,291934,8,1,,103163782,89594,Active,113105.0,1141.0,9.33254,EC50,Agonist activity at alpha-4-beta-2 in IMR-32cells assessed as calcium influx by FLIPR assay,Confirmatory,17585748.0,
873,291934,8,1,,103163782,89594,Active,1351848.0,1137.0,9.33254,EC50,Agonist activity at alpha-4-beta-2 in IMR-32cells assessed as calcium influx by FLIPR assay,Confirmatory,17585748.0,
874,291935,5,1,,103163782,89594,Active,,,0.19952999999999999,EC50,Agonist activity at rat striatal tissue assessed as dopamine release,Confirmatory,17585748.0,
875,297961,13,2,,103163782,89594,Active,6226548.0,54239.0,0.0062,Ki,Displacement of [3H]epibatidine from rat recombinant alpha-4-beta-2 nAChR in HEK293 cell line,Confirmatory,17722904.0,
876,297961,13,2,,103163782,89594,Active,8469182.0,25590.0,0.0062,Ki,Displacement of [3H]epibatidine from rat recombinant alpha-4-beta-2 nAChR in HEK293 cell line,Confirmatory,17722904.0,
877,297962,12,2,,103163782,89594,Active,113061.0,25101.0,0.22,Ki,Displacement of [3H]epibatidine from recombinant rat alpha-3-beta-4 nAChr in HEK293 cell line,Confirmatory,17722904.0,
878,297962,12,2,,103163782,89594,Active,113111.0,25103.0,0.22,Ki,Displacement of [3H]epibatidine from recombinant rat alpha-3-beta-4 nAChr in HEK293 cell line,Confirmatory,17722904.0,
879,297963,13,2,,103163782,89594,Active,113111.0,25103.0,0.033,Ki,Displacement of [3H]epibatidine from recombinant rat alpha-4-beta-4 nAChr in HEK293 cell line,Confirmatory,17722904.0,
880,297963,13,2,,103163782,89594,Active,8469182.0,25590.0,0.033,Ki,Displacement of [3H]epibatidine from recombinant rat alpha-4-beta-4 nAChr in HEK293 cell line,Confirmatory,17722904.0,
881,297964,11,2,,103163782,89594,Active,2506127.0,1139.0,24.0,Ki,Displacement of [3H]methyllycaconitine from human alpha-7 in tsA201 cells coexpressed with 5HT3A receptor,Confirmatory,17722904.0,
882,297965,11,2,,103163782,89594,Active,2506127.0,1139.0,12.0,Ki,Displacement of [3H]methyllycaconitine from alpha7 nAChR in tsA201 cells co-expressed with Ric3,Confirmatory,17722904.0,
883,297966,11,2,,103163782,89594,Inconclusive,1168222.0,3359.0,,Ki,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,Confirmatory,17722904.0,
884,298244,8,5,,103163782,89594,Active,6226548.0,54239.0,0.0068,Ki,Displacement of [3H]cytisine from alpha-4-beta-2 nAChR in rat cerebral cortex,Confirmatory,17850058.0,
885,298244,8,5,,103163782,89594,Active,8469182.0,25590.0,0.0068,Ki,Displacement of [3H]cytisine from alpha-4-beta-2 nAChR in rat cerebral cortex,Confirmatory,17850058.0,
886,298245,8,5,,103163782,89594,Active,6226548.0,54239.0,0.003,Ki,Displacement of [3H]epibatidine from alpha-4-beta-2 nAChR in rat cerebral cortex,Confirmatory,17850058.0,
887,298245,8,5,,103163782,89594,Active,8469182.0,25590.0,0.003,Ki,Displacement of [3H]epibatidine from alpha-4-beta-2 nAChR in rat cerebral cortex,Confirmatory,17850058.0,
888,298246,8,5,,103163782,89594,Active,146345356.0,25302.0,0.45,Ki,Displacement of [3H]alpha-bungarotoxin from alpha-7 nAChR in rat cerebral cortex,Confirmatory,17850058.0,
889,302772,5,1,,103163782,89594,Active,,,0.001,Ki,Displacement of [3H]cytisine from neuronal nicotinic acetylcholine receptor in rat brain membrane,Confirmatory,17929796.0,
890,302773,8,1,,103163782,89594,Active,113105.0,1141.0,6.6,EC50,Agonist activity at recombinant human alpha-4-beta-2 nAChR expressed in HEK293 cells assessed as induction of calcium influx by FLIPR assay,Confirmatory,17929796.0,
891,302773,8,1,,103163782,89594,Active,1351848.0,1137.0,6.6,EC50,Agonist activity at recombinant human alpha-4-beta-2 nAChR expressed in HEK293 cells assessed as induction of calcium influx by FLIPR assay,Confirmatory,17929796.0,
892,302774,8,1,,103163782,89594,Active,2506129.0,1143.0,8.0,EC50,Agonist activity at recombinant human alpha-3-beta-4 nAChR expressed in HEK293 cells assessed as induction of calcium influx by FLIPR assay,Confirmatory,17929796.0,
893,302774,8,1,,103163782,89594,Active,254763435.0,1136.0,8.0,EC50,Agonist activity at recombinant human alpha-3-beta-4 nAChR expressed in HEK293 cells assessed as induction of calcium influx by FLIPR assay,Confirmatory,17929796.0,
894,302775,3,11,,103163782,89594,Unspecified,113105.0,1141.0,,,Agonist activity at recombinant human alpha-4-beta-2 nAChR expressed in HEK293 cells assessed as induction of calcium influx by FLIPR assay relative to nicotine,Other,17929796.0,
895,302775,3,11,,103163782,89594,Unspecified,1351848.0,1137.0,,,Agonist activity at recombinant human alpha-4-beta-2 nAChR expressed in HEK293 cells assessed as induction of calcium influx by FLIPR assay relative to nicotine,Other,17929796.0,
896,302776,3,11,,103163782,89594,Unspecified,2506129.0,1143.0,,,Agonist activity at recombinant human alpha3beta4 nAChR expressed in HEK293 cells assessed as induction of calcium influx by FLIPR assay relative to nicotine,Other,17929796.0,
897,302776,3,11,,103163782,89594,Unspecified,254763435.0,1136.0,,,Agonist activity at recombinant human alpha3beta4 nAChR expressed in HEK293 cells assessed as induction of calcium influx by FLIPR assay relative to nicotine,Other,17929796.0,
898,304128,8,5,,103163782,89594,Active,113105.0,1141.0,0.0015,Ki,Displacement of [3H]epibatidine from alpha-4-beta-2 nAChR,Confirmatory,17994682.0,
899,304128,8,5,,103163782,89594,Active,1351848.0,1137.0,0.0015,Ki,Displacement of [3H]epibatidine from alpha-4-beta-2 nAChR,Confirmatory,17994682.0,
900,310931,3,4,,103163782,89594,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,17300161.0,
901,310932,3,6,,103163782,89594,Unspecified,,,,,Permeability across human Skin,Other,17300161.0,
902,310933,3,4,,103163782,89594,Unspecified,,,,,Permeability across PAMPA membrane after 7 hrs,Other,17300161.0,
903,311367,3,6,,103163782,89594,Unspecified,,,,,Permeability coefficient in human skin,Other,17827020.0,
904,315940,8,5,,103163782,89594,Active,6226548.0,54239.0,0.006999999999999999,Ki,Displacement of [3H]cytisine from alpha-4-beta-2 nAChR in rat brain membrane,Confirmatory,18006307.0,
905,315940,8,5,,103163782,89594,Active,8469182.0,25590.0,0.006999999999999999,Ki,Displacement of [3H]cytisine from alpha-4-beta-2 nAChR in rat brain membrane,Confirmatory,18006307.0,
906,317438,7,6,,103163782,89594,Active,146345356.0,25302.0,1.5,EC50,Agonist activity at rat alpha-7 nAChR expressed in GH4C1-F7 cells assessed as effect on calcium influx by FLIPR,Confirmatory,18078760.0,
907,318725,4,3,,103163782,89594,Active,,,0.415,Ki,Displacement of [3H]ACE from Aplysia AChBP expressed in HEK293S cells by scintillation proximity assay,Confirmatory,17485662.0,
908,318726,4,3,,103163782,89594,Active,,,0.26,Ki,Displacement of [3H]EPI from Aplysia AChBP expressed in HEK293S cells by scintillation proximity assay,Confirmatory,17485662.0,
909,320061,8,5,,103163782,89594,Active,6226548.0,54239.0,0.004,Ki,Displacement of [3H]cystisine from nicotinic alpha-4-beta-2 receptor in rat brain,Confirmatory,18262785.0,
910,320061,8,5,,103163782,89594,Active,8469182.0,25590.0,0.004,Ki,Displacement of [3H]cystisine from nicotinic alpha-4-beta-2 receptor in rat brain,Confirmatory,18262785.0,
911,320062,8,5,,103163782,89594,Active,146345356.0,25302.0,1.5,Ki,Displacement of [3H]alpha-bungaro-toxine from nicotinic alpha-7 receptor in rat brain,Confirmatory,18262785.0,
912,320063,4,3,,103163782,89594,Unspecified,,,10.0,Ki,Displacement of [3H]oxotremorine from muscarinic receptor in rat brain,Confirmatory,18262785.0,
913,322331,9,5,,103163782,89594,Active,6226548.0,54239.0,0.0015,Ki,Displacement of [3H]epibatidine from alpha-4-beta-2 nAChR in rat cerebral cortex,Confirmatory,17964169.0,
914,322331,9,5,,103163782,89594,Active,8469182.0,25590.0,0.0015,Ki,Displacement of [3H]epibatidine from alpha-4-beta-2 nAChR in rat cerebral cortex,Confirmatory,17964169.0,
915,322332,8,5,,103163782,89594,Active,146345356.0,25302.0,0.67,Ki,Displacement of [125I]iodoMLA from alpha-7 nAChR in rat cerebral cortex,Confirmatory,17964169.0,
916,322334,6,2,,103163782,89594,Unspecified,,,,,Antinociceptive activity in sc dosed acute pain mouse model by tail flick method,Other,17964169.0,
917,322339,6,2,,103163782,89594,Unspecified,,,,,Antinociceptive activity in sc dosed in acute pain mouse model by hot plate method,Other,17964169.0,
918,322347,6,2,,103163782,89594,Unspecified,,,,,Antinociceptive activity in sc dosed mouse assessed as inhibition of nicotin induced hypothermia,Other,17964169.0,
919,322358,6,2,,103163782,89594,Unspecified,,,,,Effect on locomotor activity in sc dosed mouse assessed as spontaneous activity,Other,17964169.0,
920,338152,4,4,,103163782,89594,Active,,,0.0009,Ki,Displacement of [3H]NMCI from nicotinic acetylcholine receptor,Confirmatory,8496700.0,
921,338189,3,4,,103163782,89594,Unspecified,,,,,Displacement of [3H]NMCI from nicotinic acetylcholine receptor assessed as specific binding relative to total binding,Other,8496700.0,
922,346667,12,2,,103163782,89594,Active,8469182.0,25590.0,0.022000000000000002,Ki,Displacement of [3H]epibatidine from rat recombinant alpha4beta2 nAChR expressed in HEK293 cells,Confirmatory,18989912.0,
923,346668,12,2,,103163782,89594,Active,113061.0,25101.0,0.6,Ki,Displacement of [3H]epibatidine from rat recombinant alpha-3-beta-4 nAChR expressed in HEK293 cells,Confirmatory,18989912.0,
924,346669,12,2,,103163782,89594,Active,8469182.0,25590.0,0.15,Ki,Displacement of [3H]epibatidine from rat recombinant alpha-4-beta-4 nAChR expressed in HEK293 cells,Confirmatory,18989912.0,
925,346670,12,2,,103163782,89594,Active,,,16.0,Ki,Displacement of [3H]MLA from rat alpha-7 nAChR/mouse 5HT3A chimera expressed in human tsA-201 cells,Confirmatory,18989912.0,
926,350216,3,3,,103163782,89594,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,19397318.0,
927,350218,3,4,,103163782,89594,Unspecified,,,,,"Octanol-water partition coefficient, log PC of the compound",Other,19397318.0,
928,350219,3,4,,103163782,89594,Unspecified,,,,,"Lipophilicity, log K at pH 2 by by hydrophilic interaction chromatography using 95% acetonitrile as mobile phase",Other,19397318.0,
929,350220,3,4,,103163782,89594,Unspecified,,,,,"Lipophilicity, log K at pH 2 by by hydrophilic interaction chromatography using 100% water as mobile phase",Other,19397318.0,
930,370943,10,5,,103163782,89594,Active,8469182.0,25590.0,0.004,Ki,Displacement of [3H]epibatidine from alpha-4-beta-2 nAchR in rat brain cortex membrane,Confirmatory,19097783.0,
931,370944,9,5,,103163782,89594,Active,146345356.0,25302.0,0.23399999999999999,Ki,Displacement of [125I]alpha-Bungarotoxin from alpha-7 nAchR in rat brain cortex membrane,Confirmatory,19097783.0,
932,386623,4,8,,103163782,89594,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
933,392051,8,5,,103163782,89594,Unspecified,7531135.0,3757.0,245.47099999999998,IC50,Inhibition of human ERG channel in HEK293 cells by voltage-clamp method,Confirmatory,18262683.0,
934,395325,3,3,,103163782,89594,Unspecified,,,,,"Lipophilicity, log P by microemulsion electrokinetic chromatography",Other,19256501.0,
935,395328,3,3,,103163782,89594,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,19256501.0,
936,397743,11,2,,103163782,89594,Unspecified,7531135.0,3757.0,244.3,IC50,Inhibition of human ERG channel,Confirmatory,19534531.0,
937,397989,8,5,,103163782,89594,Active,8469182.0,25590.0,0.0009400000000000001,Ki,Displacement of [3H]cytisine from alpha4beta2 nicotinic acetylcholine receptor in rat brain minus cerebellum membrane,Confirmatory,19552432.0,
938,397990,8,5,,103163782,89594,Active,146345356.0,25302.0,0.17600000000000002,Ki,Displacement of [3H]A585539 from alpha7 nicotinic acetylcholine receptor in rat brain minus cerebellum membrane,Confirmatory,19552432.0,
939,397991,3,3,,103163782,89594,Unspecified,,,,,Selectivity ratio of Ki for alpha7 nicotinic acetylcholine receptor to Ki for alpha4beta2 nicotinic acetylcholine receptor in rat brain minus cerebellum membrane,Other,19552432.0,
940,397992,7,6,,103163782,89594,Active,1351848.0,1137.0,6.6,EC50,Agonist activity at human recombinant alpha4beta2 nicotinic acetylcholine receptor expressed in HEK293 cells assessed as changes in intracellular calcium level by FLIPR,Confirmatory,19552432.0,
941,397994,7,6,,103163782,89594,Unspecified,2506127.0,1139.0,91.0,EC50,Agonist activity at human recombinant alpha7 nicotinic acetylcholine receptor expressed in xenopus laevis oocytes by parallel oocyte electrophysiological assay,Confirmatory,19552432.0,
942,404304,3,10,,103163782,89594,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
943,408340,8,5,,103163782,89594,Unspecified,7531135.0,3757.0,245.47099999999998,IC50,Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique,Confirmatory,18448342.0,
944,415528,8,5,,103163782,89594,Active,14285341.0,,0.0631,Ki,Displacement of [125I]alpha-bungarotoxin from Lymnaea stagnalis His-tagged AchBP,Confirmatory,19331415.0,
945,415530,8,5,,103163782,89594,Active,2506127.0,1139.0,1.0,Ki,Displacement of [125I]alpha-bungarotoxin from human alpha7 nAChR expressed in human SH-SY5Y cells,Confirmatory,19331415.0,
946,415531,5,2,,103163782,89594,Active,,,0.39810999999999996,Ki,Displacement of [3H]epibatidine from Aplysia californica AchBP,Confirmatory,19331415.0,
947,417950,8,5,,103163782,89594,Active,8469182.0,25590.0,0.0009400000000000001,Ki,Displacement of [3H]cytisine from alpha4beta2 nAChR in rat brain membrane,Confirmatory,19232492.0,
948,417951,7,6,,103163782,89594,Active,1351848.0,1137.0,4.7,EC50,Agonist activity at human recombinant alpha4beta2 nAChR expressed in human IMR32 cells assessed as calcium dynamics by FLIPR assay,Confirmatory,19232492.0,
949,417953,7,6,,103163782,89594,Active,254763435.0,1136.0,9.4,EC50,Agonist activity at human recombinant alpha3beta4 nAChR expressed in human IMR32 cells assessed as calcium dynamics by FLIPR assay,Confirmatory,19232492.0,
950,418232,6,6,,103163782,89594,Unspecified,2506127.0,1139.0,,EC50,Agonist activity at human recombinant alpha7 nAChR expressed in rat GH3 cells by calcium influx assay,Confirmatory,19208472.0,
951,420670,5,7,,103163782,89594,Unspecified,117196.0,13087.0,159.95600000000002,IC50,Inhibition of mouse CYP2A5,Confirmatory,19110342.0,
952,420671,5,7,,103163782,89594,Unspecified,308153612.0,1548.0,579.429,IC50,Inhibition of human CYP2A6,Confirmatory,19110342.0,
953,425652,7,2,,103163782,89594,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
954,425653,7,2,,103163782,89594,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
955,427648,8,5,,103163782,89594,Active,2851491.0,170945.0,0.012,Ki,Displacement of [3H]epibatidine from rat alpha2beta2 nicotinic receptor expressed in human HEK293 cells by liquid scintillation counting,Confirmatory,19481945.0,
956,427649,8,5,,103163782,89594,Active,2851491.0,170945.0,0.11,Ki,Displacement of [3H]epibatidine from rat alpha2beta4 nicotinic receptor expressed in human HEK293 cells by liquid scintillation counting,Confirmatory,19481945.0,
957,427650,8,5,,103163782,89594,Active,113061.0,25101.0,0.047,Ki,Displacement of [3H]epibatidine from rat alpha3beta2 nicotinic receptor expressed in human HEK293 cells by liquid scintillation counting,Confirmatory,19481945.0,
958,427651,8,5,,103163782,89594,Active,113061.0,25101.0,0.44,Ki,Displacement of [3H]epibatidine from rat alpha3beta4 nicotinic receptor expressed in human HEK293 cells by liquid scintillation counting,Confirmatory,19481945.0,
959,427652,8,5,,103163782,89594,Active,8469182.0,25590.0,0.01,Ki,Displacement of [3H]epibatidine from rat alpha4beta2 nicotinic receptor expressed in human HEK293 cells by liquid scintillation counting,Confirmatory,19481945.0,
960,427654,8,5,,103163782,89594,Active,8469182.0,25590.0,0.04,Ki,Displacement of [3H]epibatidine from rat alpha4beta4 nicotinic receptor expressed in human HEK293 cells by liquid scintillation counting,Confirmatory,19481945.0,
961,427655,3,3,,103163782,89594,Unspecified,,,,,Selectivity ratio of Ki for rat alpha3beta4 nicotinic receptor to Ki for rat alpha4beta2 nicotinic receptor,Other,19481945.0,
962,431142,8,5,,103163782,89594,Active,8469182.0,25590.0,0.00165,IC50,Displacement of L-[3H]Nicotine from alpha4beta2 nAChR in rat brain homogenate by rapid filtration method,Confirmatory,19576766.0,
963,434955,1,2,,56314824,89594,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
964,434959,1,1,,85788514,89594,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
965,434962,1,2,,56314824,89594,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
966,434973,1,3,,56314824,89594,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
967,434989,1,1,,56314824,89594,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
968,435003,1,3,,56314824,89594,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
969,435005,1,1,,56314824,89594,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
970,435022,2,2,,56314824,89594,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
971,435030,1,2,,56314824,89594,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
972,435030,1,2,,56314824,89594,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
973,444050,7,1,,103163782,89594,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
974,444051,6,2,,103163782,89594,Unspecified,,,,,Total clearance in human,Other,20070106.0,
975,444052,6,2,,103163782,89594,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
976,444053,6,2,,103163782,89594,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
977,444054,6,1,,103163782,89594,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
978,444055,3,3,,103163782,89594,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
979,444056,3,3,,103163782,89594,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
980,444057,3,3,,103163782,89594,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
981,444058,6,2,,103163782,89594,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
982,449728,1,2,,56314824,89594,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
983,449762,1,2,,56314824,89594,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
984,449763,1,3,,56314824,89594,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
985,455986,3,5,,103163782,89594,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
986,459740,5,2,,103163782,89594,Active,,,0.33,Ki,Displacement of [3H]MLA from alpha7 nAChR in rat brain homogenate by liquid scintillation spectrophotometry,Confirmatory,20036131.0,
987,459741,7,1,,103163782,89594,Active,6226548.0,54239.0,0.0014,Ki,Displacement of [3H]nicotine from alpha4beta2 nAChR in rat brain homogenate by liquid scintillation spectrophotometry,Confirmatory,20036131.0,
988,459741,7,1,,103163782,89594,Active,8469182.0,25590.0,0.0014,Ki,Displacement of [3H]nicotine from alpha4beta2 nAChR in rat brain homogenate by liquid scintillation spectrophotometry,Confirmatory,20036131.0,
989,463079,1,2,,56314824,89594,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
990,463082,1,1,,56314824,89594,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
991,463104,1,2,,56314824,89594,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
992,463106,1,2,,90341453,89594,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
993,463111,1,1,,56314824,89594,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
994,463141,1,2,,56314824,89594,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
995,463165,1,1,,56314824,89594,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
996,463190,1,2,,56314824,89594,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
997,463195,1,2,,56314824,89594,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
998,463210,1,2,,56314824,89594,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
999,463212,1,1,,56314824,89594,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
1000,463254,1,1,,56314824,89594,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1001,464230,8,5,,103163782,89594,Active,6226548.0,54239.0,0.0015,Ki,Displacement of [3H]epibatidine from alpha4beta2 nAChR in rat cerebral cortex after 4 hrs by scintillation counting,Confirmatory,20038125.0,
1002,464230,8,5,,103163782,89594,Active,8469182.0,25590.0,0.0015,Ki,Displacement of [3H]epibatidine from alpha4beta2 nAChR in rat cerebral cortex after 4 hrs by scintillation counting,Confirmatory,20038125.0,
1003,464232,6,2,,103163782,89594,Unspecified,,,,,Antinociceptive activity in sc dosed mouse after 5 mins by tail flick test,Other,20038125.0,
1004,464234,6,2,,103163782,89594,Unspecified,,,,,Antinociceptive activity in sc dosed mouse assessed as reaction time taken to jump or lick paw after 5 mins by hot plate test,Other,20038125.0,
1005,464236,6,2,,103163782,89594,Unspecified,,,,,Effect on rectal body temperature in sc dosed mouse assessed as change in temperature after 30 mins by inducible hypothermia test,Other,20038125.0,
1006,464237,8,1,,103163782,89594,Unspecified,,,,,Effect on locomotory activity in sc dosed mouse assessed as change in spontaneous activity after 5 mins by photocell interruption readings,Other,20038125.0,
1007,482142,8,2,,103163782,89594,Active,,,17.0,EC50,Activation of TRPA1 channel,Confirmatory,20356305.0,
1008,485270,1,1,,56314824,89594,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1009,485272,1,1,,56314824,89594,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
1010,485273,2,1,,56314824,89594,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
1011,485275,1,3,,56314824,89594,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
1012,485281,1,1,,26752744,89594,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1013,485281,1,1,,26752745,89594,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1014,485290,1,1,,17389805,89594,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1015,485290,1,1,,26752744,89594,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1016,485290,1,1,,26752745,89594,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1017,485290,1,1,,50105392,89594,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1018,485294,1,1,,56314824,89594,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
1019,485295,1,2,,90341453,89594,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
1020,485297,1,1,,56314824,89594,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1021,485297,1,1,,90341453,89594,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1022,485298,1,1,,56314824,89594,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1023,485298,1,1,,90341453,89594,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1024,485313,1,2,,56314824,89594,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1025,485313,1,2,,90341453,89594,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1026,485317,1,2,,56314824,89594,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
1027,485341,1,1,,56314824,89594,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
1028,485342,1,2,,90341453,89594,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1029,485344,1,1,,56314824,89594,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
1030,485345,1,2,,90341453,89594,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1031,485346,1,1,,56314824,89594,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1032,485346,1,1,,56314824,89594,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1033,485347,1,2,,56314824,89594,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
1034,485349,1,1,,56314824,89594,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
1035,485358,1,1,,56314824,89594,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
1036,485360,1,1,,56314824,89594,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
1037,485364,1,1,,56314824,89594,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
1038,485366,1,2,,90341453,89594,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1039,485367,1,2,,56314824,89594,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1040,485368,1,2,,90341453,89594,Inactive,72386991.0,3656265.0,,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1041,488772,1,1,,90341453,89594,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1042,488773,1,2,,90341453,89594,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1043,488816,1,1,,90341453,89594,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
1044,488837,1,1,,56314824,89594,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1045,488837,1,1,,90341453,89594,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1046,488839,1,1,,56314824,89594,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1047,488839,1,1,,56314824,89594,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1048,488847,1,3,,56314824,89594,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
1049,488862,1,1,,56314824,89594,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1050,488890,1,2,,56314824,89594,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
1051,488895,1,2,,56314824,89594,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1052,488896,1,1,,56314824,89594,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1053,488899,1,1,,56314824,89594,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1054,488922,1,2,,56314824,89594,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
1055,488949,1,2,,90341453,89594,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1056,488953,1,1,,90341453,89594,Inconclusive,187960037.0,10951.0,79.4328,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1057,488965,1,2,,56314824,89594,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1058,488966,1,1,,56314824,89594,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
1059,488975,1,2,,56314824,89594,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
1060,488977,1,2,,56314824,89594,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
1061,488978,1,1,,90341453,89594,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
1062,488981,1,1,,90341453,89594,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
1063,488982,1,1,,90341453,89594,Inconclusive,4503383.0,1812.0,0.1458,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
1064,488983,1,1,,90341453,89594,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
1065,489030,2,1,,56314824,89594,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
1066,489031,2,1,,56314824,89594,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
1067,492947,1,1,,56314824,89594,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1068,492953,1,1,,56314824,89594,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
1069,492956,1,1,,56314824,89594,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
1070,492972,1,1,,56314824,89594,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
1071,493005,1,1,,56314824,89594,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1072,493008,1,1,,56314824,89594,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1073,493008,1,1,,56314824,89594,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1074,493008,1,1,,56314824,89594,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1075,493008,1,1,,56314824,89594,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1076,493011,1,1,,56314824,89594,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1077,493012,1,1,,56314824,89594,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1078,493014,1,1,,56314824,89594,Inactive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1079,493036,1,2,,56314824,89594,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
1080,493056,1,1,,56314824,89594,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
1081,493084,1,1,,56314824,89594,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
1082,493087,1,1,,56314824,89594,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
1083,493091,1,1,,56314824,89594,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
1084,493098,1,1,,56314824,89594,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
1085,493106,1,1,,90341453,89594,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1086,493107,1,1,,90341453,89594,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1087,493131,1,1,,56314824,89594,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
1088,493153,1,1,,90341453,89594,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
1089,493153,1,1,,90341453,89594,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
1090,493160,1,1,,56314824,89594,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
1091,493164,1,2,,90341453,89594,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1092,493164,1,2,,90341453,89594,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1093,493164,1,2,,90341453,89594,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1094,493187,1,2,,56314824,89594,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
1095,493244,1,1,,56314824,89594,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1096,493244,1,1,,56314824,89594,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1097,493244,1,1,,56314824,89594,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1098,493244,1,1,,56314824,89594,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1099,495031,5,1,,103163782,89594,Active,,,0.00946,Ki,Displacement of [3H]epibatidine from alpha4beta2 nicotinic receptor expressed in human HEK293 cells,Confirmatory,20663668.0,
1100,495032,5,2,,103163782,89594,Active,,,1.48,Ki,Binding affinity to alpha-1-beta-gamma-delta nicotinic receptor,Confirmatory,20663668.0,
1101,495033,5,1,,103163782,89594,Active,,,0.39399999999999996,Ki,Displacement of [3H]epibatidine from alpha3beta4 nicotinic receptor expressed in human HEK293 cells,Confirmatory,20663668.0,
1102,495034,2,4,,103163782,89594,Active,,,0.168,Ki,Displacement of [3H]epibatidine from alpha6/4beta4 nicotinic receptor expressed in human HEK293 cells,Confirmatory,20663668.0,
1103,495035,5,1,,103163782,89594,Active,,,2.11,Ki,Displacement of [3H]epibatidine from alpha7 nicotinic receptor expressed in human HEK293 cells,Confirmatory,20663668.0,
1104,495036,2,6,,103163782,89594,Unspecified,,,,EC50,Agonist activity at alpha3beta4 nicotinic receptor expressed in human HEK cells assessed as intracellular calcium efflux by FLIPR,Confirmatory,20663668.0,
1105,496866,5,2,,103163782,89594,Unspecified,,,,,Anticonvulsant activity in po dosed mouse assessed as inhibition of MES-induced tonic seizures,Other,20356304.0,
1106,504326,1,2,,56314824,89594,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1107,504326,1,2,,56314824,89594,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1108,504327,1,1,,26752744,89594,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1109,504327,1,1,,26752745,89594,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1110,504327,1,1,,50105392,89594,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1111,504327,1,1,,56314824,89594,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1112,504327,1,1,,90341453,89594,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1113,504329,1,1,,56314824,89594,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
1114,504332,1,1,,26752744,89594,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1115,504332,1,1,,26752745,89594,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1116,504332,1,1,,56314824,89594,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1117,504332,1,1,,90341453,89594,Inconclusive,168985070.0,,26.6795,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1118,504333,1,1,,56314824,89594,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
1119,504339,1,1,,56314824,89594,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
1120,504357,1,1,,56314824,89594,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1121,504357,1,1,,56314824,89594,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1122,504406,1,1,,56314824,89594,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
1123,504408,2,1,,56314824,89594,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
1124,504411,1,1,,56314824,89594,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
1125,504414,1,1,,56314824,89594,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1126,504414,1,1,,56314824,89594,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1127,504423,1,1,,56314824,89594,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1128,504441,1,1,,56314824,89594,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1129,504444,1,1,,56314824,89594,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
1130,504454,1,3,,56314824,89594,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
1131,504462,1,1,,56314824,89594,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
1132,504466,1,1,,56314824,89594,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1133,504467,1,1,,56314824,89594,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1134,504490,1,2,,56314824,89594,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
1135,504523,1,1,,56314824,89594,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1136,504523,1,1,,56314824,89594,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1137,504536,1,1,,90341453,89594,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
1138,504547,1,1,,90341453,89594,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1139,504548,1,2,,90341453,89594,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
1140,504558,1,1,,56314824,89594,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1141,504577,2,2,,56314824,89594,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1142,504582,2,1,,56314824,89594,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1143,504621,1,1,,56314824,89594,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1144,504634,1,1,,56314824,89594,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1145,504648,1,1,,56314824,89594,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
1146,504651,1,1,,56314824,89594,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
1147,504652,1,1,,56314824,89594,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
1148,504660,1,1,,56314824,89594,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
1149,504690,1,3,,56314824,89594,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
1150,504692,2,2,,56314824,89594,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1151,504700,1,1,,56314824,89594,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1152,504700,1,1,,56314824,89594,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1153,504706,1,1,,56314824,89594,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
1154,504707,1,1,,56314824,89594,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1155,504707,1,1,,56314824,89594,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1156,504720,1,1,,56314824,89594,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
1157,504734,1,1,,56314824,89594,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
1158,504766,2,1,,56314824,89594,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
1159,504775,1,1,,56314824,89594,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
1160,504803,1,1,,56314824,89594,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
1161,504810,1,2,,56314824,89594,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1162,504810,1,2,,90341453,89594,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1163,504812,1,2,,56314824,89594,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1164,504812,1,2,,90341453,89594,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1165,504832,1,1,,56314824,89594,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1166,504834,1,1,,56314824,89594,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1167,504836,1,2,,90341453,89594,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
1168,504842,1,1,,56314824,89594,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
1169,504845,1,1,,26752744,89594,Inconclusive,86301163.0,5999.0,0.4228,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1170,504845,1,1,,26752745,89594,Inconclusive,86301163.0,5999.0,0.0947,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1171,504845,1,1,,50105392,89594,Inactive,86301163.0,5999.0,2.6679,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1172,504845,1,1,,56314824,89594,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1173,504845,1,1,,90341453,89594,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1174,504847,1,1,,26752744,89594,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1175,504847,1,1,,26752745,89594,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1176,504847,1,1,,50105392,89594,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1177,504847,1,1,,56314824,89594,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1178,504847,1,1,,90341453,89594,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1179,504865,1,1,,50105392,89594,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1180,504865,1,1,,90341453,89594,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1181,504884,1,2,,56314824,89594,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1182,504891,1,1,,56314824,89594,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
1183,504894,1,1,,56314824,89594,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
1184,504937,1,2,,56314824,89594,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
1185,517363,5,6,,103163782,89594,Active,113105.0,1141.0,0.3,EC50,Agonist activity at human nAChR alpha4beta2 in human SH-EP1 cells assessed as induction in rubidium efflux,Confirmatory,20822184.0,
1186,517363,5,6,,103163782,89594,Active,1351848.0,1137.0,0.3,EC50,Agonist activity at human nAChR alpha4beta2 in human SH-EP1 cells assessed as induction in rubidium efflux,Confirmatory,20822184.0,
1187,517364,6,5,,103163782,89594,Active,2851491.0,170945.0,0.0055,Ki,Displacement of [3H]epibatidine from rat nAChR alpha2beta2,Confirmatory,20822184.0,
1188,517364,6,5,,103163782,89594,Active,6226548.0,54239.0,0.0055,Ki,Displacement of [3H]epibatidine from rat nAChR alpha2beta2,Confirmatory,20822184.0,
1189,517365,6,5,,103163782,89594,Active,113111.0,25103.0,0.07,Ki,Displacement of [3H]epibatidine from rat nAChR alpha2beta4,Confirmatory,20822184.0,
1190,517365,6,5,,103163782,89594,Active,2851491.0,170945.0,0.07,Ki,Displacement of [3H]epibatidine from rat nAChR alpha2beta4,Confirmatory,20822184.0,
1191,517366,6,5,,103163782,89594,Active,113061.0,25101.0,0.028999999999999998,Ki,Displacement of [3H]epibatidine from rat nAChR alpha3beta2,Confirmatory,20822184.0,
1192,517366,6,5,,103163782,89594,Active,6226548.0,54239.0,0.028999999999999998,Ki,Displacement of [3H]epibatidine from rat nAChR alpha3beta2,Confirmatory,20822184.0,
1193,517367,6,5,,103163782,89594,Active,6226548.0,54239.0,0.0049,Ki,Displacement of [3H]epibatidine from rat nAChR alpha4beta2,Confirmatory,20822184.0,
1194,517367,6,5,,103163782,89594,Active,8469182.0,25590.0,0.0049,Ki,Displacement of [3H]epibatidine from rat nAChR alpha4beta2,Confirmatory,20822184.0,
1195,517368,6,5,,103163782,89594,Active,6226548.0,54239.0,0.0098,Ki,Displacement of [3H]epibatidine from rat forebrain nAChR alpha4beta2,Confirmatory,20822184.0,
1196,517368,6,5,,103163782,89594,Active,8469182.0,25590.0,0.0098,Ki,Displacement of [3H]epibatidine from rat forebrain nAChR alpha4beta2,Confirmatory,20822184.0,
1197,517369,6,5,,103163782,89594,Active,113111.0,25103.0,0.023,Ki,Displacement of [3H]epibatidine from rat nAChR alpha4beta4,Confirmatory,20822184.0,
1198,517369,6,5,,103163782,89594,Active,8469182.0,25590.0,0.023,Ki,Displacement of [3H]epibatidine from rat nAChR alpha4beta4,Confirmatory,20822184.0,
1199,517370,6,5,,103163782,89594,Active,113061.0,25101.0,0.26,Ki,Displacement of [3H]epibatidine from rat nAChR alpha3beta4,Confirmatory,20822184.0,
1200,517370,6,5,,103163782,89594,Active,113111.0,25103.0,0.26,Ki,Displacement of [3H]epibatidine from rat nAChR alpha3beta4,Confirmatory,20822184.0,
1201,517371,2,11,,103163782,89594,Unspecified,113105.0,1141.0,,,Agonist activity at human nAChR alpha4beta2 in human SH-EP1 cells assessed as induction in rubidium efflux relative to carbamylcholine,Other,20822184.0,
1202,517371,2,11,,103163782,89594,Unspecified,1351848.0,1137.0,,,Agonist activity at human nAChR alpha4beta2 in human SH-EP1 cells assessed as induction in rubidium efflux relative to carbamylcholine,Other,20822184.0,
1203,517372,8,5,,103163782,89594,Active,113105.0,1141.0,0.43,IC50,Inactivation of nAChR alpha4beta2 in human SH-EP1 cells,Confirmatory,20822184.0,
1204,517372,8,5,,103163782,89594,Active,1351848.0,1137.0,0.43,IC50,Inactivation of nAChR alpha4beta2 in human SH-EP1 cells,Confirmatory,20822184.0,
1205,517373,2,11,,103163782,89594,Unspecified,113105.0,1141.0,,,Inactivation of nAChR alpha4beta2 in human SH-EP1 cells relative to carbamylcholine,Other,20822184.0,
1206,517373,2,11,,103163782,89594,Unspecified,1351848.0,1137.0,,,Inactivation of nAChR alpha4beta2 in human SH-EP1 cells relative to carbamylcholine,Other,20822184.0,
1207,517469,6,4,,103163782,89594,Active,14285341.0,,0.47863,Kd,Binding affinity to Lymnaea stagnalis His6-AChBP expressed in Bac-to-Bac baculovirus expression system by surface plasmon resonance biosensor assay,Confirmatory,20828128.0,
1208,517470,4,1,,103163782,89594,Active,,,2.88403,Kd,Binding affinity to Aplysia californica His6-AChBP expressed in Bac-to-Bac baculovirus expression system by surface plasmon resonance biosensor assay,Confirmatory,20828128.0,
1209,517471,8,4,,103163782,89594,Active,14285341.0,,0.33113000000000004,Ki,Displacement of [3H]epibatidine from Lymnaea stagnalis His6-AChBP expressed in Bac-to-Bac baculovirus expression system,Confirmatory,20828128.0,
1210,517472,7,5,,103163782,89594,Active,2506127.0,1139.0,1.02329,Ki,Displacement of [3H]-MLA from human alpha7 nAChR expressed in human SH-SY5Y cells,Confirmatory,20828128.0,
1211,536862,6,5,,103163782,89594,Active,113061.0,25101.0,0.48100000000000004,Ki,Displacement of [3H]epibatidine from rat alpha3beta4 nAChR expressed in HEK292 cells after 3 hrs,Confirmatory,20979364.0,
1212,536862,6,5,,103163782,89594,Active,113111.0,25103.0,0.48100000000000004,Ki,Displacement of [3H]epibatidine from rat alpha3beta4 nAChR expressed in HEK292 cells after 3 hrs,Confirmatory,20979364.0,
1213,536863,6,5,,103163782,89594,Active,6226548.0,54239.0,0.0111,Ki,Displacement of [3H]epibatidine from rat alpha4beta2 nAChR expressed in HEK292 cells after 3 hrs,Confirmatory,20979364.0,
1214,536863,6,5,,103163782,89594,Active,8469182.0,25590.0,0.0111,Ki,Displacement of [3H]epibatidine from rat alpha4beta2 nAChR expressed in HEK292 cells after 3 hrs,Confirmatory,20979364.0,
1215,540209,4,3,,103163782,89594,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
1216,540210,4,3,,103163782,89594,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
1217,540211,2,5,,103163782,89594,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
1218,540212,4,3,,103163782,89594,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
1219,540213,4,3,,103163782,89594,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
1220,540214,4,3,,103163782,89594,Unspecified,,,,,Clearance in rat after iv administration,Other,15920768.0,
1221,540215,3,2,,103163782,89594,Unspecified,,,,,Volume of distribution at steady state in rat after iv administration,Other,15920768.0,
1222,540216,4,3,,103163782,89594,Unspecified,,,,,Clearance in dog after iv administration,Other,15920768.0,
1223,540217,4,3,,103163782,89594,Unspecified,,,,,Volume of distribution at steady state in dog after iv administration,Other,15920768.0,
1224,540218,4,3,,103163782,89594,Unspecified,,,,,Clearance in monkey after iv administration,Other,15920768.0,
1225,540219,4,3,,103163782,89594,Unspecified,,,,,Volume of distribution at steady state in monkey after iv administration,Other,15920768.0,
1226,540220,4,3,,103163782,89594,Unspecified,,,,,Clearance in human after iv administration,Other,15920768.0,
1227,540221,4,3,,103163782,89594,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,15920768.0,
1228,540253,1,1,,56314824,89594,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1229,540253,1,1,,56314824,89594,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1230,540253,1,1,,56314824,89594,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1231,540256,1,2,,90341453,89594,Inconclusive,,,0.0041,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1232,540263,1,1,,56314824,89594,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1233,540263,1,1,,56314824,89594,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1234,540267,1,1,,56314824,89594,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
1235,540275,1,1,,56314824,89594,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
1236,540276,1,2,,17389805,89594,Inconclusive,420597.0,,3.5481,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1237,540276,1,2,,26752744,89594,Inconclusive,420597.0,,3.5481,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1238,540276,1,2,,26752745,89594,Inconclusive,420597.0,,3.5481,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1239,540276,1,2,,26752746,89594,Inconclusive,420597.0,,3.5481,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1240,540276,1,2,,50105392,89594,Inconclusive,420597.0,,3.5481,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1241,540276,1,2,,50105393,89594,Inconclusive,420597.0,,20.5878,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1242,540276,1,2,,90341453,89594,Inconclusive,420597.0,,20.5878,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1243,540277,1,1,,56314824,89594,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
1244,540295,1,1,,56314824,89594,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
1245,540303,1,1,,56314824,89594,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1246,540303,1,1,,56314824,89594,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1247,540303,1,1,,56314824,89594,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1248,540308,1,1,,56314824,89594,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
1249,540317,1,1,,56314824,89594,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1250,540336,1,1,,56314824,89594,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1251,540336,1,1,,56314824,89594,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1252,540364,1,2,,56314824,89594,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
1253,548366,8,5,,103163782,89594,Active,6226548.0,54239.0,0.002,Ki,Displacement of [3H]epibatidine from alpha4beta2 nAChR in rat cortical membranes by beta counting,Confirmatory,20932609.0,
1254,548366,8,5,,103163782,89594,Active,8469182.0,25590.0,0.002,Ki,Displacement of [3H]epibatidine from alpha4beta2 nAChR in rat cortical membranes by beta counting,Confirmatory,20932609.0,
1255,548367,7,5,,103163782,89594,Active,146345356.0,25302.0,0.469,Ki,Displacement of [125I]-alpha-Bungarotoxin from alpha7 nAChR rat cortical membranes by gamma counting,Confirmatory,20932609.0,
1256,566269,2,4,,103163782,89594,Active,,,0.01,IC50,Inhibition of rat neuronal-type nicotinic acetylcholine receptor,Confirmatory,20875743.0,
1257,574278,4,2,,103163782,89594,Active,,,5.8,IC50,Antiparasitic activity against Ancylostoma caninum isolate NT assessed as compound concentration required to inhibit parasitic contraction by larval arrested morphology assay,Confirmatory,18710918.0,
1258,574279,4,2,,103163782,89594,Active,,,6.2,IC50,Antiparasitic activity against Ancylostoma caninum isolate PR assessed as compound concentration required to inhibit parasitic contraction by larval arrested morphology assay,Confirmatory,18710918.0,
1259,574280,2,3,,103163782,89594,Unspecified,,,,,Ratio of IC50 for Ancylostoma caninum isolate NT to IC50 for Ancylostoma caninum isolate PR by larval arrested morphology assay,Other,18710918.0,
1260,574281,4,2,,103163782,89594,Active,,,3.7,IC50,Antiparasitic activity against Ancylostoma caninum isolate NT assessed as compound concentration required to inhibit parasitic contraction by larval motility assay,Confirmatory,18710918.0,
1261,574282,4,2,,103163782,89594,Active,,,3.6,IC50,Antiparasitic activity against Ancylostoma caninum isolate PR assessed as compound concentration required to inhibit parasitic contraction by larval motility assay,Confirmatory,18710918.0,
1262,574283,2,3,,103163782,89594,Unspecified,,,,,Ratio of IC50 for Ancylostoma caninum isolate NT to IC50 for Ancylostoma caninum isolate PR by larval motility assay,Other,18710918.0,
1263,574286,4,2,,103163782,89594,Unspecified,,,941.6,EC50,Antiparasitic activity against Ancylostoma caninum isolate NT assessed as concentration of drug required to cause a force of contraction half that of the KCl-induced maximal contraction by force transduction assay,Confirmatory,18710918.0,
1264,574287,4,2,,103163782,89594,Unspecified,,,1963.0,EC50,Antiparasitic activity against Ancylostoma caninum isolate PR assessed as concentration of drug required to cause a force of contraction half that of the KCl-induced maximal contraction by force transduction assay,Confirmatory,18710918.0,
1265,574288,2,3,,103163782,89594,Unspecified,,,,,Ratio of EC50 for Ancylostoma caninum isolate PR to IC50 for Ancylostoma caninum isolate NT by by force transduction assay,Other,18710918.0,
1266,588211,2,3,,103163782,89594,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
1267,588212,2,3,,103163782,89594,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
1268,588213,2,3,,103163782,89594,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
1269,588214,2,3,,103163782,89594,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
1270,588215,2,3,,103163782,89594,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
1271,588216,2,3,,103163782,89594,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
1272,588217,2,3,,103163782,89594,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
1273,588218,2,3,,103163782,89594,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
1274,588219,2,3,,103163782,89594,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
1275,588334,1,1,,56314824,89594,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
1276,588335,1,1,,56314824,89594,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
1277,588342,1,1,,56314824,89594,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
1278,588349,1,1,,90341453,89594,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
1279,588352,1,2,,56314824,89594,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
1280,588354,1,1,,56314824,89594,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
1281,588358,1,2,,56314824,89594,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
1282,588378,1,1,,90341453,89594,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
1283,588379,1,2,,50105392,89594,Inactive,13399304.0,60489.0,,Potency,qHTS for inhibitors of Vif-A3G interactions: Validation,Confirmatory,,
1284,588391,1,1,,56314824,89594,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1285,588405,1,1,,56314824,89594,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
1286,588413,1,2,,56314824,89594,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
1287,588436,1,1,,56314824,89594,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
1288,588453,1,1,,56314824,89594,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1289,588453,1,1,,90341453,89594,Inactive,8659577.0,58819.0,44.6684,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1290,588456,1,1,,56314824,89594,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1291,588456,1,1,,90341453,89594,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1292,588458,1,1,,56314824,89594,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
1293,588473,1,1,,56314824,89594,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1294,588473,1,1,,56314824,89594,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1295,588475,1,2,,56314824,89594,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1296,588475,1,2,,56314824,89594,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1297,588478,1,2,,124799453,89594,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
1298,588489,1,1,,56314824,89594,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
1299,588492,1,1,,56314824,89594,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
1300,588493,1,2,,56314824,89594,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
1301,588497,1,2,,56314824,89594,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
1302,588497,1,2,,56314824,89594,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
1303,588497,1,2,,56314824,89594,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
1304,588499,1,3,,56314824,89594,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
1305,588499,1,3,,56314824,89594,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
1306,588499,1,3,,56314824,89594,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
1307,588501,1,2,,56314824,89594,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
1308,588501,1,2,,56314824,89594,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
1309,588501,1,2,,56314824,89594,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
1310,588511,1,2,,56314824,89594,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
1311,588513,1,1,,17389805,89594,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
1312,588513,1,1,,26752746,89594,Inconclusive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
1313,588514,1,1,,17389805,89594,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
1314,588514,1,1,,26752746,89594,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
1315,588515,1,1,,17389805,89594,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
1316,588515,1,1,,26752746,89594,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
1317,588516,1,1,,17389805,89594,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
1318,588516,1,1,,26752746,89594,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
1319,588526,1,1,,17389805,89594,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
1320,588526,1,1,,26752746,89594,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
1321,588527,1,1,,17389805,89594,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
1322,588527,1,1,,26752746,89594,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
1323,588532,1,1,,17389805,89594,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
1324,588532,1,1,,26752746,89594,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
1325,588533,1,1,,17389805,89594,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
1326,588533,1,1,,26752746,89594,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
1327,588534,1,1,,17389805,89594,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1328,588534,1,1,,26752746,89594,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1329,588535,1,1,,17389805,89594,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1330,588535,1,1,,26752746,89594,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1331,588536,1,1,,17389805,89594,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1332,588536,1,1,,26752746,89594,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1333,588537,1,1,,17389805,89594,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1334,588537,1,1,,26752746,89594,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1335,588541,1,1,,17389805,89594,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
1336,588541,1,1,,26752746,89594,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
1337,588543,1,1,,17389805,89594,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
1338,588543,1,1,,26752746,89594,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
1339,588544,1,1,,17389805,89594,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
1340,588544,1,1,,26752746,89594,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
1341,588545,1,1,,17389805,89594,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
1342,588545,1,1,,26752746,89594,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
1343,588546,1,1,,17389805,89594,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
1344,588546,1,1,,26752746,89594,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
1345,588547,1,1,,17389805,89594,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
1346,588547,1,1,,26752746,89594,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
1347,588549,1,1,,56314824,89594,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1348,588579,1,1,,26752744,89594,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1349,588579,1,1,,26752745,89594,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1350,588579,1,1,,50105392,89594,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1351,588579,1,1,,56314824,89594,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1352,588579,1,1,,90341453,89594,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1353,588590,1,1,,56314824,89594,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1354,588591,1,1,,56314824,89594,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
1355,588621,1,1,,56314824,89594,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
1356,588627,1,1,,56314824,89594,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
1357,588664,1,2,,56314824,89594,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1358,588664,1,2,,56314824,89594,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1359,588674,1,2,,56314824,89594,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1360,588675,1,1,,56314824,89594,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
1361,588676,1,1,,56314824,89594,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
1362,588689,1,1,,56314824,89594,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
1363,588692,2,1,,56314824,89594,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1364,588726,1,2,,56314824,89594,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
1365,588727,1,1,,56314824,89594,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
1366,588795,1,1,,56314824,89594,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1367,588795,1,1,,90341453,89594,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1368,588814,1,3,,56314824,89594,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
1369,588819,1,4,,56314824,89594,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
1370,588834,2,1,,17389805,89594,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1371,588850,1,1,,56314824,89594,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
1372,588852,1,3,,56314824,89594,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
1373,588855,1,1,,56314824,89594,Inactive,18418623.0,4088.0,3.1623,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
1374,588856,1,1,,56314824,89594,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
1375,589032,1,10,,103163782,89594,Unspecified,308153612.0,1548.0,,,"Clinically relevant substrates of human liver microsomal P450 enzymes, isoform CYP2A6",Other,,
1376,589225,1,11,,103163782,89594,Unspecified,308153612.0,1548.0,,,Mechanism based inhibition of human cytochrome P450 2A6 measured by coumarin 7-hydroxylation,Other,16248836.0,
1377,592681,1,4,,103163782,89594,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
1378,602123,1,1,,56314824,89594,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
1379,602141,1,1,,56314824,89594,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
1380,602162,1,1,,56314824,89594,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
1381,602163,1,1,,56314824,89594,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
1382,602179,1,2,,56314824,89594,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
1383,602229,1,1,,56314824,89594,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
1384,602233,1,1,,56314824,89594,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1385,602244,1,2,,56314824,89594,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
1386,602247,1,2,,56314824,89594,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1387,602248,1,2,,56314824,89594,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1388,602250,1,2,,56314824,89594,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
1389,602252,1,1,,56314824,89594,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1390,602252,1,1,,56314824,89594,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1391,602261,1,1,,56314824,89594,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
1392,602274,1,2,,56314824,89594,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
1393,602281,1,1,,56314824,89594,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1394,602281,1,1,,56314824,89594,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1395,602310,1,2,,56314824,89594,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
1396,602313,1,1,,56314824,89594,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
1397,602329,1,1,,56314824,89594,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1398,602332,1,1,,26752744,89594,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1399,602332,1,1,,26752745,89594,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1400,602332,1,1,,50105392,89594,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1401,602332,1,1,,56314824,89594,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1402,602332,1,1,,90341453,89594,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1403,602340,1,2,,56314824,89594,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
1404,602342,2,1,,56314824,89594,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1405,602346,1,1,,56314824,89594,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1406,602363,1,1,,56314824,89594,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
1407,602393,1,1,,56314824,89594,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1408,602396,1,2,,56314824,89594,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
1409,602399,1,2,,56314824,89594,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
1410,602405,1,1,,56314824,89594,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1411,602410,1,1,,56314824,89594,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
1412,602429,1,1,,56314824,89594,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
1413,602438,1,1,,56314824,89594,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
1414,602440,1,1,,56314824,89594,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
1415,602449,1,2,,56314824,89594,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
1416,602481,1,1,,56314824,89594,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1417,603953,1,3,,103163782,89594,Unspecified,,,,,"In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat",Other,17544548.0,
1418,617051,3,3,,103163782,89594,Active,,,0.0047,IC50,Displacement of [3H]-cytisine from nAChR in rat brain membranes,Confirmatory,21824774.0,
1419,620032,6,5,,103163782,89594,Active,14285341.0,,0.31623,Ki,Displacement of [3H]-epibatidine from histidine-tagged Lymnaea stagnalis AChBP expressed in Sf9 cells after 1.5 hrs by liquid scintillation counting,Confirmatory,21920761.0,
1420,620034,6,5,,103163782,89594,Active,2506127.0,1139.0,1.0,Ki,Displacement of [3H]-MLA from human alpha7 nAChR expressed in human SH-SY5Y cells after 1.5 hrs by liquid scintillation counting,Confirmatory,21920761.0,
1421,622116,1,10,,103163782,89594,Unspecified,113105.0,1141.0,,,Agonist activity at human alpha4beta2 nAChR expressed in human SH-EP1 cells assessed as increase of carbamylcholine-induced 86Rb+ ion efflux by liquid scintillation counting relative to carbamylcholine,Other,21905669.0,
1422,622116,1,10,,103163782,89594,Unspecified,1351848.0,1137.0,,,Agonist activity at human alpha4beta2 nAChR expressed in human SH-EP1 cells assessed as increase of carbamylcholine-induced 86Rb+ ion efflux by liquid scintillation counting relative to carbamylcholine,Other,21905669.0,
1423,622117,2,6,,103163782,89594,Active,113105.0,1141.0,0.29,EC50,Agonist activity at human alpha4beta2 nAChR expressed in human SH-EP1 cells assessed as increase of carbamylcholine-induced 86Rb+ ion efflux by liquid scintillation counting,Confirmatory,21905669.0,
1424,622117,2,6,,103163782,89594,Active,1351848.0,1137.0,0.29,EC50,Agonist activity at human alpha4beta2 nAChR expressed in human SH-EP1 cells assessed as increase of carbamylcholine-induced 86Rb+ ion efflux by liquid scintillation counting,Confirmatory,21905669.0,
1425,622282,5,5,,103163782,89594,Active,113111.0,25103.0,0.023,Ki,Displacement of [3H]epibatidine from rat alpha4beta4 nAChR receptor,Confirmatory,21905669.0,
1426,622282,5,5,,103163782,89594,Active,8469182.0,25590.0,0.023,Ki,Displacement of [3H]epibatidine from rat alpha4beta4 nAChR receptor,Confirmatory,21905669.0,
1427,622283,5,5,,103163782,89594,Active,6226548.0,54239.0,0.0049,Ki,Displacement of [3H]epibatidine from rat alpha4beta2 nAChR receptor,Confirmatory,21905669.0,
1428,622283,5,5,,103163782,89594,Active,8469182.0,25590.0,0.0049,Ki,Displacement of [3H]epibatidine from rat alpha4beta2 nAChR receptor,Confirmatory,21905669.0,
1429,622284,5,5,,103163782,89594,Active,113061.0,25101.0,0.26,Ki,Displacement of [3H]epibatidine from rat alpha3beta4 nAChR receptor,Confirmatory,21905669.0,
1430,622284,5,5,,103163782,89594,Active,113111.0,25103.0,0.26,Ki,Displacement of [3H]epibatidine from rat alpha3beta4 nAChR receptor,Confirmatory,21905669.0,
1431,622285,5,5,,103163782,89594,Active,113111.0,25103.0,0.07,Ki,Displacement of [3H]epibatidine from rat alpha2beta4 receptor,Confirmatory,21905669.0,
1432,622285,5,5,,103163782,89594,Active,2851491.0,170945.0,0.07,Ki,Displacement of [3H]epibatidine from rat alpha2beta4 receptor,Confirmatory,21905669.0,
1433,622286,5,5,,103163782,89594,Active,113061.0,25101.0,0.028999999999999998,Ki,Displacement of [3H]epibatidine from rat alpha3beta2 receptor,Confirmatory,21905669.0,
1434,622286,5,5,,103163782,89594,Active,6226548.0,54239.0,0.028999999999999998,Ki,Displacement of [3H]epibatidine from rat alpha3beta2 receptor,Confirmatory,21905669.0,
1435,622287,5,5,,103163782,89594,Active,2851491.0,170945.0,0.0055,Ki,Displacement of [3H]epibatidine from rat alpha2beta2 receptor,Confirmatory,21905669.0,
1436,622287,5,5,,103163782,89594,Active,6226548.0,54239.0,0.0055,Ki,Displacement of [3H]epibatidine from rat alpha2beta2 receptor,Confirmatory,21905669.0,
1437,622288,2,6,,103163782,89594,Active,113105.0,1141.0,0.43,IC50,Antagonist activity at human alpha4beta2 nAChR expressed in SH-EP1 cells assessed as inhibition of carbamylcholine-induced 86Rb+ ion efflux by liquid scintillation counting,Confirmatory,21905669.0,
1438,622288,2,6,,103163782,89594,Active,1351848.0,1137.0,0.43,IC50,Antagonist activity at human alpha4beta2 nAChR expressed in SH-EP1 cells assessed as inhibition of carbamylcholine-induced 86Rb+ ion efflux by liquid scintillation counting,Confirmatory,21905669.0,
1439,622289,1,10,,103163782,89594,Unspecified,113105.0,1141.0,,,Antagonist activity at human alpha4beta2 nAChR expressed in SH-EP1 cells assessed as inhibition of carbamylcholine-induced 86Rb+ ion efflux by liquid scintillation counting relative to mecamylamine,Other,21905669.0,
1440,622289,1,10,,103163782,89594,Unspecified,1351848.0,1137.0,,,Antagonist activity at human alpha4beta2 nAChR expressed in SH-EP1 cells assessed as inhibition of carbamylcholine-induced 86Rb+ ion efflux by liquid scintillation counting relative to mecamylamine,Other,21905669.0,
1441,622295,5,5,,103163782,89594,Active,6226548.0,54239.0,0.0049,Ki,Displacement of [3H]epibatidine from rat alpha4beta2 receptor expressed in HEK cells,Confirmatory,21905669.0,
1442,622295,5,5,,103163782,89594,Active,8469182.0,25590.0,0.0049,Ki,Displacement of [3H]epibatidine from rat alpha4beta2 receptor expressed in HEK cells,Confirmatory,21905669.0,
1443,623870,1,1,,56314824,89594,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1444,623870,1,1,,56314824,89594,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1445,623877,1,1,,56314824,89594,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
1446,623901,1,1,,56314824,89594,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
1447,624037,1,3,,56314824,89594,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1448,624038,1,3,,56314824,89594,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1449,624040,1,3,,56314824,89594,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1450,624101,1,2,,85788514,89594,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1451,624125,1,4,,56314824,89594,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1452,624126,1,3,,56314824,89594,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1453,624127,1,2,,56314824,89594,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1454,624136,1,1,,85788514,89594,Inactive,208342286.0,7157.0,,,mutant P53 Measured in Biochemical System Using Small Molecule MicroArray - 2077-01_Other_SinglePoint_HTS_Activity,Screening,,
1455,624138,1,1,,85788514,89594,Inactive,21618340.0,6774.0,,,SMM STAT-3 Measured in Biochemical System Using Small Molecule MicroArray - 2076-01_Other_SinglePoint_HTS_Activity_Set2,Screening,,
1456,624139,1,1,,85788514,89594,Inactive,34577122.0,4790.0,,,NF-KappaB Measured in Biochemical System Using Small Molecule MicroArray - 2080-01_Other_SinglePoint_HTS_Activity,Screening,,
1457,624141,1,1,,85788514,89594,Inactive,71774083.0,4609.0,,,SMM c-myc Measured in Biochemical System Using Small Molecule MicroArray - 2081-01_Other_SinglePoint_HTS_Activity,Screening,,
1458,624146,1,1,,90341453,89594,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
1459,624147,1,1,,90341453,89594,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
1460,624148,1,2,,90341453,89594,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
1461,624149,1,1,,90341453,89594,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
1462,624151,1,1,,85788514,89594,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Re-Activators of the P53 Mutant Pathway Measured in Cell-Based System Using Plate Reader - 2071-01_Activator_SinglePoint_HTS_Activity,Screening,,
1463,624156,1,1,,85788514,89594,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
1464,624168,1,1,,56314824,89594,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
1465,624169,1,1,,56314824,89594,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
1466,624170,1,1,,56314824,89594,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1467,624171,1,1,,56314824,89594,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
1468,624172,1,1,,56314824,89594,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1469,624173,1,3,,56314824,89594,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1470,624178,1,1,,56314824,89594,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1471,624202,1,1,,56314824,89594,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1472,624204,1,2,,56314824,89594,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
1473,624246,1,1,,56314824,89594,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
1474,624256,1,2,,56314824,89594,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
1475,624263,1,1,,56314824,89594,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1476,624263,1,1,,56314824,89594,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1477,624267,1,2,,56314824,89594,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1478,624267,1,2,,56314824,89594,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1479,624268,1,3,,56314824,89594,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
1480,624288,1,1,,56314824,89594,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
1481,624296,1,1,,56314824,89594,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1482,624297,1,1,,56314824,89594,Inactive,7705682.0,51053.0,0.8913,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1483,624304,1,2,,56314824,89594,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
1484,624330,1,2,,56314824,89594,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
1485,624349,1,2,,121362441,89594,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1486,624352,1,1,,56314824,89594,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
1487,624354,1,1,,56314824,89594,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
1488,624377,1,1,,56314824,89594,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
1489,624414,1,1,,56314824,89594,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1490,624415,1,2,,56314824,89594,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1491,624416,1,1,,56314824,89594,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
1492,624417,1,1,,56314824,89594,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
1493,624418,1,1,,56314824,89594,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
1494,624455,1,1,,90341453,89594,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
1495,624463,1,1,,56314824,89594,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
1496,624464,1,1,,56314824,89594,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
1497,624465,1,1,,56314824,89594,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
1498,624466,1,3,,56314824,89594,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1499,624467,1,1,,56314824,89594,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1500,624483,1,1,,56314824,89594,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
1501,625144,5,5,,103163782,89594,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
1502,625145,4,7,,103163782,89594,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
1503,625146,5,5,,103163782,89594,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
1504,625147,4,7,,103163782,89594,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1505,625148,4,7,,103163782,89594,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1506,625149,4,7,,103163782,89594,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1507,625150,5,5,,103163782,89594,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
1508,625151,4,7,,103163782,89594,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1509,625152,4,7,,103163782,89594,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1510,625153,4,7,,103163782,89594,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1511,625154,4,7,,103163782,89594,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1512,625155,4,7,,103163782,89594,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1513,625156,1,9,,103163782,89594,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
1514,625157,6,2,,103163782,89594,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
1515,625158,3,4,,103163782,89594,Active,,,0.012,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
1516,625159,5,5,,103163782,89594,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
1517,625160,1,9,,103163782,89594,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
1518,625161,4,7,,103163782,89594,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
1519,625162,4,7,,103163782,89594,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1520,625163,4,7,,103163782,89594,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1521,625164,1,6,,103163782,89594,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
1522,625165,3,4,,103163782,89594,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1523,625166,3,4,,103163782,89594,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1524,625167,5,5,,103163782,89594,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
1525,625168,4,7,,103163782,89594,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
1526,625169,1,6,,103163782,89594,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
1527,625170,3,4,,103163782,89594,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
1528,625171,4,7,,103163782,89594,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
1529,625172,4,7,,103163782,89594,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
1530,625173,5,5,,103163782,89594,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
1531,625174,5,5,,103163782,89594,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
1532,625175,5,5,,103163782,89594,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
1533,625176,1,9,,103163782,89594,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
1534,625177,5,5,,103163782,89594,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1535,625178,5,5,,103163782,89594,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1536,625179,1,9,,103163782,89594,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
1537,625180,5,5,,103163782,89594,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1538,625181,5,5,,103163782,89594,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1539,625182,5,5,,103163782,89594,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1540,625183,5,5,,103163782,89594,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
1541,625184,5,5,,103163782,89594,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1542,625185,5,5,,103163782,89594,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1543,625186,5,5,,103163782,89594,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1544,625187,5,5,,103163782,89594,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1545,625188,1,9,,103163782,89594,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
1546,625189,1,7,,103163782,89594,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
1547,625190,4,5,,103163782,89594,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
1548,625191,4,7,,103163782,89594,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1549,625192,4,7,,103163782,89594,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
1550,625193,5,5,,103163782,89594,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
1551,625194,4,7,,103163782,89594,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
1552,625195,4,7,,103163782,89594,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
1553,625196,5,6,,103163782,89594,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
1554,625197,3,4,,103163782,89594,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
1555,625198,4,7,,103163782,89594,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1556,625199,4,7,,103163782,89594,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1557,625200,4,7,,103163782,89594,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1558,625201,4,7,,103163782,89594,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
1559,625202,4,7,,103163782,89594,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
1560,625203,4,7,,103163782,89594,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
1561,625204,4,7,,103163782,89594,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1562,625205,4,7,,103163782,89594,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
1563,625206,4,7,,103163782,89594,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1564,625207,4,7,,103163782,89594,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1565,625208,5,5,,103163782,89594,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
1566,625209,4,7,,103163782,89594,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
1567,625210,3,4,,103163782,89594,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
1568,625211,1,6,,103163782,89594,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
1569,625212,3,4,,103163782,89594,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
1570,625213,4,7,,103163782,89594,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
1571,625214,1,9,,103163782,89594,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
1572,625215,3,4,,103163782,89594,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
1573,625216,3,4,,103163782,89594,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
1574,625217,4,7,,103163782,89594,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1575,625218,4,7,,103163782,89594,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
1576,625219,3,4,,103163782,89594,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
1577,625220,4,7,,103163782,89594,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
1578,625221,4,7,,103163782,89594,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1579,625222,4,7,,103163782,89594,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
1580,625223,4,7,,103163782,89594,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
1581,625224,3,4,,103163782,89594,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
1582,625225,3,4,,103163782,89594,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
1583,625226,4,7,,103163782,89594,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
1584,625227,4,7,,103163782,89594,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
1585,625228,4,7,,103163782,89594,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
1586,625229,5,5,,103163782,89594,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
1587,625230,1,6,,103163782,89594,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
1588,625231,4,7,,103163782,89594,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
1589,625232,1,9,,103163782,89594,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
1590,625233,4,7,,103163782,89594,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
1591,625234,3,4,,103163782,89594,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
1592,625235,4,7,,103163782,89594,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
1593,625236,5,5,,103163782,89594,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
1594,625237,4,7,,103163782,89594,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
1595,625238,4,7,,103163782,89594,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
1596,625239,4,7,,103163782,89594,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
1597,625240,1,9,,103163782,89594,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
1598,625241,4,7,,103163782,89594,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
1599,625242,4,7,,103163782,89594,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
1600,625243,5,5,,103163782,89594,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1601,625244,5,5,,103163782,89594,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1602,625245,5,5,,103163782,89594,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1603,625246,1,9,,103163782,89594,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
1604,625247,5,5,,103163782,89594,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1605,625248,5,5,,103163782,89594,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1606,625249,5,5,,103163782,89594,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1607,625250,5,5,,103163782,89594,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1608,625251,5,5,,103163782,89594,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
1609,625252,4,7,,103163782,89594,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
1610,625253,4,7,,103163782,89594,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1611,625254,4,7,,103163782,89594,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1612,625255,4,7,,103163782,89594,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1613,625256,4,7,,103163782,89594,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1614,625257,4,7,,103163782,89594,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
1615,625258,4,7,,103163782,89594,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1616,625259,4,7,,103163782,89594,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1617,625260,3,4,,103163782,89594,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
1618,625261,3,4,,103163782,89594,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
1619,625262,3,4,,103163782,89594,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
1620,625263,4,7,,103163782,89594,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
1621,625264,3,4,,103163782,89594,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
1622,625265,1,6,,103163782,89594,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
1623,625266,3,4,,103163782,89594,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
1624,625267,3,4,,103163782,89594,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
1625,625268,4,2,,103163782,89594,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1626,625268,4,2,,103163782,89594,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1627,625268,4,2,,103163782,89594,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1628,625268,4,2,,103163782,89594,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1629,625269,4,7,,103163782,89594,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
1630,625270,4,7,,103163782,89594,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
1631,625271,5,5,,103163782,89594,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
1632,625272,3,4,,103163782,89594,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
1633,625273,4,6,,103163782,89594,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
1634,625274,1,6,,103163782,89594,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
1635,625275,3,4,,103163782,89594,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
1636,625279,1,3,,103163782,89594,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
1637,625280,1,3,,103163782,89594,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
1638,625281,1,3,,103163782,89594,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
1639,625282,1,3,,103163782,89594,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
1640,625283,1,3,,103163782,89594,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
1641,625284,1,3,,103163782,89594,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
1642,625285,1,3,,103163782,89594,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
1643,625286,1,3,,103163782,89594,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
1644,625287,1,3,,103163782,89594,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
1645,625288,1,3,,103163782,89594,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
1646,625289,1,3,,103163782,89594,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
1647,625290,1,3,,103163782,89594,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
1648,625291,1,3,,103163782,89594,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
1649,625292,1,3,,103163782,89594,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
1650,629807,1,10,,103163782,89594,Active,113061.0,25101.0,,,Agonist activity at rat alpha3beta4 nAChR assessed as [3H]noradrenaline release from rat striatum at 100 uM by beta counting,Other,21942635.0,
1651,629807,1,10,,103163782,89594,Active,113111.0,25103.0,,,Agonist activity at rat alpha3beta4 nAChR assessed as [3H]noradrenaline release from rat striatum at 100 uM by beta counting,Other,21942635.0,
1652,629817,6,2,,103163782,89594,Active,6226548.0,54239.0,0.067,EC50,Partial agonist activity at Nicotinic acetylcholine alpha4beta2 receptor in rat striatum assessed as [3H]dopamine release by beta counting,Confirmatory,21942635.0,
1653,629817,6,2,,103163782,89594,Active,8469182.0,25590.0,0.067,EC50,Partial agonist activity at Nicotinic acetylcholine alpha4beta2 receptor in rat striatum assessed as [3H]dopamine release by beta counting,Confirmatory,21942635.0,
1654,644038,6,5,,103163782,89594,Active,14285341.0,,0.31623,Ki,Displacement of [3H]epibatidine from Lymnaea stagnalis acetylcholine binding protein expressed using baculoviral system after 1.5 hrs by scintillation counting,Confirmatory,22243960.0,
1655,644039,6,5,,103163782,89594,Active,74820297.0,,2.51189,Ki,Displacement of [3H]epibatidine from Aplysia californica acetylcholine binding protein expressed using baculoviral system after 1.5 hrs by scintillation counting,Confirmatory,22243960.0,
1656,644040,6,5,,103163782,89594,Active,2506127.0,1139.0,1.0,Ki,Displacement of [3H]MLA from nAChR alpha7 receptor in human SH-SY5Y cells by scintillation counting,Confirmatory,22243960.0,
1657,644041,6,5,,103163782,89594,Active,113105.0,1141.0,0.01259,Ki,Displacement of [3H]epibatidine from human nAChR alpha4beta2 receptor expressed in human HEK293T cells by scintillation counting,Confirmatory,22243960.0,
1658,644041,6,5,,103163782,89594,Active,1351848.0,1137.0,0.01259,Ki,Displacement of [3H]epibatidine from human nAChR alpha4beta2 receptor expressed in human HEK293T cells by scintillation counting,Confirmatory,22243960.0,
1659,646471,4,5,,103163782,89594,Active,146345356.0,25302.0,1.4,Ki,Displacement of [3H]methyllylcaconitine from alpha7 nAChR in rat brain,Confirmatory,22281189.0,
1660,651550,1,1,,56314824,89594,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
1661,651560,1,1,,56314824,89594,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
1662,651572,1,2,,56314824,89594,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
1663,651582,1,1,,56314824,89594,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
1664,651602,1,1,,56314824,89594,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1665,651602,1,1,,56314824,89594,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1666,651602,1,1,,56314824,89594,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1667,651610,2,1,,56314824,89594,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1668,651631,4,1,,144209012,89594,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1669,651631,4,1,,144210494,89594,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1670,651632,4,1,,144209012,89594,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1671,651632,4,1,,144210494,89594,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1672,651633,4,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1673,651633,4,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1674,651634,4,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1675,651634,4,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1676,651635,1,3,,56314824,89594,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1677,651635,1,3,,90341453,89594,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1678,651636,1,1,,56314824,89594,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
1679,651640,1,1,,56314824,89594,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
1680,651644,1,1,,56314824,89594,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
1681,651647,1,1,,56314824,89594,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
1682,651654,1,1,,56314824,89594,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1683,651658,1,1,,56314824,89594,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1684,651661,2,1,,56314824,89594,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1685,651699,1,1,,56314824,89594,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1686,651699,1,1,,56314824,89594,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1687,651702,1,2,,56314824,89594,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
1688,651704,2,1,,56314824,89594,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1689,651710,1,1,,56314824,89594,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1690,651711,2,1,,56314824,89594,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1691,651718,1,2,,56314824,89594,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
1692,651719,1,2,,56314824,89594,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
1693,651724,1,1,,56314824,89594,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
1694,651725,1,1,,56314824,89594,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
1695,651741,1,1,,17389805,89594,Inconclusive,20149576.0,4780.0,47.3079,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1696,651741,1,1,,26752746,89594,Inactive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1697,651743,1,1,,17389805,89594,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
1698,651743,1,1,,26752746,89594,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
1699,651749,1,1,,17389805,89594,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
1700,651749,1,1,,26752746,89594,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
1701,651751,1,1,,17389805,89594,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
1702,651751,1,1,,26752746,89594,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
1703,651754,1,1,,17389805,89594,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
1704,651755,1,1,,17389805,89594,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
1705,651757,1,1,,17389805,89594,Inactive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
1706,651758,1,1,,17389805,89594,Inconclusive,186368.0,3576.0,47.3079,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
1707,651768,1,2,,56314824,89594,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
1708,651777,1,1,,17389805,89594,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
1709,651777,1,1,,26752746,89594,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
1710,651778,1,1,,17389805,89594,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
1711,651778,1,1,,26752746,89594,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
1712,651800,1,1,,56314824,89594,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
1713,651802,1,1,,17389805,89594,Inactive,49066040.0,6097.0,33.4915,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1714,651819,1,1,,56314824,89594,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
1715,651820,1,1,,56314824,89594,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
1716,651821,2,4,,56314824,89594,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
1717,651828,1,2,,121362441,89594,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
1718,651838,1,1,,17389805,89594,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1719,651838,1,1,,26752746,89594,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1720,651838,1,1,1.0,17389805,89594,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1721,651838,1,1,1.0,26752746,89594,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1722,651838,1,1,2.0,17389805,89594,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1723,651838,1,1,2.0,26752746,89594,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1724,651838,1,1,3.0,17389805,89594,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1725,651838,1,1,3.0,26752746,89594,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1726,651838,1,1,4.0,17389805,89594,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1727,651838,1,1,4.0,26752746,89594,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1728,651838,1,1,5.0,17389805,89594,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1729,651838,1,1,5.0,26752746,89594,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1730,651838,1,1,6.0,17389805,89594,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1731,651838,1,1,6.0,26752746,89594,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1732,651838,1,1,7.0,17389805,89594,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1733,651838,1,1,7.0,26752746,89594,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1734,651838,1,1,8.0,17389805,89594,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1735,651838,1,1,8.0,26752746,89594,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1736,651957,1,1,,56314824,89594,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
1737,651958,1,1,,56314824,89594,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
1738,651965,1,1,,56314824,89594,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
1739,651999,1,1,,56314824,89594,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
1740,652010,1,1,,56314824,89594,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
1741,652017,1,1,,56314824,89594,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
1742,652025,1,1,,56314824,89594,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
1743,652039,1,1,,56314824,89594,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
1744,652048,1,2,,56314824,89594,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1745,652051,1,1,,56314824,89594,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1746,652054,1,1,,56314824,89594,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
1747,652067,1,4,,56314824,89594,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
1748,652104,1,1,,56314824,89594,Inconclusive,20140568.0,23435.0,39.8107,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
1749,652105,1,1,,56314824,89594,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
1750,652106,1,1,,56314824,89594,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1751,652106,1,1,,90341453,89594,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1752,652115,1,1,,56314824,89594,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
1753,652126,1,3,,56314824,89594,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
1754,652154,1,1,,56314824,89594,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1755,652162,2,1,,56314824,89594,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1756,652163,1,1,,56314824,89594,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1757,652197,1,1,,56314824,89594,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1758,652257,1,1,,56314824,89594,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
1759,658712,4,5,,103163782,89594,Active,2851491.0,170945.0,0.0055,Ki,Displacement of [3H] epibatidine from rat alpha2beta2 nAChR by beta scintillation counting,Confirmatory,22171543.0,
1760,658712,4,5,,103163782,89594,Active,6226548.0,54239.0,0.0055,Ki,Displacement of [3H] epibatidine from rat alpha2beta2 nAChR by beta scintillation counting,Confirmatory,22171543.0,
1761,658713,4,5,,103163782,89594,Active,113111.0,25103.0,0.07,Ki,Displacement of [3H] epibatidine from rat alpha2beta4 nAChR by beta scintillation counting,Confirmatory,22171543.0,
1762,658713,4,5,,103163782,89594,Active,2851491.0,170945.0,0.07,Ki,Displacement of [3H] epibatidine from rat alpha2beta4 nAChR by beta scintillation counting,Confirmatory,22171543.0,
1763,658714,4,5,,103163782,89594,Active,113061.0,25101.0,0.028999999999999998,Ki,Displacement of [3H] epibatidine from rat alpha3beta2 nAChR by beta scintillation counting,Confirmatory,22171543.0,
1764,658714,4,5,,103163782,89594,Active,6226548.0,54239.0,0.028999999999999998,Ki,Displacement of [3H] epibatidine from rat alpha3beta2 nAChR by beta scintillation counting,Confirmatory,22171543.0,
1765,658715,4,5,,103163782,89594,Active,113061.0,25101.0,0.26,Ki,Displacement of [3H] epibatidine from rat alpha3beta4 nAChR by beta scintillation counting,Confirmatory,22171543.0,
1766,658715,4,5,,103163782,89594,Active,113111.0,25103.0,0.26,Ki,Displacement of [3H] epibatidine from rat alpha3beta4 nAChR by beta scintillation counting,Confirmatory,22171543.0,
1767,658716,4,5,,103163782,89594,Active,6226548.0,54239.0,0.0049,Ki,Displacement of [3H] epibatidine from rat alpha4beta2 nAChR by beta scintillation counting,Confirmatory,22171543.0,
1768,658716,4,5,,103163782,89594,Active,8469182.0,25590.0,0.0049,Ki,Displacement of [3H] epibatidine from rat alpha4beta2 nAChR by beta scintillation counting,Confirmatory,22171543.0,
1769,658717,4,5,,103163782,89594,Active,6226548.0,54239.0,0.0098,Ki,Displacement of [3H] epibatidine from rat alpha4beta2* nAChR in rat forebrain by beta scintillation counting,Confirmatory,22171543.0,
1770,658717,4,5,,103163782,89594,Active,8469182.0,25590.0,0.0098,Ki,Displacement of [3H] epibatidine from rat alpha4beta2* nAChR in rat forebrain by beta scintillation counting,Confirmatory,22171543.0,
1771,658718,4,5,,103163782,89594,Active,113111.0,25103.0,0.023,Ki,Displacement of [3H] epibatidine from rat alpha4beta4 nAChR by beta scintillation counting,Confirmatory,22171543.0,
1772,658718,4,5,,103163782,89594,Active,8469182.0,25590.0,0.023,Ki,Displacement of [3H] epibatidine from rat alpha4beta4 nAChR by beta scintillation counting,Confirmatory,22171543.0,
1773,658719,1,3,,103163782,89594,Unspecified,,,,,Selectivity ratio of Ki for rat alpha3beta4 to Ki for rat alpha4beta2,Other,22171543.0,
1774,658724,2,6,,103163782,89594,Active,113105.0,1141.0,0.29,EC50,Agonist activity at human alpha4beta2 nAChR expressed in SH-EP1 cells assessed as 86Rb+ ion efflux after 9.5 mins by flip-plate technique,Confirmatory,22171543.0,
1775,658724,2,6,,103163782,89594,Active,1351848.0,1137.0,0.29,EC50,Agonist activity at human alpha4beta2 nAChR expressed in SH-EP1 cells assessed as 86Rb+ ion efflux after 9.5 mins by flip-plate technique,Confirmatory,22171543.0,
1776,658725,1,9,,103163782,89594,Unspecified,113105.0,1141.0,,,Agonist activity at human high sensitive and low sensitive alpha4beta2 nAChR expressed in SH-EP1 cells assessed as 86Rb+ ion efflux by flip-plate technique relative to sazetidine-A,Other,22171543.0,
1777,658725,1,9,,103163782,89594,Unspecified,1351848.0,1137.0,,,Agonist activity at human high sensitive and low sensitive alpha4beta2 nAChR expressed in SH-EP1 cells assessed as 86Rb+ ion efflux by flip-plate technique relative to sazetidine-A,Other,22171543.0,
1778,658727,2,6,,103163782,89594,Active,113105.0,1141.0,0.43,IC50,Antagonist activity at human alpha4beta2 nAChR expressed in SH-EP1 cells assessed as inhibition of carbamylcholine induced 86Rb+ ion efflux preincubated for 10 mins prior to carbamylcholine-induction measured after 5 mins by flip-plate technique,Confirmatory,22171543.0,
1779,658727,2,6,,103163782,89594,Active,1351848.0,1137.0,0.43,IC50,Antagonist activity at human alpha4beta2 nAChR expressed in SH-EP1 cells assessed as inhibition of carbamylcholine induced 86Rb+ ion efflux preincubated for 10 mins prior to carbamylcholine-induction measured after 5 mins by flip-plate technique,Confirmatory,22171543.0,
1780,658728,1,9,,103163782,89594,Unspecified,113105.0,1141.0,,,Antagonist activity at human high sensitive and low sensitive alpha4beta2 nAChR expressed in SH-EP1 cells assessed as inhibition of carbamylcholine induced 86Rb+ ion efflux preincubated for 10 mins prior to carbamylcholine-induction measured after 5 mins by flip-plate technique relative to control,Other,22171543.0,
1781,658728,1,9,,103163782,89594,Unspecified,1351848.0,1137.0,,,Antagonist activity at human high sensitive and low sensitive alpha4beta2 nAChR expressed in SH-EP1 cells assessed as inhibition of carbamylcholine induced 86Rb+ ion efflux preincubated for 10 mins prior to carbamylcholine-induction measured after 5 mins by flip-plate technique relative to control,Other,22171543.0,
1782,658729,1,9,,103163782,89594,Inactive,113071.0,1134.0,,,Agonist activity at human alpha1beta1gammadelta nAChR expressed in TE671/RD cells at 10 uM by 86Rb+ flux assay,Other,22171543.0,
1783,658729,1,9,,103163782,89594,Inactive,543759.0,1144.0,,,Agonist activity at human alpha1beta1gammadelta nAChR expressed in TE671/RD cells at 10 uM by 86Rb+ flux assay,Other,22171543.0,
1784,658729,1,9,,103163782,89594,Inactive,21903373.0,1140.0,,,Agonist activity at human alpha1beta1gammadelta nAChR expressed in TE671/RD cells at 10 uM by 86Rb+ flux assay,Other,22171543.0,
1785,658729,1,9,,103163782,89594,Inactive,126302510.0,1146.0,,,Agonist activity at human alpha1beta1gammadelta nAChR expressed in TE671/RD cells at 10 uM by 86Rb+ flux assay,Other,22171543.0,
1786,658730,1,9,,103163782,89594,Inactive,113071.0,1134.0,,,Antagonist activity at human alpha1beta1gammadelta nAChR expressed in TE671/RD cells at 10 uM by 86Rb+ flux assay,Other,22171543.0,
1787,658730,1,9,,103163782,89594,Inactive,543759.0,1144.0,,,Antagonist activity at human alpha1beta1gammadelta nAChR expressed in TE671/RD cells at 10 uM by 86Rb+ flux assay,Other,22171543.0,
1788,658730,1,9,,103163782,89594,Inactive,21903373.0,1140.0,,,Antagonist activity at human alpha1beta1gammadelta nAChR expressed in TE671/RD cells at 10 uM by 86Rb+ flux assay,Other,22171543.0,
1789,658730,1,9,,103163782,89594,Inactive,126302510.0,1146.0,,,Antagonist activity at human alpha1beta1gammadelta nAChR expressed in TE671/RD cells at 10 uM by 86Rb+ flux assay,Other,22171543.0,
1790,658731,1,9,,103163782,89594,Inactive,113105.0,1141.0,,,Agonist activity at alpha3beta4alpha5beta2 in human SH-SY5Y cells at 10 uM by 86Rb+ flux assay,Other,22171543.0,
1791,658731,1,9,,103163782,89594,Inactive,2506126.0,1138.0,,,Agonist activity at alpha3beta4alpha5beta2 in human SH-SY5Y cells at 10 uM by 86Rb+ flux assay,Other,22171543.0,
1792,658731,1,9,,103163782,89594,Inactive,2506129.0,1143.0,,,Agonist activity at alpha3beta4alpha5beta2 in human SH-SY5Y cells at 10 uM by 86Rb+ flux assay,Other,22171543.0,
1793,658731,1,9,,103163782,89594,Inactive,254763435.0,1136.0,,,Agonist activity at alpha3beta4alpha5beta2 in human SH-SY5Y cells at 10 uM by 86Rb+ flux assay,Other,22171543.0,
1794,658732,1,9,,103163782,89594,Inactive,113105.0,1141.0,,,Antagonist activity at alpha3beta4alpha5beta2 in human SH-SY5Y cells at 10 uM by 86Rb+ flux assay,Other,22171543.0,
1795,658732,1,9,,103163782,89594,Inactive,2506126.0,1138.0,,,Antagonist activity at alpha3beta4alpha5beta2 in human SH-SY5Y cells at 10 uM by 86Rb+ flux assay,Other,22171543.0,
1796,658732,1,9,,103163782,89594,Inactive,2506129.0,1143.0,,,Antagonist activity at alpha3beta4alpha5beta2 in human SH-SY5Y cells at 10 uM by 86Rb+ flux assay,Other,22171543.0,
1797,658732,1,9,,103163782,89594,Inactive,254763435.0,1136.0,,,Antagonist activity at alpha3beta4alpha5beta2 in human SH-SY5Y cells at 10 uM by 86Rb+ flux assay,Other,22171543.0,
1798,666034,1,3,,103163782,89594,Active,,,0.129,Ki,Displacement of [3H]MLA from alpha7* nAChR in Sprague-Dawley rat brain P2 membrane after 120 mins by liquid scintillation counting,Confirmatory,22609074.0,
1799,666035,1,3,,103163782,89594,Inconclusive,,,,Ki,Displacement of [3H]epibatidine from (alpha1)2beta1gammadelta nAChR in electric ray electroplax P1 membrane after 90 mins by liquid scintillation counting,Confirmatory,22609074.0,
1800,666036,1,3,,103163782,89594,Active,,,0.0753,Ki,Displacement of [3H]epibatidine from alpha3beta4* nAChR in calf adrenal P1 membrane after 90 mins by liquid scintillation counting,Confirmatory,22609074.0,
1801,666037,1,3,,103163782,89594,Active,,,0.00085,Ki,Displacement of [3H]epibatidine from alpha4beta2* nAChR in Sprague-Dawley rat brain P2 membrane after 90 mins by liquid scintillation counting,Confirmatory,22609074.0,
1802,675880,2,1,,103163782,89594,Active,113105.0,1141.0,0.001,EC50,Agonist activity at alpha4beta 2 nAChR,Confirmatory,22591063.0,
1803,675880,2,1,,103163782,89594,Active,1351848.0,1137.0,0.001,EC50,Agonist activity at alpha4beta 2 nAChR,Confirmatory,22591063.0,
1804,680400,1,8,,103163782,89594,Unspecified,146345508.0,6583.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 60 uM, Nicotine: 1000 uM) in Xenopus laevis oocytes",Other,10215651.0,
1805,681117,3,6,,103163782,89594,Unspecified,313104181.0,6580.0,,IC50,TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells,Confirmatory,12606755.0,
1806,681442,1,7,,103163782,89594,Unspecified,50401224.0,64037.0,,,TP_TRANSPORTER: inhibition of TEA uptake by Nicotine at 5mM in Octn1-HRPE cells,Other,10825452.0,
1807,681574,3,6,,103163782,89594,Unspecified,81872095.0,24904.0,64.3,Ki,TP_TRANSPORTER: inhibition of TEA uptake (basolateral to cell) in OCT1-expressing MDCK cells,Confirmatory,9808712.0,
1808,681590,3,6,,103163782,89594,Unspecified,81872789.0,29503.0,50.5,Ki,TP_TRANSPORTER: inhibition of TEA uptake (basolateral to cell) in OCT2-expressing MDCK cells,Confirmatory,9808712.0,
1809,681638,1,7,,103163782,89594,Unspecified,81872789.0,29503.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 250 uM, Nicotine: 5000 uM) in Xenopus laevis oocytes",Other,10082798.0,
1810,681697,1,7,,103163782,89594,Unspecified,8928242.0,29726.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM, Nicotine: 2500 uM) in OCTN2-expressing HRPE cells",Other,10454528.0,
1811,681941,1,7,,103163782,89594,Unspecified,313104181.0,6580.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, Nicotine: 500 uM) in OCT1-expressing HeLa cells",Other,9655880.0,
1812,681964,1,7,,103163782,89594,Unspecified,313104182.0,6582.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (basolateral to cell) (TEA: 5 uM, Nicotine: 1000 uM) in OCT2A-expressing HEK293 cells",Other,12089365.0,
1813,681965,1,7,,103163782,89594,Unspecified,313104182.0,6582.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (basolateral to cell) (TEA: 5 uM, Nicotine: 1000 uM) in OCT2-expressing HEK293 cells",Other,12089365.0,
1814,682224,1,7,,103163782,89594,Unspecified,24212062.0,29504.0,,,"TP_TRANSPORTER: inhibition of Guanidine uptake (Guanidine: 35 uM, Nicotine: 5000 uM) in OCT3-expressing HeLa cells",Other,9632645.0,
1815,682265,1,7,,103163782,89594,Unspecified,8928257.0,6584.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM, Nicotine: 5000 uM) in OCTN2-expressing HeLa cells",Other,9618255.0,
1816,682303,1,7,,103163782,89594,Unspecified,8928257.0,6584.0,,,"TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.010? uM, Nicotine: 500 uM) in OCTN2-expressing HEK293 cells",Other,10525100.0,
1817,686940,1,1,,56314824,89594,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
1818,686964,1,1,,56314824,89594,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
1819,686970,1,2,,56314824,89594,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
1820,686971,1,2,,56314824,89594,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
1821,686978,1,1,,26752744,89594,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1822,686978,1,1,,26752745,89594,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1823,686978,1,1,,50105392,89594,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1824,686978,1,1,,56314824,89594,Inconclusive,79154014.0,55775.0,4.1095,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1825,686979,1,1,,26752744,89594,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1826,686979,1,1,,26752745,89594,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1827,686979,1,1,,50105392,89594,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1828,686979,1,1,,56314824,89594,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1829,686992,2,1,,56314824,89594,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
1830,686996,1,1,,56314824,89594,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1831,687014,1,1,,56314824,89594,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
1832,687016,1,1,,56314824,89594,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
1833,696712,1,2,,103163782,89594,Inconclusive,,,,Ki,Binding affinity to rat forebrain alpha7* nACHR at 10 uM,Confirmatory,22148173.0,
1834,696713,3,5,,103163782,89594,Inconclusive,146345356.0,25302.0,,Ki,Binding affinity to rat alpha7 nACHR at 10 uM,Confirmatory,22148173.0,
1835,697852,1,7,,103163782,89594,Unspecified,14916521.0,,,,Inhibition of electric eel AChE at 2 mg/ml by Ellman's method,Other,23062825.0,
1836,697853,1,7,,103163782,89594,Unspecified,21362409.0,100033901.0,,,Inhibition of horse BChE at 2 mg/ml by Ellman's method,Other,23062825.0,
1837,699539,1,7,,103163782,89594,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
1838,699540,1,7,,103163782,89594,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
1839,699541,1,7,,103163782,89594,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
1840,700114,3,5,,103163782,89594,Active,113111.0,25103.0,0.0055,Ki,Displacement of [3H]epibatidine from rat alpha2beta2 nACHR,Confirmatory,22148173.0,
1841,700114,3,5,,103163782,89594,Active,8469182.0,25590.0,0.0055,Ki,Displacement of [3H]epibatidine from rat alpha2beta2 nACHR,Confirmatory,22148173.0,
1842,700115,3,5,,103163782,89594,Active,113111.0,25103.0,0.07,Ki,Displacement of [3H]epibatidine from rat alpha2beta4 nACHR,Confirmatory,22148173.0,
1843,700115,3,5,,103163782,89594,Active,2851491.0,170945.0,0.07,Ki,Displacement of [3H]epibatidine from rat alpha2beta4 nACHR,Confirmatory,22148173.0,
1844,700116,3,5,,103163782,89594,Active,113061.0,25101.0,0.028999999999999998,Ki,Displacement of [3H]epibatidine from rat alpha3beta2 nACHR,Confirmatory,22148173.0,
1845,700116,3,5,,103163782,89594,Active,6226548.0,54239.0,0.028999999999999998,Ki,Displacement of [3H]epibatidine from rat alpha3beta2 nACHR,Confirmatory,22148173.0,
1846,700117,3,5,,103163782,89594,Active,113061.0,25101.0,0.26,Ki,Displacement of [3H]epibatidine from rat alpha3beta4 nACHR,Confirmatory,22148173.0,
1847,700117,3,5,,103163782,89594,Active,113111.0,25103.0,0.26,Ki,Displacement of [3H]epibatidine from rat alpha3beta4 nACHR,Confirmatory,22148173.0,
1848,700118,6,2,,103163782,89594,Active,6226548.0,54239.0,0.0049,Ki,Displacement of [3H]epibatidine from rat alpha4beta2 nACHR,Confirmatory,22148173.0,
1849,700118,6,2,,103163782,89594,Active,8469182.0,25590.0,0.0049,Ki,Displacement of [3H]epibatidine from rat alpha4beta2 nACHR,Confirmatory,22148173.0,
1850,700119,1,2,,103163782,89594,Active,,,0.0098,Ki,Displacement of [3H]epibatidine from rat forebrain alpha4beta2* nACHR,Confirmatory,22148173.0,
1851,700120,3,5,,103163782,89594,Active,113111.0,25103.0,0.023,Ki,Displacement of [3H]epibatidine from rat alpha4beta4 nACHR,Confirmatory,22148173.0,
1852,700120,3,5,,103163782,89594,Active,8469182.0,25590.0,0.023,Ki,Displacement of [3H]epibatidine from rat alpha4beta4 nACHR,Confirmatory,22148173.0,
1853,700121,2,6,,103163782,89594,Active,2506129.0,1143.0,0.29,EC50,Agonist activity at human alpha4beta2 nACHR expressed in SH-EP1 cells by 86Rb+ efflux assay,Confirmatory,22148173.0,
1854,700121,2,6,,103163782,89594,Active,254763435.0,1136.0,0.29,EC50,Agonist activity at human alpha4beta2 nACHR expressed in SH-EP1 cells by 86Rb+ efflux assay,Confirmatory,22148173.0,
1855,700122,1,8,,103163782,89594,Active,113105.0,1141.0,30.0,EC50,Agonist activity at alpha3beta4alpha5beta2 nACHR in human SH-SY5Y cells by 86Rb+ efflux assay,Confirmatory,22148173.0,
1856,700122,1,8,,103163782,89594,Active,2506126.0,1138.0,30.0,EC50,Agonist activity at alpha3beta4alpha5beta2 nACHR in human SH-SY5Y cells by 86Rb+ efflux assay,Confirmatory,22148173.0,
1857,700122,1,8,,103163782,89594,Active,2506129.0,1143.0,30.0,EC50,Agonist activity at alpha3beta4alpha5beta2 nACHR in human SH-SY5Y cells by 86Rb+ efflux assay,Confirmatory,22148173.0,
1858,700122,1,8,,103163782,89594,Active,254763435.0,1136.0,30.0,EC50,Agonist activity at alpha3beta4alpha5beta2 nACHR in human SH-SY5Y cells by 86Rb+ efflux assay,Confirmatory,22148173.0,
1859,700123,1,8,,103163782,89594,Inactive,113071.0,1134.0,,,Agonist activity at alpha1betagammadelta nACHR in human TE671/RD cells by 86Rb+ efflux assay,Other,22148173.0,
1860,700123,1,8,,103163782,89594,Inactive,543759.0,1144.0,,,Agonist activity at alpha1betagammadelta nACHR in human TE671/RD cells by 86Rb+ efflux assay,Other,22148173.0,
1861,700123,1,8,,103163782,89594,Inactive,21903373.0,1140.0,,,Agonist activity at alpha1betagammadelta nACHR in human TE671/RD cells by 86Rb+ efflux assay,Other,22148173.0,
1862,700123,1,8,,103163782,89594,Inactive,126302510.0,1146.0,,,Agonist activity at alpha1betagammadelta nACHR in human TE671/RD cells by 86Rb+ efflux assay,Other,22148173.0,
1863,700124,1,8,,103163782,89594,Unspecified,2506129.0,1143.0,,,Agonist activity at human alpha4beta2 nACHR expressed in SH-EP1 cells at 10 uM by 86Rb+ efflux assay,Other,22148173.0,
1864,700124,1,8,,103163782,89594,Unspecified,254763435.0,1136.0,,,Agonist activity at human alpha4beta2 nACHR expressed in SH-EP1 cells at 10 uM by 86Rb+ efflux assay,Other,22148173.0,
1865,700125,1,8,,103163782,89594,Unspecified,113105.0,1141.0,,,Agonist activity at alpha3beta4alpha5beta2 nACHR in human SH-SY5Y cells at 10 uM by 86Rb+ efflux assay,Other,22148173.0,
1866,700125,1,8,,103163782,89594,Unspecified,2506126.0,1138.0,,,Agonist activity at alpha3beta4alpha5beta2 nACHR in human SH-SY5Y cells at 10 uM by 86Rb+ efflux assay,Other,22148173.0,
1867,700125,1,8,,103163782,89594,Unspecified,2506129.0,1143.0,,,Agonist activity at alpha3beta4alpha5beta2 nACHR in human SH-SY5Y cells at 10 uM by 86Rb+ efflux assay,Other,22148173.0,
1868,700125,1,8,,103163782,89594,Unspecified,254763435.0,1136.0,,,Agonist activity at alpha3beta4alpha5beta2 nACHR in human SH-SY5Y cells at 10 uM by 86Rb+ efflux assay,Other,22148173.0,
1869,700126,2,6,,103163782,89594,Active,2506129.0,1143.0,0.43,IC50,Inhibition of human alpha4beta2 nACHR expressed in SH-EP1 cells by 86Rb+ efflux assay,Confirmatory,22148173.0,
1870,700126,2,6,,103163782,89594,Active,254763435.0,1136.0,0.43,IC50,Inhibition of human alpha4beta2 nACHR expressed in SH-EP1 cells by 86Rb+ efflux assay,Confirmatory,22148173.0,
1871,700127,2,5,,103163782,89594,Inconclusive,113105.0,1141.0,,IC50,Inhibition of alpha3beta4alpha5beta2 nACHR in human SH-SY5Y cells by 86Rb+ efflux assay,Confirmatory,22148173.0,
1872,700127,2,5,,103163782,89594,Inconclusive,2506126.0,1138.0,,IC50,Inhibition of alpha3beta4alpha5beta2 nACHR in human SH-SY5Y cells by 86Rb+ efflux assay,Confirmatory,22148173.0,
1873,700127,2,5,,103163782,89594,Inconclusive,2506129.0,1143.0,,IC50,Inhibition of alpha3beta4alpha5beta2 nACHR in human SH-SY5Y cells by 86Rb+ efflux assay,Confirmatory,22148173.0,
1874,700127,2,5,,103163782,89594,Inconclusive,254763435.0,1136.0,,IC50,Inhibition of alpha3beta4alpha5beta2 nACHR in human SH-SY5Y cells by 86Rb+ efflux assay,Confirmatory,22148173.0,
1875,700128,1,8,,103163782,89594,Unspecified,2506129.0,1143.0,,,Inhibition of human alpha4beta2 nACHR expressed in SH-EP1 cells at 10 uM by 86Rb+ efflux assay,Other,22148173.0,
1876,700128,1,8,,103163782,89594,Unspecified,254763435.0,1136.0,,,Inhibition of human alpha4beta2 nACHR expressed in SH-EP1 cells at 10 uM by 86Rb+ efflux assay,Other,22148173.0,
1877,700129,1,8,,103163782,89594,Inconclusive,113105.0,1141.0,,,Inhibition of alpha3beta4alpha5beta2 nACHR in human SH-SY5Y cells at 10 uM by 86Rb+ efflux assay,Other,22148173.0,
1878,700129,1,8,,103163782,89594,Inconclusive,2506126.0,1138.0,,,Inhibition of alpha3beta4alpha5beta2 nACHR in human SH-SY5Y cells at 10 uM by 86Rb+ efflux assay,Other,22148173.0,
1879,700129,1,8,,103163782,89594,Inconclusive,2506129.0,1143.0,,,Inhibition of alpha3beta4alpha5beta2 nACHR in human SH-SY5Y cells at 10 uM by 86Rb+ efflux assay,Other,22148173.0,
1880,700129,1,8,,103163782,89594,Inconclusive,254763435.0,1136.0,,,Inhibition of alpha3beta4alpha5beta2 nACHR in human SH-SY5Y cells at 10 uM by 86Rb+ efflux assay,Other,22148173.0,
1881,704959,3,6,,103163782,89594,Active,2506129.0,1143.0,7.0,EC50,Agonist activity at human alpha3beta4 nAChR expressed in CHO cells assessed as calcium flux by calcium4-based FLIPR assay,Confirmatory,22793665.0,
1882,704959,3,6,,103163782,89594,Active,254763435.0,1136.0,7.0,EC50,Agonist activity at human alpha3beta4 nAChR expressed in CHO cells assessed as calcium flux by calcium4-based FLIPR assay,Confirmatory,22793665.0,
1883,704961,3,6,,103163782,89594,Active,113105.0,1141.0,3.0,EC50,Agonist activity at alpha4beta2 nAChR in human SH-EP1 cells assessed as calcium flux by calcium4-based FLIPR assay,Confirmatory,22793665.0,
1884,704961,3,6,,103163782,89594,Active,1351848.0,1137.0,3.0,EC50,Agonist activity at alpha4beta2 nAChR in human SH-EP1 cells assessed as calcium flux by calcium4-based FLIPR assay,Confirmatory,22793665.0,
1885,704962,4,5,,103163782,89594,Active,2506127.0,1139.0,3.0,Ki,Displacement of [3H]epibatidine from human alpha7 nAChR expressed in CHO cells after 2 hrs by liquid scintillation counting,Confirmatory,22793665.0,
1886,704964,4,5,,103163782,89594,Active,2506129.0,1143.0,0.4,Ki,Displacement of [3H]epibatidine from alpha3beta4 nAChR in human SH-SY5Y cells after 2 hrs by liquid scintillation counting,Confirmatory,22793665.0,
1887,704964,4,5,,103163782,89594,Active,254763435.0,1136.0,0.4,Ki,Displacement of [3H]epibatidine from alpha3beta4 nAChR in human SH-SY5Y cells after 2 hrs by liquid scintillation counting,Confirmatory,22793665.0,
1888,704965,3,5,,103163782,89594,Active,6226548.0,54239.0,0.002,Ki,Displacement of [3H]epibatidine from alpha4beta2 nAChR in Sprague-Dawley rat cortex after 2 hrs by liquid scintillation counting,Confirmatory,22793665.0,
1889,704965,3,5,,103163782,89594,Active,8469182.0,25590.0,0.002,Ki,Displacement of [3H]epibatidine from alpha4beta2 nAChR in Sprague-Dawley rat cortex after 2 hrs by liquid scintillation counting,Confirmatory,22793665.0,
1890,704966,3,5,,103163782,89594,Active,113105.0,1141.0,0.002,Ki,Displacement of [3H]nicotine from alpha4beta2 nAChR in human SH-EP1 cells after 2 hrs by liquid scintillation assay,Confirmatory,22793665.0,
1891,704966,3,5,,103163782,89594,Active,1351848.0,1137.0,0.002,Ki,Displacement of [3H]nicotine from alpha4beta2 nAChR in human SH-EP1 cells after 2 hrs by liquid scintillation assay,Confirmatory,22793665.0,
1892,705822,1,2,,103163782,89594,Active,,,0.16699999999999998,Ki,Displacement of [125I]-epibatidine from alpha3beta4 nAChR in mouse cortical membranes,Confirmatory,23025891.0,
1893,705824,1,2,,103163782,89594,Active,,,0.0035,Ki,Displacement of [125I]-epibatidine from alpha4beta2 nAChR in mouse cortical membranes,Confirmatory,23025891.0,
1894,705825,5,2,,103163782,89594,Active,1351851.0,11441.0,0.244,Ki,Displacement of [125I]-alpha-Btx from alpha7 nAChR in mouse hippocampal membranes,Confirmatory,23025891.0,
1895,707186,3,5,,103163782,89594,Active,14285341.0,,0.496,Ki,Displacement of [3H]epibatidine from Lymnaea stagnalis AChBP,Confirmatory,22928944.0,
1896,707187,3,5,,103163782,89594,Active,74820297.0,,0.598,Ki,Displacement of [3H]epibatidine from Aplysia californica AChBP,Confirmatory,22928944.0,
1897,709381,5,2,,103163782,89594,Unspecified,146345356.0,25302.0,,EC50,Agonist activity at rat alpha7 nAchR expressed in rat GH4C1 cells assessed as stimulation of calcium flux by FLIPR,Confirmatory,23083093.0,
1898,709623,6,2,,103163782,89594,Active,113105.0,1141.0,0.002,Ki,Displacement of [3H]nicotine human alpha4beta2 nAChR in SH-EP1 cell membranes,Confirmatory,23126648.0,
1899,709623,6,2,,103163782,89594,Active,1351848.0,1137.0,0.002,Ki,Displacement of [3H]nicotine human alpha4beta2 nAChR in SH-EP1 cell membranes,Confirmatory,23126648.0,
1900,709624,1,8,,103163782,89594,Unspecified,146345356.0,25302.0,,,Agonist activity at rat alpha7 nAchR expressed in GH4C1 cells by whole cell patch clamp assay relative to untreated control,Other,23126648.0,
1901,709626,5,2,,103163782,89594,Active,146345356.0,25302.0,23.0,EC50,Agonist activity at rat alpha7 nAchR expressed in GH4C1 cells by whole cell patch clamp assay,Confirmatory,23126648.0,
1902,709627,3,5,,103163782,89594,Active,2506127.0,1139.0,3.0,Ki,Displacement of [3H]epibatidine form human alpha7 nAchR expressed in HEK293 cells,Confirmatory,23126648.0,
1903,710156,1,8,,103163782,89594,Unspecified,113071.0,1134.0,1.0,IC50,Antagonist activity at human alpha1beta1gammadelta nAChR expressed in human TE671/RD cells assessed as inhibition of 86Rb+ efflux preincubated for 10 mins by liquid scintillation counting,Confirmatory,23092294.0,
1904,710156,1,8,,103163782,89594,Unspecified,543759.0,1144.0,1.0,IC50,Antagonist activity at human alpha1beta1gammadelta nAChR expressed in human TE671/RD cells assessed as inhibition of 86Rb+ efflux preincubated for 10 mins by liquid scintillation counting,Confirmatory,23092294.0,
1905,710156,1,8,,103163782,89594,Unspecified,21903373.0,1140.0,1.0,IC50,Antagonist activity at human alpha1beta1gammadelta nAChR expressed in human TE671/RD cells assessed as inhibition of 86Rb+ efflux preincubated for 10 mins by liquid scintillation counting,Confirmatory,23092294.0,
1906,710156,1,8,,103163782,89594,Unspecified,126302510.0,1146.0,1.0,IC50,Antagonist activity at human alpha1beta1gammadelta nAChR expressed in human TE671/RD cells assessed as inhibition of 86Rb+ efflux preincubated for 10 mins by liquid scintillation counting,Confirmatory,23092294.0,
1907,710157,1,8,,103163782,89594,Unspecified,113071.0,1134.0,1.0,EC50,Agonist activity at human alpha1beta1gammadelta nAChR expressed in human TE671/RD cells assessed as stimulation of 86Rb+ efflux preincubated for 10 mins by liquid scintillation counting,Confirmatory,23092294.0,
1908,710157,1,8,,103163782,89594,Unspecified,543759.0,1144.0,1.0,EC50,Agonist activity at human alpha1beta1gammadelta nAChR expressed in human TE671/RD cells assessed as stimulation of 86Rb+ efflux preincubated for 10 mins by liquid scintillation counting,Confirmatory,23092294.0,
1909,710157,1,8,,103163782,89594,Unspecified,21903373.0,1140.0,1.0,EC50,Agonist activity at human alpha1beta1gammadelta nAChR expressed in human TE671/RD cells assessed as stimulation of 86Rb+ efflux preincubated for 10 mins by liquid scintillation counting,Confirmatory,23092294.0,
1910,710157,1,8,,103163782,89594,Unspecified,126302510.0,1146.0,1.0,EC50,Agonist activity at human alpha1beta1gammadelta nAChR expressed in human TE671/RD cells assessed as stimulation of 86Rb+ efflux preincubated for 10 mins by liquid scintillation counting,Confirmatory,23092294.0,
1911,710158,1,8,,103163782,89594,Unspecified,2506129.0,1143.0,1.0,IC50,Antagonist activity at human alpha3beta4 nAChR expressed in human SH-SY5Y cells assessed as inhibition of 86Rb+ efflux preincubated for 10 mins by liquid scintillation counting,Confirmatory,23092294.0,
1912,710158,1,8,,103163782,89594,Unspecified,254763435.0,1136.0,1.0,IC50,Antagonist activity at human alpha3beta4 nAChR expressed in human SH-SY5Y cells assessed as inhibition of 86Rb+ efflux preincubated for 10 mins by liquid scintillation counting,Confirmatory,23092294.0,
1913,710159,1,8,,103163782,89594,Unspecified,2506129.0,1143.0,1.0,EC50,Agonist activity at human alpha3beta4 nAChR expressed in human SH-SY5Y cells assessed as stimulation of 86Rb+ efflux preincubated for 10 mins by liquid scintillation counting,Confirmatory,23092294.0,
1914,710159,1,8,,103163782,89594,Unspecified,254763435.0,1136.0,1.0,EC50,Agonist activity at human alpha3beta4 nAChR expressed in human SH-SY5Y cells assessed as stimulation of 86Rb+ efflux preincubated for 10 mins by liquid scintillation counting,Confirmatory,23092294.0,
1915,710160,1,8,,103163782,89594,Unspecified,113105.0,1141.0,,,Antagonist activity at human alpha4beta2 nAChR expressed in human SH-EP1 cells assessed as inhibition of 86Rb+ efflux preincubated for 10 mins by liquid scintillation counting relative to control,Other,23092294.0,
1916,710160,1,8,,103163782,89594,Unspecified,1351848.0,1137.0,,,Antagonist activity at human alpha4beta2 nAChR expressed in human SH-EP1 cells assessed as inhibition of 86Rb+ efflux preincubated for 10 mins by liquid scintillation counting relative to control,Other,23092294.0,
1917,710161,5,2,,103163782,89594,Active,113105.0,1141.0,0.42658,IC50,Antagonist activity at human alpha4beta2 nAChR expressed in human SH-EP1 cells assessed as inhibition of 86Rb+ efflux preincubated for 10 mins by liquid scintillation counting,Confirmatory,23092294.0,
1918,710161,5,2,,103163782,89594,Active,1351848.0,1137.0,0.42658,IC50,Antagonist activity at human alpha4beta2 nAChR expressed in human SH-EP1 cells assessed as inhibition of 86Rb+ efflux preincubated for 10 mins by liquid scintillation counting,Confirmatory,23092294.0,
1919,710162,1,8,,103163782,89594,Unspecified,113105.0,1141.0,,,Agonist activity at human low-sensitivity alpha4beta2 nAChR expressed in human SH-EP1 cells assessed as stimulation of 86Rb+ efflux preincubated for 10 mins by liquid scintillation counting relative to control,Other,23092294.0,
1920,710162,1,8,,103163782,89594,Unspecified,1351848.0,1137.0,,,Agonist activity at human low-sensitivity alpha4beta2 nAChR expressed in human SH-EP1 cells assessed as stimulation of 86Rb+ efflux preincubated for 10 mins by liquid scintillation counting relative to control,Other,23092294.0,
1921,710163,1,8,,103163782,89594,Unspecified,113105.0,1141.0,,,Agonist activity at human high-sensitivity alpha4beta2 nAChR expressed in human SH-EP1 cells assessed as stimulation of 86Rb+ efflux preincubated for 10 mins by liquid scintillation counting relative to control,Other,23092294.0,
1922,710163,1,8,,103163782,89594,Unspecified,1351848.0,1137.0,,,Agonist activity at human high-sensitivity alpha4beta2 nAChR expressed in human SH-EP1 cells assessed as stimulation of 86Rb+ efflux preincubated for 10 mins by liquid scintillation counting relative to control,Other,23092294.0,
1923,710164,5,2,,103163782,89594,Active,113105.0,1141.0,0.29512,EC50,Agonist activity at human alpha4beta2 nAChR expressed in human SH-EP1 cells assessed as stimulation of 86Rb+ efflux preincubated for 10 mins by liquid scintillation counting,Confirmatory,23092294.0,
1924,710164,5,2,,103163782,89594,Active,1351848.0,1137.0,0.29512,EC50,Agonist activity at human alpha4beta2 nAChR expressed in human SH-EP1 cells assessed as stimulation of 86Rb+ efflux preincubated for 10 mins by liquid scintillation counting,Confirmatory,23092294.0,
1925,710168,5,2,,103163782,89594,Active,6226548.0,54239.0,0.0098,Ki,Displacement of [3H]Epibatidine from alpha4beta2 nAChR in rat brain by PDSP assay,Confirmatory,23092294.0,
1926,710168,5,2,,103163782,89594,Active,8469182.0,25590.0,0.0098,Ki,Displacement of [3H]Epibatidine from alpha4beta2 nAChR in rat brain by PDSP assay,Confirmatory,23092294.0,
1927,710169,4,1,,103163782,89594,Active,,,0.023,Ki,Binding affinity to alpha4beta4 nAChR by PDSP assay,Confirmatory,23092294.0,
1928,710173,4,1,,103163782,89594,Active,,,0.0049,Ki,Binding affinity to alpha4beta2 nAChR by PDSP assay,Confirmatory,23092294.0,
1929,710175,4,1,,103163782,89594,Active,,,0.26,Ki,Binding affinity to alpha3beta4 nAChR by PDSP assay,Confirmatory,23092294.0,
1930,710178,4,1,,103163782,89594,Active,,,0.028999999999999998,Ki,Binding affinity to alpha3beta2 nAChR by PDSP assay,Confirmatory,23092294.0,
1931,710180,4,1,,103163782,89594,Active,,,0.07,Ki,Binding affinity to alpha2beta4 nAChR by PDSP assay,Confirmatory,23092294.0,
1932,710183,4,1,,103163782,89594,Active,,,0.0055,Ki,Binding affinity to alpha2beta2 nAChR by PDSP assay,Confirmatory,23092294.0,
1933,712592,2,3,,103163782,89594,Active,,,0.023,Ki,Displacement of [3H]epibatidine from alpha4beta4 nAChR after 4 hrs by liquid scintillation counting analysis,Confirmatory,23641311.0,
1934,712663,5,2,,103163782,89594,Active,6226548.0,54239.0,0.0098,Ki,Displacement of [3H]epibatidine from alpha4beta2* nAChR in rat forebrain after 4 hrs by liquid scintillation counting analysis,Confirmatory,23641311.0,
1935,712663,5,2,,103163782,89594,Active,8469182.0,25590.0,0.0098,Ki,Displacement of [3H]epibatidine from alpha4beta2* nAChR in rat forebrain after 4 hrs by liquid scintillation counting analysis,Confirmatory,23641311.0,
1936,712664,2,3,,103163782,89594,Active,,,0.0049,Ki,Displacement of [3H]epibatidine from alpha4beta2 nAChR after 4 hrs by liquid scintillation counting analysis,Confirmatory,23641311.0,
1937,712665,2,3,,103163782,89594,Active,,,0.26,Ki,Displacement of [3H]epibatidine from alpha3beta4 nAChR after 4 hrs by liquid scintillation counting analysis,Confirmatory,23641311.0,
1938,712666,4,1,,103163782,89594,Active,,,0.028999999999999998,Ki,Displacement of [3H]epibatidine from alpha3beta2 nAChR after 4 hrs by liquid scintillation counting analysis,Confirmatory,23641311.0,
1939,712667,2,3,,103163782,89594,Active,,,0.07,Ki,Displacement of [3H]epibatidine from alpha2beta4 nAChR after 4 hrs by liquid scintillation counting analysis,Confirmatory,23641311.0,
1940,712668,4,1,,103163782,89594,Active,,,0.0055,Ki,Displacement of [3H]epibatidine from alpha2beta2 nAChR after 4 hrs by liquid scintillation counting analysis,Confirmatory,23641311.0,
1941,716967,1,8,,103163782,89594,Active,6226548.0,54239.0,,,Displacement of [18F]nifene from alpha4beta nAChR in Sprague-Dawley rat subiculum at 10 nM after 60 mins by autoradiographic analysis,Other,23116890.0,
1942,716967,1,8,,103163782,89594,Active,8469182.0,25590.0,,,Displacement of [18F]nifene from alpha4beta nAChR in Sprague-Dawley rat subiculum at 10 nM after 60 mins by autoradiographic analysis,Other,23116890.0,
1943,716968,1,8,,103163782,89594,Active,6226548.0,54239.0,,,Displacement of [18F]nifene from alpha4beta nAChR in Sprague-Dawley rat striatum at 10 nM after 60 mins by autoradiographic analysis,Other,23116890.0,
1944,716968,1,8,,103163782,89594,Active,8469182.0,25590.0,,,Displacement of [18F]nifene from alpha4beta nAChR in Sprague-Dawley rat striatum at 10 nM after 60 mins by autoradiographic analysis,Other,23116890.0,
1945,716969,1,8,,103163782,89594,Active,6226548.0,54239.0,,,Displacement of [18F]nifene from alpha4beta nAChR in Sprague-Dawley rat frontal cortex at 10 nM after 60 mins by autoradiographic analysis,Other,23116890.0,
1946,716969,1,8,,103163782,89594,Active,8469182.0,25590.0,,,Displacement of [18F]nifene from alpha4beta nAChR in Sprague-Dawley rat frontal cortex at 10 nM after 60 mins by autoradiographic analysis,Other,23116890.0,
1947,716970,1,8,,103163782,89594,Unspecified,6226548.0,54239.0,,,Displacement of [18F]nifene from alpha4beta nAChR in Sprague-Dawley rat thalamus at 300 uM after 60 mins by autoradiographic analysis,Other,23116890.0,
1948,716970,1,8,,103163782,89594,Unspecified,8469182.0,25590.0,,,Displacement of [18F]nifene from alpha4beta nAChR in Sprague-Dawley rat thalamus at 300 uM after 60 mins by autoradiographic analysis,Other,23116890.0,
1949,716972,1,8,,103163782,89594,Unspecified,6226548.0,54239.0,,,Displacement of [18F]nifene from alpha4beta nAChR in Sprague-Dawley rat thalamus at 10 nM after 60 mins by autoradiographic analysis,Other,23116890.0,
1950,716972,1,8,,103163782,89594,Unspecified,8469182.0,25590.0,,,Displacement of [18F]nifene from alpha4beta nAChR in Sprague-Dawley rat thalamus at 10 nM after 60 mins by autoradiographic analysis,Other,23116890.0,
1951,716974,3,5,,103163782,89594,Active,6226548.0,54239.0,0.00283,Ki,Displacement of [3H]cytisine from alpha4beta2 nAChR in Sprague-Dawley rat brain homogenate after 75 mins by scintillation counting,Confirmatory,23116890.0,
1952,716974,3,5,,103163782,89594,Active,8469182.0,25590.0,0.00283,Ki,Displacement of [3H]cytisine from alpha4beta2 nAChR in Sprague-Dawley rat brain homogenate after 75 mins by scintillation counting,Confirmatory,23116890.0,
1953,720504,1,1,,56314824,89594,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
1954,720508,1,1,,56314824,89594,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1955,720509,1,1,,56314824,89594,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1956,720511,1,1,,56314824,89594,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
1957,720516,2,1,,144209012,89594,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1958,720516,2,1,,144210494,89594,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1959,720532,1,1,,26752744,89594,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1960,720532,1,1,,26752745,89594,Inactive,420597.0,,22.3872,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1961,720532,1,1,,50105392,89594,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1962,720533,1,1,,26752744,89594,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1963,720533,1,1,,26752745,89594,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1964,720533,1,1,,50105392,89594,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1965,720538,1,2,,90341453,89594,Inactive,220983390.0,410.0,2.3934,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
1966,720542,1,2,,56314824,89594,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
1967,720543,1,1,,56314824,89594,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
1968,720551,1,2,,56314824,89594,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
1969,720552,2,1,,144209012,89594,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1970,720552,2,1,,144210494,89594,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1971,720553,1,2,,56314824,89594,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
1972,720554,1,3,,121362441,89594,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
1973,720559,1,2,,90341453,89594,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
1974,720572,1,2,,90341453,89594,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
1975,720573,1,2,,90341453,89594,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
1976,720579,2,1,,26752744,89594,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1977,720579,2,1,,26752745,89594,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1978,720579,2,1,,56314824,89594,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1979,720580,1,1,,26752744,89594,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1980,720580,1,1,,26752745,89594,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1981,720580,1,1,,56314824,89594,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1982,720582,1,1,,56314824,89594,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
1983,720596,1,1,,56314824,89594,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
1984,720634,2,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1985,720634,2,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1986,720635,2,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1987,720635,2,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1988,720636,1,1,,17389805,89594,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
1989,720636,1,1,,26752746,89594,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
1990,720637,2,1,,144209012,89594,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1991,720637,2,1,,144210494,89594,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1992,720648,1,1,,56314824,89594,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
1993,720652,1,1,,17389805,89594,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1994,720653,1,1,,17389805,89594,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
1995,720653,1,1,,26752746,89594,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
1996,720659,1,1,,17389805,89594,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
1997,720659,1,1,,26752746,89594,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
1998,720674,2,2,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1999,720674,2,2,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2000,720675,2,2,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2001,720675,2,2,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2002,720678,2,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2003,720678,2,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2004,720679,2,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2005,720679,2,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2006,720680,2,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2007,720680,2,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2008,720681,2,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2009,720681,2,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2010,720682,2,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2011,720682,2,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2012,720683,2,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2013,720683,2,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2014,720684,2,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2015,720684,2,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2016,720685,2,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2017,720685,2,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2018,720686,2,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2019,720686,2,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2020,720687,2,2,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2021,720687,2,2,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2022,720691,4,1,,144209012,89594,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2023,720691,4,1,,144210494,89594,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2024,720692,3,1,,144209012,89594,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2025,720692,3,1,,144210494,89594,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2026,720693,3,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2027,720693,3,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2028,720700,1,4,,56314824,89594,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
2029,720702,1,1,,56314824,89594,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
2030,720704,1,4,,56314824,89594,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
2031,720707,1,2,,56314824,89594,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2032,720708,1,2,,56314824,89594,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
2033,720709,1,2,,56314824,89594,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2034,720711,1,2,,56314824,89594,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
2035,720719,2,1,,144209012,89594,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2036,720719,2,1,,144210494,89594,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2037,720725,2,1,,144209012,89594,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2038,720725,2,1,,144210494,89594,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2039,724033,1,2,,103163782,89594,Unspecified,,,,,Selectivity ratio of Ki for rat recombinant alpha4beta4 nAChR to Ki for rat recombinant alpha4beta2 nAChR,Other,23256554.0,
2040,724034,1,2,,103163782,89594,Unspecified,,,,,Selectivity ratio of Ki for rat recombinant alpha3beta4 nAChR to Ki for rat recombinant alpha4beta2 nAChR,Other,23256554.0,
2041,724035,4,2,,103163782,89594,Active,113111.0,25103.0,0.14125,Ki,Displacement of [3H]epibatidine from rat recombinant alpha4beta4 nAChR expressed in HEK293 cells after 4 hrs by scintillation counting analysis,Confirmatory,23256554.0,
2042,724035,4,2,,103163782,89594,Active,8469182.0,25590.0,0.14125,Ki,Displacement of [3H]epibatidine from rat recombinant alpha4beta4 nAChR expressed in HEK293 cells after 4 hrs by scintillation counting analysis,Confirmatory,23256554.0,
2043,724036,4,2,,103163782,89594,Active,113061.0,25101.0,0.25119,Ki,Displacement of [3H]epibatidine from rat recombinant alpha3beta4 nAChR expressed in HEK293 cells after 4 hrs by scintillation counting analysis,Confirmatory,23256554.0,
2044,724036,4,2,,103163782,89594,Active,113111.0,25103.0,0.25119,Ki,Displacement of [3H]epibatidine from rat recombinant alpha3beta4 nAChR expressed in HEK293 cells after 4 hrs by scintillation counting analysis,Confirmatory,23256554.0,
2045,724037,4,2,,103163782,89594,Inconclusive,146345356.0,25302.0,,Ki,Displacement of [3H]MLA from rat nAChR alpha7 linked to ion channel portion of 5-HT3A receptor expressed in human tsA-201 cells after 2.5 hrs by scintillation counting analysis,Confirmatory,23256554.0,
2046,724038,4,2,,103163782,89594,Active,6226548.0,54239.0,0.00759,Ki,Displacement of [3H]epibatidine from rat recombinant alpha4beta2 nAChR expressed in HEK293 cells after 4 hrs by scintillation counting analysis,Confirmatory,23256554.0,
2047,724038,4,2,,103163782,89594,Active,8469182.0,25590.0,0.00759,Ki,Displacement of [3H]epibatidine from rat recombinant alpha4beta2 nAChR expressed in HEK293 cells after 4 hrs by scintillation counting analysis,Confirmatory,23256554.0,
2048,724039,4,2,,103163782,89594,Active,14285341.0,,0.08317999999999999,Ki,Displacement of [3H]epibatidine from Lymnaea stagnalis AChBP linked to ion channel portion of 5-HT3A receptor expressed in HEK293 cells after 4 hrs by scintillation counting analysis,Confirmatory,23256554.0,
2049,729072,2,5,,103163782,89594,Unspecified,113061.0,25101.0,10.0,IC50,Desensitization of rat alpha3beta4 nACHR expressed in HEK293 cells assessed as inhibition of 86Rb+ efflux preincubated for 10 mins measured after 2 hrs by liquid scintillation counting analysis,Confirmatory,23540678.0,
2050,729072,2,5,,103163782,89594,Unspecified,113111.0,25103.0,10.0,IC50,Desensitization of rat alpha3beta4 nACHR expressed in HEK293 cells assessed as inhibition of 86Rb+ efflux preincubated for 10 mins measured after 2 hrs by liquid scintillation counting analysis,Confirmatory,23540678.0,
2051,729074,1,6,,103163782,89594,Unspecified,113061.0,25101.0,,,Agonist activity at rat alpha3beta4 nACHR expressed in HEK293 cells assessed as stimulation of 86Rb+ efflux after 2 hrs by liquid scintillation counting analysis relative to nicotine,Other,23540678.0,
2052,729074,1,6,,103163782,89594,Unspecified,113111.0,25103.0,,,Agonist activity at rat alpha3beta4 nACHR expressed in HEK293 cells assessed as stimulation of 86Rb+ efflux after 2 hrs by liquid scintillation counting analysis relative to nicotine,Other,23540678.0,
2053,729075,2,5,,103163782,89594,Active,113061.0,25101.0,23.0,EC50,Agonist activity at rat alpha3beta4 nACHR expressed in HEK293 cells assessed as stimulation of 86Rb+ efflux after 2 hrs by liquid scintillation counting analysis,Confirmatory,23540678.0,
2054,729075,2,5,,103163782,89594,Active,113111.0,25103.0,23.0,EC50,Agonist activity at rat alpha3beta4 nACHR expressed in HEK293 cells assessed as stimulation of 86Rb+ efflux after 2 hrs by liquid scintillation counting analysis,Confirmatory,23540678.0,
2055,729076,2,5,,103163782,89594,Active,113105.0,1141.0,0.37,IC50,Desensitization of human alpha4beta2 nACHR expressed in HEK293 cells assessed as inhibition of 86Rb+ efflux preincubated for 10 mins measured after 2 hrs by liquid scintillation counting analysis,Confirmatory,23540678.0,
2056,729076,2,5,,103163782,89594,Active,1351848.0,1137.0,0.37,IC50,Desensitization of human alpha4beta2 nACHR expressed in HEK293 cells assessed as inhibition of 86Rb+ efflux preincubated for 10 mins measured after 2 hrs by liquid scintillation counting analysis,Confirmatory,23540678.0,
2057,729077,1,6,,103163782,89594,Unspecified,113105.0,1141.0,,,Agonist activity at human alpha4beta2 nACHR expressed in HEK293 cells assessed as stimulation of 86Rb+ efflux after 2 hrs by liquid scintillation counting analysis relative to nicotine,Other,23540678.0,
2058,729077,1,6,,103163782,89594,Unspecified,1351848.0,1137.0,,,Agonist activity at human alpha4beta2 nACHR expressed in HEK293 cells assessed as stimulation of 86Rb+ efflux after 2 hrs by liquid scintillation counting analysis relative to nicotine,Other,23540678.0,
2059,729078,2,5,,103163782,89594,Active,113105.0,1141.0,2.4,EC50,Agonist activity at human alpha4beta2 nACHR expressed in HEK293 cells assessed as stimulation of 86Rb+ efflux after 2 hrs by liquid scintillation counting analysis,Confirmatory,23540678.0,
2060,729078,2,5,,103163782,89594,Active,1351848.0,1137.0,2.4,EC50,Agonist activity at human alpha4beta2 nACHR expressed in HEK293 cells assessed as stimulation of 86Rb+ efflux after 2 hrs by liquid scintillation counting analysis,Confirmatory,23540678.0,
2061,729079,1,2,,103163782,89594,Unspecified,,,,,Selectivity ratio of Ki for rat alpha7 nACHR to rat alpha4beta2 nACHR,Other,23540678.0,
2062,729080,1,2,,103163782,89594,Unspecified,,,,,Selectivity ratio of Ki for rat alpha3beta4 nACHR to rat alpha4beta2 nACHR,Other,23540678.0,
2063,729081,1,2,,103163782,89594,Unspecified,,,,,Displacement of [3H]-Epibatidine from rat nACHR fore-brain by liquid scintillation counting analysis,Other,23540678.0,
2064,729082,2,5,,103163782,89594,Active,146345356.0,25302.0,0.517,Ki,Displacement of [3H]-Epibatidine from rat alpha7 nACHR expressed in HEK293 cell membranes by liquid scintillation counting analysis,Confirmatory,23540678.0,
2065,729083,2,5,,103163782,89594,Active,113111.0,25103.0,0.04,Ki,Displacement of [3H]-Epibatidine from rat alpha4beta4 nACHR expressed in HEK293 cell membranes by liquid scintillation counting analysis,Confirmatory,23540678.0,
2066,729083,2,5,,103163782,89594,Active,8469182.0,25590.0,0.04,Ki,Displacement of [3H]-Epibatidine from rat alpha4beta4 nACHR expressed in HEK293 cell membranes by liquid scintillation counting analysis,Confirmatory,23540678.0,
2067,729084,2,5,,103163782,89594,Active,6226548.0,54239.0,0.01,Ki,Displacement of [3H]-Epibatidine from rat alpha4beta2 nACHR expressed in HEK293 cell membranes by liquid scintillation counting analysis,Confirmatory,23540678.0,
2068,729084,2,5,,103163782,89594,Active,8469182.0,25590.0,0.01,Ki,Displacement of [3H]-Epibatidine from rat alpha4beta2 nACHR expressed in HEK293 cell membranes by liquid scintillation counting analysis,Confirmatory,23540678.0,
2069,729085,2,5,,103163782,89594,Active,113061.0,25101.0,0.44,Ki,Displacement of [3H]-Epibatidine from rat alpha3beta4 nACHR expressed in HEK293 cell membranes by liquid scintillation counting analysis,Confirmatory,23540678.0,
2070,729085,2,5,,103163782,89594,Active,113111.0,25103.0,0.44,Ki,Displacement of [3H]-Epibatidine from rat alpha3beta4 nACHR expressed in HEK293 cell membranes by liquid scintillation counting analysis,Confirmatory,23540678.0,
2071,729086,2,5,,103163782,89594,Active,113061.0,25101.0,0.047,Ki,Displacement of [3H]-Epibatidine from rat alpha3beta2 nACHR expressed in HEK293 cell membranes by liquid scintillation counting analysis,Confirmatory,23540678.0,
2072,729086,2,5,,103163782,89594,Active,6226548.0,54239.0,0.047,Ki,Displacement of [3H]-Epibatidine from rat alpha3beta2 nACHR expressed in HEK293 cell membranes by liquid scintillation counting analysis,Confirmatory,23540678.0,
2073,729087,2,5,,103163782,89594,Active,113111.0,25103.0,0.11,Ki,Displacement of [3H]-Epibatidine from rat alpha2beta4 nACHR expressed in HEK293 cell membranes by liquid scintillation counting analysis,Confirmatory,23540678.0,
2074,729087,2,5,,103163782,89594,Active,2851491.0,170945.0,0.11,Ki,Displacement of [3H]-Epibatidine from rat alpha2beta4 nACHR expressed in HEK293 cell membranes by liquid scintillation counting analysis,Confirmatory,23540678.0,
2075,729088,2,5,,103163782,89594,Active,2851491.0,170945.0,0.012,Ki,Displacement of [3H]-Epibatidine from rat alpha2beta2 nACHR expressed in HEK293 cell membranes by liquid scintillation counting analysis,Confirmatory,23540678.0,
2076,729088,2,5,,103163782,89594,Active,6226548.0,54239.0,0.012,Ki,Displacement of [3H]-Epibatidine from rat alpha2beta2 nACHR expressed in HEK293 cell membranes by liquid scintillation counting analysis,Confirmatory,23540678.0,
2077,735354,2,5,,103163782,89594,Active,6226548.0,54239.0,0.22,EC50,Agonist activity at alpha4beta2 nAChR in rat brain striatal slices assessed as release of [3H]dopamine release,Confirmatory,23461628.0,
2078,735354,2,5,,103163782,89594,Active,8469182.0,25590.0,0.22,EC50,Agonist activity at alpha4beta2 nAChR in rat brain striatal slices assessed as release of [3H]dopamine release,Confirmatory,23461628.0,
2079,735355,1,4,,103163782,89594,Inconclusive,113071.0,1134.0,,Ki,Displacement of [125I]alpha-bungarotoxin from human alpha2betagammadelta nAChR,Confirmatory,23461628.0,
2080,735355,1,4,,103163782,89594,Inconclusive,543759.0,1144.0,,Ki,Displacement of [125I]alpha-bungarotoxin from human alpha2betagammadelta nAChR,Confirmatory,23461628.0,
2081,735355,1,4,,103163782,89594,Inconclusive,21903373.0,1140.0,,Ki,Displacement of [125I]alpha-bungarotoxin from human alpha2betagammadelta nAChR,Confirmatory,23461628.0,
2082,735355,1,4,,103163782,89594,Inconclusive,126302510.0,1146.0,,Ki,Displacement of [125I]alpha-bungarotoxin from human alpha2betagammadelta nAChR,Confirmatory,23461628.0,
2083,735356,2,5,,103163782,89594,Active,146345356.0,25302.0,0.23,Ki,Displacement of [125I]alpha-bungarotoxin from alpha7 nAChR from rat hippocampus,Confirmatory,23461628.0,
2084,735357,2,5,,103163782,89594,Active,2506129.0,1143.0,0.26,Ki,Displacement of [3H]epibatidine from human alpha3beta4 nAChR expressed in HEK cells,Confirmatory,23461628.0,
2085,735357,2,5,,103163782,89594,Active,254763435.0,1136.0,0.26,Ki,Displacement of [3H]epibatidine from human alpha3beta4 nAChR expressed in HEK cells,Confirmatory,23461628.0,
2086,735358,2,5,,103163782,89594,Active,6226548.0,54239.0,0.01,Ki,Displacement of [3H]epibatidine from alpha4beta2 nAChR in rat cortex,Confirmatory,23461628.0,
2087,735358,2,5,,103163782,89594,Active,8469182.0,25590.0,0.01,Ki,Displacement of [3H]epibatidine from alpha4beta2 nAChR in rat cortex,Confirmatory,23461628.0,
2088,743012,3,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2089,743012,3,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2090,743014,3,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2091,743014,3,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2092,743015,3,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2093,743015,3,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2094,743033,3,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2095,743033,3,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2096,743035,2,1,,144209012,89594,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2097,743035,2,1,,144210494,89594,Inconclusive,124375976.0,367.0,24.5412,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2098,743036,2,1,,144209012,89594,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2099,743036,2,1,,144210494,89594,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2100,743040,3,1,,144209012,89594,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2101,743040,3,1,,144210494,89594,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2102,743041,3,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2103,743041,3,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2104,743042,3,1,,144209012,89594,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2105,743042,3,1,,144210494,89594,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2106,743053,2,1,,144209012,89594,Inconclusive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2107,743053,2,1,,144210494,89594,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2108,743054,2,1,,144209012,89594,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2109,743054,2,1,,144210494,89594,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2110,743063,2,1,,144209012,89594,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2111,743063,2,1,,144210494,89594,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2112,743064,3,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2113,743064,3,1,,144210494,89594,Inconclusive,,,24.3365,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2114,743065,3,1,,144209012,89594,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2115,743065,3,1,,144210494,89594,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2116,743066,3,1,,144209012,89594,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2117,743066,3,1,,144210494,89594,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2118,743067,2,1,,144209012,89594,Inconclusive,399498506.0,24831.0,25.5428,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2119,743067,2,1,,144210494,89594,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2120,743069,2,1,,144209012,89594,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2121,743069,2,1,,144210494,89594,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2122,743074,2,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2123,743074,2,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2124,743075,2,1,,144209012,89594,Inconclusive,348019627.0,2099.0,54.4439,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2125,743075,2,1,,144210494,89594,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2126,743077,2,1,,144209012,89594,Inconclusive,348019627.0,2099.0,48.5232,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2127,743077,2,1,,144210494,89594,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2128,743078,2,1,,144209012,89594,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2129,743078,2,1,,144210494,89594,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2130,743079,3,1,,144209012,89594,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2131,743079,3,1,,144210494,89594,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2132,743080,3,1,,144209012,89594,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2133,743080,3,1,,144210494,89594,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2134,743081,3,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2135,743081,3,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2136,743083,3,1,,144209012,89594,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2137,743083,3,1,,144210494,89594,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2138,743084,3,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2139,743084,3,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2140,743085,3,1,,144209012,89594,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2141,743085,3,1,,144210494,89594,Inconclusive,51095037.0,196.0,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2142,743086,3,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2143,743086,3,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2144,743091,2,1,,144209012,89594,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2145,743091,2,1,,144210494,89594,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2146,743094,3,1,,144209012,89594,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2147,743094,3,1,,144210494,89594,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2148,743122,2,1,,144209012,89594,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2149,743122,2,1,,144210494,89594,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2150,743126,1,1,,56314824,89594,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
2151,743139,2,1,,144209012,89594,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2152,743139,2,1,,144210494,89594,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2153,743140,2,1,,144209012,89594,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2154,743140,2,1,,144210494,89594,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2155,743191,3,1,,144209012,89594,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2156,743191,3,1,,144210494,89594,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2157,743194,3,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2158,743194,3,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2159,743199,2,1,,144209012,89594,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2160,743199,2,1,,144210494,89594,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2161,743202,4,1,,144209012,89594,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2162,743202,4,1,,144210494,89594,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2163,743203,3,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2164,743203,3,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2165,743205,1,1,,90341453,89594,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
2166,743205,1,1,,90341453,89594,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
2167,743206,1,1,,90341453,89594,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
2168,743206,1,1,,90341453,89594,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
2169,743207,1,1,,90341453,89594,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
2170,743207,1,1,,90341453,89594,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
2171,743209,3,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2172,743209,3,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2173,743210,4,1,,144209012,89594,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2174,743210,4,1,,144210494,89594,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2175,743211,3,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2176,743211,3,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2177,743212,3,1,,144209012,89594,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2178,743212,3,1,,144210494,89594,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2179,743213,3,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2180,743213,3,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2181,743215,3,1,,144209012,89594,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2182,743215,3,1,,144210494,89594,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2183,743217,3,1,,144209012,89594,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2184,743217,3,1,,144210494,89594,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2185,743218,3,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2186,743218,3,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2187,743219,3,1,,144209012,89594,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2188,743219,3,1,,144210494,89594,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2189,743220,3,1,,144209012,89594,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2190,743220,3,1,,144210494,89594,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2191,743221,3,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2192,743221,3,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2193,743222,3,1,,144209012,89594,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2194,743222,3,1,,144210494,89594,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2195,743223,3,1,,144209012,89594,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2196,743223,3,1,,144210494,89594,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2197,743224,3,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2198,743224,3,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2199,743225,3,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2200,743225,3,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2201,743226,2,1,,144209012,89594,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2202,743226,2,1,,144210494,89594,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2203,743227,2,1,,144209012,89594,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2204,743227,2,1,,144210494,89594,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2205,743228,3,1,,144209012,89594,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2206,743228,3,1,,144210494,89594,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2207,743238,1,1,,56314824,89594,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
2208,743239,2,1,,144209012,89594,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2209,743239,2,1,,144210494,89594,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2210,743240,2,1,,144209012,89594,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2211,743240,2,1,,144210494,89594,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2212,743241,2,1,,144209012,89594,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2213,743241,2,1,,144210494,89594,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2214,743242,2,1,,144209012,89594,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2215,743242,2,1,,144210494,89594,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2216,743244,1,1,,90341453,89594,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
2217,743247,1,2,,56314824,89594,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2218,743255,1,1,,56314824,89594,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
2219,743266,1,2,,56314824,89594,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
2220,743268,1,1,,172080700,89594,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
2221,743269,1,1,,56314824,89594,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2222,743269,1,1,,56314824,89594,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2223,743270,1,1,,172080700,89594,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
2224,743271,1,1,,172080700,89594,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
2225,743272,1,1,,172080700,89594,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
2226,743279,1,2,,56314824,89594,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
2227,743288,1,1,,17389805,89594,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
2228,743288,1,1,,26752746,89594,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
2229,743292,1,1,,17389805,89594,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
2230,743292,1,1,,26752746,89594,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
2231,743397,1,1,,56314824,89594,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2232,743398,1,1,,56314824,89594,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
2233,746422,2,3,,103163782,89594,Active,113105.0,1141.0,,IC50,Displacement of [3H]cytisine from human alpha4beta2 nAChR overexpressed in human SHEP cells after 75 mins by liquid scintillation spectrometric analysis,Confirmatory,23561269.0,
2234,746422,2,3,,103163782,89594,Active,1351848.0,1137.0,,IC50,Displacement of [3H]cytisine from human alpha4beta2 nAChR overexpressed in human SHEP cells after 75 mins by liquid scintillation spectrometric analysis,Confirmatory,23561269.0,
2235,746423,2,3,,103163782,89594,Active,2506127.0,1139.0,,IC50,Displacement of [125I]alpha-bungarotoxin from human alpha7 nAChR overexpressed in human SH-SY5Y cells after 120 mins by liquid scintillation spectrometric analysis,Confirmatory,23561269.0,
2236,760691,1,5,,103163782,89594,Unspecified,2506129.0,1143.0,,,Agonist activity at human alpha3beta4 nACHR expressed in CHO cell membranes assessed as stimulation of calcium flux by FLIPR assay relative to control,Other,23692872.0,
2237,760691,1,5,,103163782,89594,Unspecified,254763435.0,1136.0,,,Agonist activity at human alpha3beta4 nACHR expressed in CHO cell membranes assessed as stimulation of calcium flux by FLIPR assay relative to control,Other,23692872.0,
2238,760692,2,3,,103163782,89594,Active,2506129.0,1143.0,7.0,EC50,Agonist activity at human alpha3beta4 nACHR expressed in CHO cell membranes assessed as stimulation of calcium flux by FLIPR assay,Confirmatory,23692872.0,
2239,760692,2,3,,103163782,89594,Active,254763435.0,1136.0,7.0,EC50,Agonist activity at human alpha3beta4 nACHR expressed in CHO cell membranes assessed as stimulation of calcium flux by FLIPR assay,Confirmatory,23692872.0,
2240,760693,2,3,,103163782,89594,Active,113105.0,1141.0,3.0,EC50,Agonist activity at alpha4beta2 nACHR in human SHEP1 cell membranes assessed as stimulation of calcium flux by FLIPR assay,Confirmatory,23692872.0,
2241,760693,2,3,,103163782,89594,Active,1351848.0,1137.0,3.0,EC50,Agonist activity at alpha4beta2 nACHR in human SHEP1 cell membranes assessed as stimulation of calcium flux by FLIPR assay,Confirmatory,23692872.0,
2242,760694,1,5,,103163782,89594,Unspecified,113105.0,1141.0,,,Agonist activity at alpha4beta2 nACHR in human SHEP1 cell membranes assessed as stimulation of calcium flux by FLIPR assay relative to control,Other,23692872.0,
2243,760694,1,5,,103163782,89594,Unspecified,1351848.0,1137.0,,,Agonist activity at alpha4beta2 nACHR in human SHEP1 cell membranes assessed as stimulation of calcium flux by FLIPR assay relative to control,Other,23692872.0,
2244,760695,2,3,,103163782,89594,Active,2506127.0,1139.0,3.0,Ki,Displacement of [3H]Epibatidine from human alpha7 nACHR expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,Confirmatory,23692872.0,
2245,760696,2,3,,103163782,89594,Active,2506129.0,1143.0,0.4,Ki,Displacement of [3H]Epibatidine from human alpha3beta4 nACHR expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,Confirmatory,23692872.0,
2246,760696,2,3,,103163782,89594,Active,254763435.0,1136.0,0.4,Ki,Displacement of [3H]Epibatidine from human alpha3beta4 nACHR expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,Confirmatory,23692872.0,
2247,760697,2,3,,103163782,89594,Active,113105.0,1141.0,0.002,Ki,Displacement of [3H]Nicotine from alpha4beta2 nACHR in human SHEP1 cell membranes after 2 hrs by liquid scintillation counting analysis,Confirmatory,23692872.0,
2248,760697,2,3,,103163782,89594,Active,1351848.0,1137.0,0.002,Ki,Displacement of [3H]Nicotine from alpha4beta2 nACHR in human SHEP1 cell membranes after 2 hrs by liquid scintillation counting analysis,Confirmatory,23692872.0,
2249,761151,1,5,,103163782,89594,Unspecified,113105.0,1141.0,,,Antagonist activity at human alpha6/alpha3beta2beta3 nAChR expressed in human SHEP1 cells assessed as inhibition of carbamylcholine-induced 86Rb+ ion efflux preincubated for 10 mins by liquid scintillation counting analysis relative to control,Other,23734673.0,
2250,761151,1,5,,103163782,89594,Unspecified,2492620.0,8973.0,,,Antagonist activity at human alpha6/alpha3beta2beta3 nAChR expressed in human SHEP1 cells assessed as inhibition of carbamylcholine-induced 86Rb+ ion efflux preincubated for 10 mins by liquid scintillation counting analysis relative to control,Other,23734673.0,
2251,761151,1,5,,103163782,89594,Unspecified,2506128.0,1142.0,,,Antagonist activity at human alpha6/alpha3beta2beta3 nAChR expressed in human SHEP1 cells assessed as inhibition of carbamylcholine-induced 86Rb+ ion efflux preincubated for 10 mins by liquid scintillation counting analysis relative to control,Other,23734673.0,
2252,761151,1,5,,103163782,89594,Unspecified,254763435.0,1136.0,,,Antagonist activity at human alpha6/alpha3beta2beta3 nAChR expressed in human SHEP1 cells assessed as inhibition of carbamylcholine-induced 86Rb+ ion efflux preincubated for 10 mins by liquid scintillation counting analysis relative to control,Other,23734673.0,
2253,761152,2,3,,103163782,89594,Active,113105.0,1141.0,0.0848,IC50,Antagonist activity at human alpha6/alpha3beta2beta3 nAChR expressed in human SHEP1 cells assessed as inhibition of carbamylcholine-induced 86Rb+ ion efflux preincubated for 10 mins by liquid scintillation counting analysis,Confirmatory,23734673.0,
2254,761152,2,3,,103163782,89594,Active,2492620.0,8973.0,0.0848,IC50,Antagonist activity at human alpha6/alpha3beta2beta3 nAChR expressed in human SHEP1 cells assessed as inhibition of carbamylcholine-induced 86Rb+ ion efflux preincubated for 10 mins by liquid scintillation counting analysis,Confirmatory,23734673.0,
2255,761152,2,3,,103163782,89594,Active,2506128.0,1142.0,0.0848,IC50,Antagonist activity at human alpha6/alpha3beta2beta3 nAChR expressed in human SHEP1 cells assessed as inhibition of carbamylcholine-induced 86Rb+ ion efflux preincubated for 10 mins by liquid scintillation counting analysis,Confirmatory,23734673.0,
2256,761152,2,3,,103163782,89594,Active,254763435.0,1136.0,0.0848,IC50,Antagonist activity at human alpha6/alpha3beta2beta3 nAChR expressed in human SHEP1 cells assessed as inhibition of carbamylcholine-induced 86Rb+ ion efflux preincubated for 10 mins by liquid scintillation counting analysis,Confirmatory,23734673.0,
2257,761153,1,5,,103163782,89594,Unspecified,113105.0,1141.0,,,Antagonist activity at human high sensitivity/low sensitivity alpha4beta2 nACHR expressed in human SHEP1 cells assessed as inhibition of carbamylcholine-induced 86Rb+ ion efflux preincubated for 10 mins by liquid scintillation counting analysis relative to control,Other,23734673.0,
2258,761153,1,5,,103163782,89594,Unspecified,1351848.0,1137.0,,,Antagonist activity at human high sensitivity/low sensitivity alpha4beta2 nACHR expressed in human SHEP1 cells assessed as inhibition of carbamylcholine-induced 86Rb+ ion efflux preincubated for 10 mins by liquid scintillation counting analysis relative to control,Other,23734673.0,
2259,761154,2,3,,103163782,89594,Active,113105.0,1141.0,0.43,IC50,Antagonist activity at human alpha4beta2 nACHR expressed in human SHEP1 cells assessed as inhibition of carbamylcholine-induced 86Rb+ ion efflux preincubated for 10 mins by liquid scintillation counting analysis,Confirmatory,23734673.0,
2260,761154,2,3,,103163782,89594,Active,1351848.0,1137.0,0.43,IC50,Antagonist activity at human alpha4beta2 nACHR expressed in human SHEP1 cells assessed as inhibition of carbamylcholine-induced 86Rb+ ion efflux preincubated for 10 mins by liquid scintillation counting analysis,Confirmatory,23734673.0,
2261,761159,1,5,,103163782,89594,Unspecified,113105.0,1141.0,,,Agonist activity at human alpha6/alpha3beta2beta3 nAChR expressed in human SHEP1 cells assessed as stimulation of 86Rb+ ion efflux after 5 mins by liquid scintillation counting analysis relative to carbamylcholine,Other,23734673.0,
2262,761159,1,5,,103163782,89594,Unspecified,2492620.0,8973.0,,,Agonist activity at human alpha6/alpha3beta2beta3 nAChR expressed in human SHEP1 cells assessed as stimulation of 86Rb+ ion efflux after 5 mins by liquid scintillation counting analysis relative to carbamylcholine,Other,23734673.0,
2263,761159,1,5,,103163782,89594,Unspecified,2506128.0,1142.0,,,Agonist activity at human alpha6/alpha3beta2beta3 nAChR expressed in human SHEP1 cells assessed as stimulation of 86Rb+ ion efflux after 5 mins by liquid scintillation counting analysis relative to carbamylcholine,Other,23734673.0,
2264,761159,1,5,,103163782,89594,Unspecified,254763435.0,1136.0,,,Agonist activity at human alpha6/alpha3beta2beta3 nAChR expressed in human SHEP1 cells assessed as stimulation of 86Rb+ ion efflux after 5 mins by liquid scintillation counting analysis relative to carbamylcholine,Other,23734673.0,
2265,761160,2,3,,103163782,89594,Active,113105.0,1141.0,0.127,EC50,Agonist activity at human alpha6/alpha3beta2beta3 nAChR expressed in human SHEP1 cells assessed as stimulation of 86Rb+ ion efflux after 5 mins by liquid scintillation counting analysis,Confirmatory,23734673.0,
2266,761160,2,3,,103163782,89594,Active,2492620.0,8973.0,0.127,EC50,Agonist activity at human alpha6/alpha3beta2beta3 nAChR expressed in human SHEP1 cells assessed as stimulation of 86Rb+ ion efflux after 5 mins by liquid scintillation counting analysis,Confirmatory,23734673.0,
2267,761160,2,3,,103163782,89594,Active,2506128.0,1142.0,0.127,EC50,Agonist activity at human alpha6/alpha3beta2beta3 nAChR expressed in human SHEP1 cells assessed as stimulation of 86Rb+ ion efflux after 5 mins by liquid scintillation counting analysis,Confirmatory,23734673.0,
2268,761160,2,3,,103163782,89594,Active,254763435.0,1136.0,0.127,EC50,Agonist activity at human alpha6/alpha3beta2beta3 nAChR expressed in human SHEP1 cells assessed as stimulation of 86Rb+ ion efflux after 5 mins by liquid scintillation counting analysis,Confirmatory,23734673.0,
2269,761161,1,5,,103163782,89594,Unspecified,113105.0,1141.0,,,Agonist activity at human high sensitivity alpha4beta2 nACHR expressed in human SHEP1 cells assessed as stimulation of 86Rb+ ion efflux after 5 mins by liquid scintillation counting analysis relative to sazetidine-A,Other,23734673.0,
2270,761161,1,5,,103163782,89594,Unspecified,1351848.0,1137.0,,,Agonist activity at human high sensitivity alpha4beta2 nACHR expressed in human SHEP1 cells assessed as stimulation of 86Rb+ ion efflux after 5 mins by liquid scintillation counting analysis relative to sazetidine-A,Other,23734673.0,
2271,761162,2,3,,103163782,89594,Active,113105.0,1141.0,0.29,EC50,Agonist activity at human alpha4beta2 nACHR expressed in human SHEP1 cells assessed as stimulation of 86Rb+ ion efflux after 5 mins by liquid scintillation counting analysis,Confirmatory,23734673.0,
2272,761162,2,3,,103163782,89594,Active,1351848.0,1137.0,0.29,EC50,Agonist activity at human alpha4beta2 nACHR expressed in human SHEP1 cells assessed as stimulation of 86Rb+ ion efflux after 5 mins by liquid scintillation counting analysis,Confirmatory,23734673.0,
2273,761169,2,3,,103163782,89594,Active,113111.0,25103.0,0.023,Ki,Displacement of [3H]Epibatidine from rat alpha4beta4 nACHR by liquid scintillation counting analysis,Confirmatory,23734673.0,
2274,761169,2,3,,103163782,89594,Active,8469182.0,25590.0,0.023,Ki,Displacement of [3H]Epibatidine from rat alpha4beta4 nACHR by liquid scintillation counting analysis,Confirmatory,23734673.0,
2275,761170,2,3,,103163782,89594,Active,6226548.0,54239.0,0.0098,Ki,Displacement of [3H]Epibatidine from alpha4beta2 nACHR in rat forebrain by liquid scintillation counting analysis,Confirmatory,23734673.0,
2276,761170,2,3,,103163782,89594,Active,8469182.0,25590.0,0.0098,Ki,Displacement of [3H]Epibatidine from alpha4beta2 nACHR in rat forebrain by liquid scintillation counting analysis,Confirmatory,23734673.0,
2277,761171,2,3,,103163782,89594,Active,6226548.0,54239.0,0.0049,Ki,Displacement of [3H]Epibatidine from rat alpha4beta2 nACHR by liquid scintillation counting analysis,Confirmatory,23734673.0,
2278,761171,2,3,,103163782,89594,Active,8469182.0,25590.0,0.0049,Ki,Displacement of [3H]Epibatidine from rat alpha4beta2 nACHR by liquid scintillation counting analysis,Confirmatory,23734673.0,
2279,761172,2,3,,103163782,89594,Active,113061.0,25101.0,0.26,Ki,Displacement of [3H]Epibatidine from rat alpha3beta4 nACHR by liquid scintillation counting analysis,Confirmatory,23734673.0,
2280,761172,2,3,,103163782,89594,Active,113111.0,25103.0,0.26,Ki,Displacement of [3H]Epibatidine from rat alpha3beta4 nACHR by liquid scintillation counting analysis,Confirmatory,23734673.0,
2281,761173,2,3,,103163782,89594,Active,113061.0,25101.0,0.028999999999999998,Ki,Displacement of [3H]Epibatidine from rat alpha3beta2 nACHR by liquid scintillation counting analysis,Confirmatory,23734673.0,
2282,761173,2,3,,103163782,89594,Active,6226548.0,54239.0,0.028999999999999998,Ki,Displacement of [3H]Epibatidine from rat alpha3beta2 nACHR by liquid scintillation counting analysis,Confirmatory,23734673.0,
2283,761174,2,3,,103163782,89594,Active,113111.0,25103.0,0.07,Ki,Displacement of [3H]Epibatidine from rat alpha2beta4 nACHR by liquid scintillation counting analysis,Confirmatory,23734673.0,
2284,761174,2,3,,103163782,89594,Active,2851491.0,170945.0,0.07,Ki,Displacement of [3H]Epibatidine from rat alpha2beta4 nACHR by liquid scintillation counting analysis,Confirmatory,23734673.0,
2285,761175,2,3,,103163782,89594,Active,2851491.0,170945.0,0.0055,Ki,Displacement of [3H]Epibatidine from rat alpha2beta2 nACHR by liquid scintillation counting analysis,Confirmatory,23734673.0,
2286,761175,2,3,,103163782,89594,Active,6226548.0,54239.0,0.0055,Ki,Displacement of [3H]Epibatidine from rat alpha2beta2 nACHR by liquid scintillation counting analysis,Confirmatory,23734673.0,
2287,781207,1,5,,103163782,89594,Inactive,543761.0,1133.0,,Ki,Displacement of [3H]NMS from human muscarinic M5 receptor expressed in CHO cells,Confirmatory,24128660.0,
2288,781208,1,5,,103163782,89594,Inactive,23503039.0,1132.0,,Ki,Displacement of [3H]NMS from human muscarinic M4 receptor expressed in CHO cells,Confirmatory,24128660.0,
2289,781209,1,5,,103163782,89594,Inactive,113125.0,1131.0,,Ki,Displacement of [3H]NMS from human muscarinic M3 receptor expressed in CHO cells,Confirmatory,24128660.0,
2290,781210,1,5,,103163782,89594,Inactive,113118.0,1128.0,,Ki,Displacement of [3H]NMS from human muscarinic M1 receptor expressed in CHO cells,Confirmatory,24128660.0,
2291,781211,1,5,,103163782,89594,Inactive,113122.0,1129.0,,Ki,Displacement of [3H]NMS from human muscarinic M2 receptor expressed in CHO cells,Confirmatory,24128660.0,
2292,781212,2,3,,103163782,89594,Active,146345356.0,25302.0,0.23399999999999999,Ki,Displacement of [125I]-alpha-bungarotoxin from alpha7 nAChR in rat hippocampus membranes,Confirmatory,24128660.0,
2293,781213,2,3,,103163782,89594,Active,6226548.0,54239.0,0.004,Ki,Displacement of [3H]-epibatidine from alpha4beta2 nAChR in rat cortex hippocampus,Confirmatory,24128660.0,
2294,781213,2,3,,103163782,89594,Active,8469182.0,25590.0,0.004,Ki,Displacement of [3H]-epibatidine from alpha4beta2 nAChR in rat cortex hippocampus,Confirmatory,24128660.0,
2295,781326,1,2,,103163782,89594,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X,Other,24249037.0,
2296,781328,1,2,,103163782,89594,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 2005,Other,24249037.0,
2297,943055,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020325,Other,,
2298,943056,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020325,Other,,
2299,943057,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020325,Other,,
2300,943058,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020325,Other,,
2301,943059,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020325,Other,,
2302,943060,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020325,Other,,
2303,943061,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020325,Other,,
2304,943062,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020325,Other,,
2305,943063,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020325",Other,,
2306,943064,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020325,Other,,
2307,943065,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020325,Other,,
2308,943066,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020325,Other,,
2309,943067,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020325,Other,,
2310,943068,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020325,Other,,
2311,943069,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020325,Other,,
2312,943070,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020325,Other,,
2313,943071,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020325,Other,,
2314,943072,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020325,Other,,
2315,943073,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020325,Other,,
2316,945900,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020325,Other,,
2317,945901,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020325,Other,,
2318,945902,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020325,Other,,
2319,945903,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020325",Other,,
2320,945904,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020325,Other,,
2321,945905,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020325,Other,,
2322,945906,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020325,Other,,
2323,945907,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020325,Other,,
2324,945908,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020325,Other,,
2325,945909,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020325,Other,,
2326,945910,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020325,Other,,
2327,945911,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020325,Other,,
2328,945912,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020325,Other,,
2329,945913,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020325,Other,,
2330,945914,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020325,Other,,
2331,945915,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020325,Other,,
2332,945916,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020325,Other,,
2333,945917,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020325,Other,,
2334,945918,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020325,Other,,
2335,950788,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020325,Other,,
2336,950789,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020325,Other,,
2337,950790,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020325,Other,,
2338,950791,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020325,Other,,
2339,950792,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020325,Other,,
2340,950793,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020325,Other,,
2341,950794,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020325,Other,,
2342,950795,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020325,Other,,
2343,950796,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020325,Other,,
2344,950797,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020325,Other,,
2345,950798,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020325,Other,,
2346,950799,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020325,Other,,
2347,950800,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020325,Other,,
2348,950801,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020325,Other,,
2349,950802,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020325,Other,,
2350,950803,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020325,Other,,
2351,950804,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020325,Other,,
2352,950805,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020325,Other,,
2353,952827,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020325,Other,,
2354,974761,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020325,Other,,
2355,974762,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020325,Other,,
2356,976786,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020325,Other,,
2357,976787,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020325,Other,,
2358,976788,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020325,Other,,
2359,976789,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020325,Other,,
2360,976790,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020325,Other,,
2361,976791,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020325,Other,,
2362,976792,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020325,Other,,
2363,976793,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020325,Other,,
2364,976794,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020325,Other,,
2365,976795,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020325,Other,,
2366,976796,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020325,Other,,
2367,976797,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020325,Other,,
2368,976798,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020325,Other,,
2369,976799,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020325,Other,,
2370,976800,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020325,Other,,
2371,976801,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020325,Other,,
2372,977431,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020325,Other,,
2373,977611,3,1,,46393352,89594,Active,47169320.0,,0.0452,Kd,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Other,,
2374,977611,3,1,,46393352,89594,Active,47169321.0,,0.0452,Kd,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Other,,
2375,985981,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020325",Other,,
2376,985982,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020325",Other,,
2377,985983,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020325,Other,,
2378,985984,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020325",Other,,
2379,985985,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020325",Other,,
2380,985986,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020325,Other,,
2381,985987,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020325",Other,,
2382,985988,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020325",Other,,
2383,985989,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020325",Other,,
2384,985990,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020325",Other,,
2385,985991,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020325",Other,,
2386,985992,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020325",Other,,
2387,990928,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020325",Other,,
2388,990929,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020325",Other,,
2389,992794,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020325",Other,,
2390,992795,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020325",Other,,
2391,992796,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020325",Other,,
2392,992797,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020325",Other,,
2393,992798,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020325,Other,,
2394,992799,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020325",Other,,
2395,992800,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020325,Other,,
2396,992801,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020325",Other,,
2397,992802,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020325",Other,,
2398,992803,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020325",Other,,
2399,993386,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020325",Other,,
2400,993387,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020325",Other,,
2401,993388,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020325",Other,,
2402,993389,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020325",Other,,
2403,993390,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020325",Other,,
2404,993391,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020325",Other,,
2405,993392,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020325",Other,,
2406,993393,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020325",Other,,
2407,993394,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020325",Other,,
2408,993395,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020325",Other,,
2409,993396,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020325",Other,,
2410,993397,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020325",Other,,
2411,993398,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020325",Other,,
2412,993399,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020325",Other,,
2413,993400,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020325",Other,,
2414,993401,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020325",Other,,
2415,993402,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020325",Other,,
2416,993403,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020325",Other,,
2417,993404,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020325,Other,,
2418,993405,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020325,Other,,
2419,993406,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020325",Other,,
2420,993407,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020325",Other,,
2421,993408,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020325",Other,,
2422,993409,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020325",Other,,
2423,993410,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020325,Other,,
2424,993411,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020325",Other,,
2425,993412,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020325",Other,,
2426,993413,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020325",Other,,
2427,993414,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020325",Other,,
2428,993415,1,3,,103163782,89594,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020325,Other,,
2429,995274,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020325",Other,,
2430,995275,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020325",Other,,
2431,995276,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020325",Other,,
2432,995277,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020325",Other,,
2433,995278,1,3,,103163782,89594,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020325",Other,,
2434,1053197,1,1,,56314824,89594,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
2435,1053292,1,4,,103163782,89594,Unspecified,113061.0,25101.0,10.0,IC50,Antagonist activity at rat alpha3beta4 nAChR expressed in HEK293 cells assessed as inhibition of nicotine-induced [86Rb+] efflux preincubated for 10 mins before nicotine exposure by liquid scintillation counting,Confirmatory,24047231.0,
2436,1053292,1,4,,103163782,89594,Unspecified,113111.0,25103.0,10.0,IC50,Antagonist activity at rat alpha3beta4 nAChR expressed in HEK293 cells assessed as inhibition of nicotine-induced [86Rb+] efflux preincubated for 10 mins before nicotine exposure by liquid scintillation counting,Confirmatory,24047231.0,
2437,1053293,1,4,,103163782,89594,Unspecified,113061.0,25101.0,,,Agonist activity at rat alpha3beta4 nAChR expressed in HEK293 cells assessed as stimulation of [86Rb+] efflux after 2 mins by liquid scintillation counting relative to nicotine,Other,24047231.0,
2438,1053293,1,4,,103163782,89594,Unspecified,113111.0,25103.0,,,Agonist activity at rat alpha3beta4 nAChR expressed in HEK293 cells assessed as stimulation of [86Rb+] efflux after 2 mins by liquid scintillation counting relative to nicotine,Other,24047231.0,
2439,1053294,2,3,,103163782,89594,Active,113061.0,25101.0,24.0,EC50,Agonist activity at rat alpha3beta4 nAChR expressed in HEK293 cells assessed as stimulation of [86Rb+] efflux after 2 mins by liquid scintillation counting,Confirmatory,24047231.0,
2440,1053294,2,3,,103163782,89594,Active,113111.0,25103.0,24.0,EC50,Agonist activity at rat alpha3beta4 nAChR expressed in HEK293 cells assessed as stimulation of [86Rb+] efflux after 2 mins by liquid scintillation counting,Confirmatory,24047231.0,
2441,1053295,2,3,,103163782,89594,Active,113105.0,1141.0,0.37,IC50,Antagonist activity at human alpha4beta2 nAChR assessed as inhibition of nicotine-induced [86Rb+] efflux preincubated for 10 mins before nicotine exposure by cell-based liquid scintillation counting,Confirmatory,24047231.0,
2442,1053295,2,3,,103163782,89594,Active,1351848.0,1137.0,0.37,IC50,Antagonist activity at human alpha4beta2 nAChR assessed as inhibition of nicotine-induced [86Rb+] efflux preincubated for 10 mins before nicotine exposure by cell-based liquid scintillation counting,Confirmatory,24047231.0,
2443,1053296,1,4,,103163782,89594,Unspecified,113105.0,1141.0,,,Agonist activity at human alpha4beta2 nAChR assessed as stimulation of [86Rb+] efflux after 2 mins by cell-based liquid scintillation counting relative to nicotine,Other,24047231.0,
2444,1053296,1,4,,103163782,89594,Unspecified,1351848.0,1137.0,,,Agonist activity at human alpha4beta2 nAChR assessed as stimulation of [86Rb+] efflux after 2 mins by cell-based liquid scintillation counting relative to nicotine,Other,24047231.0,
2445,1053297,2,3,,103163782,89594,Active,113105.0,1141.0,2.4,EC50,Agonist activity at human alpha4beta2 nAChR assessed as stimulation of [86Rb+] efflux after 2 mins by cell-based liquid scintillation counting,Confirmatory,24047231.0,
2446,1053297,2,3,,103163782,89594,Active,1351848.0,1137.0,2.4,EC50,Agonist activity at human alpha4beta2 nAChR assessed as stimulation of [86Rb+] efflux after 2 mins by cell-based liquid scintillation counting,Confirmatory,24047231.0,
2447,1053299,1,1,,103163782,89594,Unspecified,,,,,Selectivity ratio of Ki for rat alpha3beta4 nAChR expressed in HEK293 cells to Ki for human alpha4beta2 nAChR,Other,24047231.0,
2448,1053300,1,1,,103163782,89594,Active,,,0.012,Ki,Displacement of [3H]epibatidine from nAChR in rat forebrain,Confirmatory,24047231.0,
2449,1053301,2,3,,103163782,89594,Active,146345356.0,25302.0,0.52,Ki,Displacement of [3H]epibatidine from rat alpha7 nAChR expressed in HEK293 cells after 4 hrs,Confirmatory,24047231.0,
2450,1053302,2,3,,103163782,89594,Active,113111.0,25103.0,0.04,Ki,Displacement of [3H]epibatidine from rat alpha4beta4 nAChR expressed in HEK293 cells after 4 hrs,Confirmatory,24047231.0,
2451,1053302,2,3,,103163782,89594,Active,8469182.0,25590.0,0.04,Ki,Displacement of [3H]epibatidine from rat alpha4beta4 nAChR expressed in HEK293 cells after 4 hrs,Confirmatory,24047231.0,
2452,1053303,2,3,,103163782,89594,Active,113105.0,1141.0,0.01,Ki,Displacement of [3H]epibatidine from human alpha4beta2 nAChR after 4 hrs by cell-based assay,Confirmatory,24047231.0,
2453,1053303,2,3,,103163782,89594,Active,1351848.0,1137.0,0.01,Ki,Displacement of [3H]epibatidine from human alpha4beta2 nAChR after 4 hrs by cell-based assay,Confirmatory,24047231.0,
2454,1053304,2,3,,103163782,89594,Active,113061.0,25101.0,0.44,Ki,Displacement of [3H]epibatidine from rat alpha3beta4 nAChR expressed in HEK293 cells after 4 hrs,Confirmatory,24047231.0,
2455,1053304,2,3,,103163782,89594,Active,113111.0,25103.0,0.44,Ki,Displacement of [3H]epibatidine from rat alpha3beta4 nAChR expressed in HEK293 cells after 4 hrs,Confirmatory,24047231.0,
2456,1053305,2,3,,103163782,89594,Active,113061.0,25101.0,0.047,Ki,Displacement of [3H]epibatidine from rat alpha3beta2 nAChR expressed in HEK293 cells after 4 hrs,Confirmatory,24047231.0,
2457,1053305,2,3,,103163782,89594,Active,6226548.0,54239.0,0.047,Ki,Displacement of [3H]epibatidine from rat alpha3beta2 nAChR expressed in HEK293 cells after 4 hrs,Confirmatory,24047231.0,
2458,1053306,2,3,,103163782,89594,Active,113111.0,25103.0,0.11,Ki,Displacement of [3H]epibatidine from rat alpha2beta4 nAChR expressed in HEK293 cells after 4 hrs,Confirmatory,24047231.0,
2459,1053306,2,3,,103163782,89594,Active,2851491.0,170945.0,0.11,Ki,Displacement of [3H]epibatidine from rat alpha2beta4 nAChR expressed in HEK293 cells after 4 hrs,Confirmatory,24047231.0,
2460,1053307,2,3,,103163782,89594,Active,2851491.0,170945.0,0.012,Ki,Displacement of [3H]epibatidine from rat alpha2beta2 nAChR expressed in HEK293 cells after 4 hrs,Confirmatory,24047231.0,
2461,1053307,2,3,,103163782,89594,Active,6226548.0,54239.0,0.012,Ki,Displacement of [3H]epibatidine from rat alpha2beta2 nAChR expressed in HEK293 cells after 4 hrs,Confirmatory,24047231.0,
2462,1069875,1,1,,103163782,89594,Unspecified,,,,,Hemolytic activity in human erythrocytes assessed as discocytic shape up to 1 mg/mL after 60 mins by SEM analysis,Other,24461290.0,
2463,1069888,1,1,,103163782,89594,Unspecified,,,,,Hemolytic activity in human erythrocytes assessed as increase in cell permeability up to 1 mg/mL after 60 mins,Other,24461290.0,
2464,1074597,1,2,,103163782,89594,Unspecified,,,,,Effect on spontaneous activity in sc dosed mouse after 5 mins,Other,24428686.0,
2465,1074598,1,2,,103163782,89594,Unspecified,,,,,Effect on hypothermia in sc dosed mouse after 30 mins,Other,24428686.0,
2466,1074599,1,2,,103163782,89594,Unspecified,,,,,Antinociceptive activity in sc dosed mouse by hot plate test,Other,24428686.0,
2467,1074600,1,2,,103163782,89594,Unspecified,,,,,Antinociceptive activity in sc dosed mouse after 5 mins by tail flick test,Other,24428686.0,
2468,1074608,1,4,,103163782,89594,Inconclusive,146345356.0,25302.0,,,Antagonist activity at rat alpha7 nAChR expressed in Xenopus laevis oocytes assessed as inhibition of acetylcholine-induced current at 100 uM by two-electrode voltage clamp electrophysiological analysis relative to acetylcholine,Other,24428686.0,
2469,1074609,1,4,,103163782,89594,Inconclusive,113061.0,25101.0,,,Antagonist activity at rat alpha3beta4 nAChR expressed in Xenopus laevis oocytes assessed as inhibition of acetylcholine-induced current at 100 uM by two-electrode voltage clamp electrophysiological analysis relative to acetylcholine,Other,24428686.0,
2470,1074609,1,4,,103163782,89594,Inconclusive,113111.0,25103.0,,,Antagonist activity at rat alpha3beta4 nAChR expressed in Xenopus laevis oocytes assessed as inhibition of acetylcholine-induced current at 100 uM by two-electrode voltage clamp electrophysiological analysis relative to acetylcholine,Other,24428686.0,
2471,1074610,1,4,,103163782,89594,Inconclusive,6226548.0,54239.0,,,Antagonist activity at rat alpha4beta2 nAChR expressed in Xenopus laevis oocytes assessed as inhibition of acetylcholine-induced current at 100 uM by two-electrode voltage clamp electrophysiological analysis relative to acetylcholine,Other,24428686.0,
2472,1074610,1,4,,103163782,89594,Inconclusive,8469182.0,25590.0,,,Antagonist activity at rat alpha4beta2 nAChR expressed in Xenopus laevis oocytes assessed as inhibition of acetylcholine-induced current at 100 uM by two-electrode voltage clamp electrophysiological analysis relative to acetylcholine,Other,24428686.0,
2473,1074611,1,4,,103163782,89594,Unspecified,146345356.0,25302.0,,,Agonist activity at rat alpha7 nAChR expressed in Xenopus laevis oocytes assessed as stimulation of acetylcholine-induced current at 100 uM by two-electrode voltage clamp electrophysiological analysis relative to acetylcholine,Other,24428686.0,
2474,1074612,1,4,,103163782,89594,Unspecified,113061.0,25101.0,,,Agonist activity at rat alpha3beta4 nAChR expressed in Xenopus laevis oocytes assessed as stimulation of acetylcholine-induced current at 100 uM by two-electrode voltage clamp electrophysiological analysis relative to acetylcholine,Other,24428686.0,
2475,1074612,1,4,,103163782,89594,Unspecified,113111.0,25103.0,,,Agonist activity at rat alpha3beta4 nAChR expressed in Xenopus laevis oocytes assessed as stimulation of acetylcholine-induced current at 100 uM by two-electrode voltage clamp electrophysiological analysis relative to acetylcholine,Other,24428686.0,
2476,1074613,1,4,,103163782,89594,Unspecified,6226548.0,54239.0,,,Agonist activity at rat alpha4beta2 nAChR expressed in Xenopus laevis oocytes assessed as stimulation of acetylcholine-induced current at 100 uM by two-electrode voltage clamp electrophysiological analysis relative to acetylcholine,Other,24428686.0,
2477,1074613,1,4,,103163782,89594,Unspecified,8469182.0,25590.0,,,Agonist activity at rat alpha4beta2 nAChR expressed in Xenopus laevis oocytes assessed as stimulation of acetylcholine-induced current at 100 uM by two-electrode voltage clamp electrophysiological analysis relative to acetylcholine,Other,24428686.0,
2478,1074614,1,3,,103163782,89594,Active,,,0.0015,Ki,Displacement of [3H]-epibatidine from alpha4beta2* nAChR in Sprague-Dawley rat cerebral cortex after 4 hrs by liquid scintillation counting analysis,Confirmatory,24428686.0,
2479,1076763,1,1,,103163782,89594,Active,,,,,Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 100 uM by trypan blue exclusion assay,Other,24581918.0,
2480,1076764,1,1,,103163782,89594,Unspecified,,,,,Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 100 uM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay relative to control,Other,24581918.0,
2481,1076765,1,1,,103163782,89594,Unspecified,,,,,Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 10 uM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay relative to control,Other,24581918.0,
2482,1076766,1,1,,103163782,89594,Unspecified,,,,,Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 1 uM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay relative to control,Other,24581918.0,
2483,1076767,1,1,,103163782,89594,Unspecified,,,,,Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 100 nM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay relative to control,Other,24581918.0,
2484,1076768,1,1,,103163782,89594,Unspecified,,,,,Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 10 nM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay relative to control,Other,24581918.0,
2485,1076769,1,1,,103163782,89594,Unspecified,,,,,Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 10 uM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 24 hrs by MTT assay relative to control,Other,24581918.0,
2486,1076770,1,1,,103163782,89594,Unspecified,,,,,Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 1 uM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 24 hrs by MTT assay relative to control,Other,24581918.0,
2487,1076771,1,1,,103163782,89594,Unspecified,,,,,Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 100 nM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 24 hrs by MTT assay relative to control,Other,24581918.0,
2488,1076772,1,1,,103163782,89594,Unspecified,,,,,Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 10 nM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 24 hrs by MTT assay relative to control,Other,24581918.0,
2489,1076774,1,1,,103163782,89594,Active,,,,,Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 0.1 uM by trypan blue exclusion assay,Other,24581918.0,
2490,1076775,1,1,,103163782,89594,Unspecified,,,,,Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 100 uM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 24 hrs by MTT assay relative to control,Other,24581918.0,
2491,1092034,2,3,,103163782,89594,Active,14285341.0,,0.1,Ki,Binding affinity to freshwater snail Lymnaea stagnalis AChBP assessed as [3H]EPI binding by radioligand binding assay,Confirmatory,21341671.0,
2492,1092035,2,3,,103163782,89594,Active,74820297.0,,0.03,Ki,Binding affinity to salt water mollusc Aplysia californica AChBP Y55W mutant assessed as [3H]acetamiprid binding by radioligand binding assay,Confirmatory,21341671.0,
2493,1092036,2,3,,103163782,89594,Active,113062.0,395606.0,0.0019,Ki,Binding affinity to recombinant Gallus gallus (chicken) alpha4beta2 nicotinic acetylcholine receptor assessed as [3H]NIC binding by radioligand binding assay,Confirmatory,21341671.0,
2494,1092037,2,1,,103163782,89594,Active,,,2.7,Ki,Binding affinity to Drosophila brain nicotinic acetylcholine receptor assessed as [3H]IMI binding by radioligand binding assay,Confirmatory,21341671.0,
2495,1093587,2,3,,103163782,89594,Active,113105.0,1141.0,0.00105,Ki,Inhibition of alpha4beta2 nicotinic acetylcholine receptor (unknown origin),Confirmatory,,
2496,1093587,2,3,,103163782,89594,Active,1351848.0,1137.0,0.00105,Ki,Inhibition of alpha4beta2 nicotinic acetylcholine receptor (unknown origin),Confirmatory,,
2497,1101288,1,1,,103163782,89594,Unspecified,,,,,Retention time under basic conditions using 20 mM Na2HPO4 (pH9.9)/MeOH (1:1) mobile phase by HPLC method,Other,11312774.0,
2498,1101289,1,1,,103163782,89594,Unspecified,,,,,Retention time under acidic conditions using H20/MeOH mobile phase containing 0.1% TFA (1:1) by HPLC method,Other,11312774.0,
2499,1101290,1,1,,103163782,89594,Unspecified,,,,,Retention time under neutral conditions using H20/MeOH (1:1) mobile phase by HPLC method,Other,11312774.0,
2500,1101291,2,3,,103163782,89594,Active,34978348.0,11438.0,0.006999999999999999,IC50,Inhibition of [3H]nicotine binding to alpha4 nicotinic acetylcholine receptor in Mus musculus (mouse) M10 cells co-expressing beta2 nicotinic acetylcholine receptor subunits,Confirmatory,11312774.0,
2501,1101292,2,3,,103163782,89594,Active,254763435.0,1136.0,0.045,IC50,Inhibition of [3H]nicotine binding to alpha3 nicotinic acetylcholine receptor in Homo sapiens (human) SH-SY5Y cells co-expressing beta2beta4alpha5 Nicotinic acetylcholine receptor subunits,Confirmatory,11312774.0,
2502,1101293,2,3,,103163782,89594,Active,2506127.0,1139.0,21.0,IC50,Inhibition of [3H]alpha-BGT binding to alpha7 nicotinic acetylcholine receptor in Homo sapiens (human) SH-SY5Y cells,Confirmatory,11312774.0,
2503,1101295,2,3,,103163782,89594,Active,113071.0,1134.0,21.0,IC50,Inhibition of [3H]alpha-BGT binding to alpha1 nicotinic acetylcholine receptor in Homo sapiens (human) TE671 cells co-expressing gammaalpha1deltabeta1 nicotinic acetylcholine receptor subunits,Confirmatory,11312774.0,
2504,1101296,1,1,,103163782,89594,Unspecified,,,,,Toxicity against Musca domestica (house fly) dosed with compound through intra-thoracic injection pre-treated with 100 ug/g metabolic detoxification inhibitor O-propyl O-(2-propynyl)phenylphosphonate,Other,11312774.0,
2505,1101297,1,1,,103163782,89594,Unspecified,,,,,Toxicity in ip dosed Mus musculus (mouse),Other,11312774.0,
2506,1101298,2,3,,103163782,89594,Active,14286096.0,42920.0,4.0,IC50,Inhibition of [3H]IMI binding to Drosophila melanogaster neuronal acetylcholine receptor,Confirmatory,11312774.0,
2507,1102410,2,1,,103163782,89594,Active,,,11.9,IC50,Displacement of [3HIMI from nicotinic acetylcholine receptor in Musca domestica (house fly) head membranes incubated for 60 min by liquid scintillation counting method,Confirmatory,12834274.0,
2508,1108431,1,2,,103163782,89594,Unspecified,,,,,"Disocciation constant, pKa of the compound at 37 degC",Other,,
2509,1108432,1,2,,103163782,89594,Active,,,1.48,Ki,Displacement of [3H]alpha-bungarotoxin from nAChR in honeybee head membrane after 60 min by scintillation counting,Confirmatory,,
2510,1108433,2,1,,103163782,89594,Active,,,2.48,Ki,Displacement of [3H]alpha-bungarotoxin from nAChR in Musca domestica (house fly) head membrane after 60 min by scintillation counting,Confirmatory,,
2511,1108434,2,3,,103163782,89594,Unspecified,75012521.0,,2600.0,IC50,Inhibition of Musca domestica (house fly) acetylcholinesterase,Confirmatory,,
2512,1108435,1,2,,103163782,89594,Unspecified,,,,,"Disocciation constant, pKa of the compound at 25 degC",Other,,
2513,1108436,1,2,,103163782,89594,Unspecified,,,,,Insecticidal activity against Musca domestica (house fly) assessed as mortality relative to nicotine,Other,,
2514,1108717,1,2,,103163782,89594,Inactive,,,,,Increase in [3H]PCP binding to nAChR in Torpedo nobiliana electric organs in presence of carbachol,Other,,
2515,1108718,1,2,,103163782,89594,Active,,,,,Increase in [3H]PCP binding to nAChR in Torpedo nobiliana electric organs,Other,,
2516,1108723,1,2,,103163782,89594,Active,,,1.25,IC50,Displacement of [3H]alpha-BGT from nAChR in Apis mellifera (honeybee) head,Confirmatory,,
2517,1108724,2,1,,103163782,89594,Active,,,23.1,IC50,Displacement of [3H]alpha-BGT from nAChR in Torpedo nobiliana electric organs,Confirmatory,,
2518,1108725,1,2,,103163782,89594,Active,,,0.0096,IC50,Displacement of [3H]nicotine from nAChR in Sprague-Dawley Rattus norvegicus (rat) whole brain homogenates,Confirmatory,,
2519,1108834,1,2,,103163782,89594,Active,,,,,Increase in [3H]PCP binding to nAChR in Torpedo nobiliana electric organs membranes by scintillation counting method,Other,,
2520,1108836,2,1,,103163782,89594,Active,,,23.1,IC50,Displacement of [3H]alpha-BGT from nAChR in Torpedo nobiliana electric organs membranes by scintillation counting method,Confirmatory,,
2521,1108840,1,2,,103163782,89594,Active,,,,,Insecticidal activity against 3 to 5 day old female Musca domestica (house fly) assessed as induction of convulsions and paralysis applied topically on notum measured after 24 hr,Other,,
2522,1108844,1,3,,103163782,89594,Active,,,1.55,IC50,Displacement of [3H]alpha-BGT from nAChR in Apis mellifera (honeybee) head homogenates,Confirmatory,,
2523,1108845,1,3,,103163782,89594,Active,,,1.14,IC50,Displacement of [3H]PCP from nAChR in Apis mellifera (honeybee0 head homogenates,Confirmatory,,
2524,1108846,1,2,,103163782,89594,Unspecified,,,,,Insecticidal activity against 3 to 5 day old female Musca domestica (house fly) assessed as compound level causing insect mortality per female applied topically on notum measured after 24 hr,Other,,
2525,1109414,1,4,,103163782,89594,Unspecified,117525.0,,,,Inhibition of Pantoea ananatis lycopene cyclase assessed as residual enzyme activity at 10 mM,Other,,
2526,1109416,2,3,,103163782,89594,Active,117525.0,,4.8,IC50,Inhibition of Pantoea ananatis lycopene cyclase,Confirmatory,,
2527,1110221,1,2,,103163782,89594,Unspecified,,,,,Insecticidal activity against Musca domestica (house fly) at 30 ug administered through injection measured after 6.5 hr,Other,,
2528,1110222,1,2,,103163782,89594,Active,,,,,Displacement of [3H]IMI from Musca domestica (house fly) head membrane nicotinic acetylcholine receptor,Other,,
2529,1110225,1,2,,103163782,89594,Unspecified,,,,,Insecticidal activity against Periplaneta americana (American cockroach) compound administered through injection into abdomen,Other,,
2530,1110226,1,2,,103163782,89594,Unspecified,,,,,Insecticidal activity against Periplaneta americana (American cockroach) compound administered through injection into abdomen in presence of piperonyl butoxide and NIA 16388,Other,,
2531,1112902,1,1,,103163782,89594,Active,,,0.8,Ki,Displacement of [3H]IMD from nAChR in Myzus persicae 4106A (green peach aphid) membrane after 70 min,Confirmatory,23112103.0,
2532,1112903,1,1,,103163782,89594,Active,,,0.146,Ki,Displacement of [3H]-methyl-SFX from nAChR in Myzus persicae 4106A (green peach aphid) membrane after 70 min,Confirmatory,23112103.0,
2533,1127711,2,2,,103163782,89594,Active,146345356.0,25302.0,0.61,Ki,Displacement of [125I]-alpha-BTX from rat alpha7 nAChR after 4 hrs by liquid scintillation counting analysis,Confirmatory,24050653.0,
2534,1143928,1,1,,103163782,89594,Unspecified,,,,,In vivo stimulation of [3H]epibatidine binding to nicotinic acetylcholine receptor in rat prefrontal cortex relative to control,Other,24942641.0,
2535,1159509,1,1,,144209012,89594,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
2536,1159509,1,1,,144210494,89594,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
2537,1159515,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
2538,1159515,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
2539,1159516,1,1,,144209012,89594,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
2540,1159516,1,1,,144210494,89594,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
2541,1159517,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
2542,1159517,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
2543,1159518,1,1,,144209012,89594,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
2544,1159518,1,1,,144210494,89594,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
2545,1159519,1,1,,144209012,89594,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
2546,1159519,1,1,,144210494,89594,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
2547,1159520,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2548,1159520,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2549,1159521,1,1,,144209012,89594,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2550,1159521,1,1,,144210494,89594,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2551,1159523,1,1,,144209012,89594,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
2552,1159523,1,1,,144210494,89594,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
2553,1159524,1,1,,26752744,89594,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2554,1159524,1,1,,26752745,89594,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2555,1159524,1,1,,56314824,89594,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2556,1159525,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
2557,1159525,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
2558,1159526,1,1,,144209012,89594,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
2559,1159526,1,1,,144210494,89594,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
2560,1159527,1,1,,144209012,89594,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
2561,1159527,1,1,,144210494,89594,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
2562,1159528,1,1,,144209012,89594,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
2563,1159528,1,1,,144210494,89594,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
2564,1159529,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
2565,1159529,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
2566,1159531,1,1,,144209012,89594,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
2567,1159531,1,1,,144210494,89594,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
2568,1159551,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
2569,1159551,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
2570,1159552,1,1,,144209012,89594,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2571,1159552,1,1,,144210494,89594,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2572,1159553,2,1,,144209012,89594,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2573,1159553,2,1,,144210494,89594,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2574,1159555,1,1,,144209012,89594,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
2575,1159555,1,1,,144210494,89594,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
2576,1159580,2,1,,268734423,89594,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
2577,1159606,1,1,,56314824,89594,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
2578,1159607,2,1,,312310269,89594,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
2579,1159620,1,1,,103163782,89594,Active,,,,,Summary of drug indications.,Other,,
2580,1171285,1,1,,103163782,89594,Active,,,0.0055,Ki,Displacement of [3H]epibatidine from rat forebrain alpha2beta2 nAChR by competition binding assay,Confirmatory,25408831.0,
2581,1171286,1,1,,103163782,89594,Active,,,0.07,Ki,Displacement of [3H]epibatidine from rat forebrain alpha2beta4 nAChR by competition binding assay,Confirmatory,25408831.0,
2582,1171287,1,1,,103163782,89594,Active,,,0.028999999999999998,Ki,Displacement of [3H]epibatidine from rat forebrain alpha3beta2 nAChR by competition binding assay,Confirmatory,25408831.0,
2583,1171288,1,1,,103163782,89594,Active,,,0.26,Ki,Displacement of [3H]epibatidine from rat forebrain alpha3beta4 nAChR by competition binding assay,Confirmatory,25408831.0,
2584,1171289,1,1,,103163782,89594,Active,,,0.0049,Ki,Displacement of [3H]epibatidine from rat forebrain alpha4beta2 nAChR by competition binding assay,Confirmatory,25408831.0,
2585,1171290,1,1,,103163782,89594,Active,,,0.0098,Ki,Displacement of [3H]epibatidine from rat forebrain alpha4beta2* nAChR by competition binding assay,Confirmatory,25408831.0,
2586,1171291,1,1,,103163782,89594,Active,,,0.023,Ki,Displacement of [3H]epibatidine from rat forebrain alpha4beta4 nAChR by competition binding assay,Confirmatory,25408831.0,
2587,1171292,1,1,,103163782,89594,Unspecified,,,,,Selectivity ratio of Ki for rat forebrain alpha3beta4 nAChR to rat forebrain alpha4beta2 nAChR,Other,25408831.0,
2588,1171293,2,1,,103163782,89594,Active,113105.0,1141.0,0.3,EC50,Agonist activity at human alpha4beta2 nAChR expressed in SH-EP1 cells by [86Rb+] ion efflux assay,Confirmatory,25408831.0,
2589,1171293,2,1,,103163782,89594,Active,1351848.0,1137.0,0.3,EC50,Agonist activity at human alpha4beta2 nAChR expressed in SH-EP1 cells by [86Rb+] ion efflux assay,Confirmatory,25408831.0,
2590,1171294,1,2,,103163782,89594,Unspecified,113105.0,1141.0,,,Agonist activity at high-sensitivity human alpha4beta2 nAChR expressed in SH-EP1 cells by [86Rb+] ion efflux assay relative to control,Other,25408831.0,
2591,1171294,1,2,,103163782,89594,Unspecified,1351848.0,1137.0,,,Agonist activity at high-sensitivity human alpha4beta2 nAChR expressed in SH-EP1 cells by [86Rb+] ion efflux assay relative to control,Other,25408831.0,
2592,1171295,1,2,,103163782,89594,Unspecified,113105.0,1141.0,,,Agonist activity at low-sensitivity human alpha4beta2 nAChR expressed in SH-EP1 cells by [86Rb+] ion efflux assay relative to control,Other,25408831.0,
2593,1171295,1,2,,103163782,89594,Unspecified,1351848.0,1137.0,,,Agonist activity at low-sensitivity human alpha4beta2 nAChR expressed in SH-EP1 cells by [86Rb+] ion efflux assay relative to control,Other,25408831.0,
2594,1171296,2,1,,103163782,89594,Active,113105.0,1141.0,0.43,IC50,Inactivation of human alpha4beta2 nAChR expressed in SH-EP1 cells by [86Rb+] ion efflux assay,Confirmatory,25408831.0,
2595,1171296,2,1,,103163782,89594,Active,1351848.0,1137.0,0.43,IC50,Inactivation of human alpha4beta2 nAChR expressed in SH-EP1 cells by [86Rb+] ion efflux assay,Confirmatory,25408831.0,
2596,1171297,1,2,,103163782,89594,Unspecified,113105.0,1141.0,,,Inactivation of human alpha4beta2 nAChR expressed in SH-EP1 cells by [86Rb+] ion efflux assay relative to control,Other,25408831.0,
2597,1171297,1,2,,103163782,89594,Unspecified,1351848.0,1137.0,,,Inactivation of human alpha4beta2 nAChR expressed in SH-EP1 cells by [86Rb+] ion efflux assay relative to control,Other,25408831.0,
2598,1209278,1,2,,103163782,89594,Unspecified,308153612.0,1548.0,470.0,Kd,Binding affinity to CYP2A6 (unknown origin) assessed as type 1 interaction as increase in absorbance 379 to 387 nm and decrease in 414 to 420 nm,Confirmatory,22696418.0,
2599,1209280,1,1,,103163782,89594,Unspecified,,,,,Ratio of Kd for CYP2A6 (unknown origin) to Kd for CYP2A13 assessed as type 1 interaction as increase in absorbance 379 to 387 nm and decrease in 414 to 420 nm,Other,22696418.0,
2600,1209281,1,2,,103163782,89594,Unspecified,77416854.0,1553.0,72.0,Ki,Competitive inhibition of CYP2A13 (unknown origin),Confirmatory,22696418.0,
2601,1209282,1,2,,103163782,89594,Unspecified,308153612.0,1548.0,130.0,Ki,Competitive inhibition of CYP2A6 (unknown origin),Confirmatory,22696418.0,
2602,1209285,1,1,,103163782,89594,Unspecified,,,,,Ratio of Ki for CYP2A6 (unknown origin) to Ki for CYP2A13 (unknown origin),Other,22696418.0,
2603,1209287,1,2,,103163782,89594,Unspecified,77416854.0,1553.0,54.0,Kd,Binding affinity to CYP2A13 (unknown origin) assessed as type 1 interaction as increase in absorbance 379 to 387 nm and decrease in 414 to 420 nm,Confirmatory,22696418.0,
2604,1210303,1,2,,103163782,89594,Unspecified,74713147.0,222962.0,,,Induction of human PMAT activity expressed in Xenopus laevis oocytes assessed as induction of inward current at 2.5 mM in NaCl buffer at pH 6 by two-microelectrode voltage-clamp method,Other,22396231.0,
2605,1210304,1,2,,103163782,89594,Unspecified,74713147.0,222962.0,,,Induction of human PMAT activity expressed in Xenopus laevis oocytes assessed as induction of inward current at 2.5 mM in NaCl buffer at pH 7.5 by two-microelectrode voltage-clamp method,Other,22396231.0,
2606,1224834,3,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
2607,1224834,3,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
2608,1224835,1,1,,144209012,89594,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
2609,1224835,1,1,,144210494,89594,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
2610,1224836,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2611,1224836,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2612,1224837,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2613,1224837,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2614,1224838,1,1,,144209012,89594,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2615,1224838,1,1,,144210494,89594,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2616,1224839,1,1,,144209012,89594,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2617,1224839,1,1,,144210494,89594,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2618,1224840,3,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
2619,1224840,3,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
2620,1224841,3,1,,144209012,89594,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2621,1224841,3,1,,144210494,89594,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2622,1224842,3,1,,144209012,89594,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2623,1224842,3,1,,144210494,89594,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2624,1224843,1,1,,144209012,89594,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
2625,1224843,1,1,,144210494,89594,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
2626,1224844,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
2627,1224844,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
2628,1224845,1,1,,144209012,89594,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
2629,1224845,1,1,,144210494,89594,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
2630,1224846,1,1,,144209012,89594,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
2631,1224846,1,1,,144210494,89594,Inconclusive,11995455.0,3091.0,0.1949,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
2632,1224847,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
2633,1224847,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
2634,1224848,3,1,,144209012,89594,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
2635,1224848,3,1,,144210494,89594,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
2636,1224849,3,1,,144209012,89594,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
2637,1224849,3,1,,144210494,89594,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
2638,1224859,2,1,,90341453,89594,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
2639,1224863,1,1,,316919609,89594,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
2640,1224865,1,2,,56314824,89594,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
2641,1224867,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
2642,1224867,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
2643,1224868,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
2644,1224868,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
2645,1224869,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
2646,1224869,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
2647,1224870,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
2648,1224870,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
2649,1224871,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
2650,1224871,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
2651,1224872,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
2652,1224872,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
2653,1224873,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
2654,1224873,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
2655,1224874,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
2656,1224874,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
2657,1224875,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
2658,1224875,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
2659,1224876,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
2660,1224876,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
2661,1224877,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
2662,1224877,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
2663,1224878,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
2664,1224878,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
2665,1224879,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
2666,1224879,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
2667,1224880,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
2668,1224880,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
2669,1224881,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
2670,1224881,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
2671,1224882,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
2672,1224882,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
2673,1224883,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
2674,1224883,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
2675,1224884,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
2676,1224884,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
2677,1224885,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
2678,1224885,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
2679,1224886,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
2680,1224886,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
2681,1224887,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
2682,1224887,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
2683,1224888,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
2684,1224888,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
2685,1224889,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
2686,1224889,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
2687,1224890,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
2688,1224890,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
2689,1224892,1,1,,144209012,89594,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
2690,1224892,1,1,,144210494,89594,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
2691,1224893,1,1,,144209012,89594,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
2692,1224893,1,1,,144210494,89594,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
2693,1224894,1,1,,144209012,89594,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
2694,1224894,1,1,,144210494,89594,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
2695,1224895,1,1,,144209012,89594,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
2696,1224895,1,1,,144210494,89594,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
2697,1224896,1,1,,144209012,89594,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
2698,1224896,1,1,,144210494,89594,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
2699,1226737,1,1,,103163782,89594,Active,,,0.011000000000000001,Ki,Displacement of [3H]epibatidine from rat alpha4beta2 nAChR transfected in HEK293 cell membrane,Confirmatory,25941557.0,
2700,1226738,1,1,,103163782,89594,Active,,,0.051,Ki,Displacement of [3H]epibatidine from rat alpha4beta4 nAChR transfected in HEK293 cell membrane,Confirmatory,25941557.0,
2701,1226739,1,1,,103163782,89594,Active,,,0.23,Ki,Displacement of [3H]epibatidine from rat alpha3beta4 nAChR transfected in HEK293 cell membrane,Confirmatory,25941557.0,
2702,1226740,1,1,,103163782,89594,Active,146345356.0,25302.0,15.0,Ki,Displacement of [3H]MLA from rat alpha7 nAChR transfected in tsA201 cell membrane,Confirmatory,25941557.0,
2703,1238213,1,1,,103163782,89594,Unspecified,146345356.0,25302.0,,,Agonist activity at rat alpha-7 nicotinic acetylcholine receptor expressed in Xenopus oocytes assessed as ratio of maximum response to compound to that induced by 1 mM acetylcholine at 1 mM treated for 3 to 4 secs followed by compound washout for 4 mins by two-electrode voltage-clamp electrophysiology assay,Other,26087938.0,
2704,1238214,1,1,,103163782,89594,Unspecified,146345356.0,25302.0,109.648,EC50,Agonist activity at rat alpha-7 nicotinic acetylcholine receptor expressed in Xenopus oocytes assessed as induction of currents treated for 3 to 4 secs followed by compound washout for 4 mins by two-electrode voltage-clamp electrophysiology assay,Confirmatory,26087938.0,
2705,1240822,1,1,,103163782,89594,Active,,,0.004,Ki,Displacement of [3H]epibatidine from alpha4beta2 nAChR in rat cortex membranes by liquid scintillation counting method,Confirmatory,26225816.0,
2706,1240823,1,1,,103163782,89594,Active,146345356.0,25302.0,0.23399999999999999,Ki,Displacement of [125I]]-alpha-bungarotoxin from alpha7 nAChR in rat hippocampus membranes by liquid scintillation counting method,Confirmatory,26225816.0,
2707,1240824,1,1,,103163782,89594,Active,,,0.261,Ki,Displacement of [3H]epibatidine from human alpha3beta4 nAChR expressed in HEK293 cell membranes by liquid scintillation counting method,Confirmatory,26225816.0,
2708,1243128,1,1,,103163782,89594,Active,,,0.0015,Ki,Displacement of [3H]-epibatidine from alpha4beta2 nAChR in rat cerebral cortex homogenates after 4 hrs by liquid scintillation counting,Confirmatory,26233800.0,
2709,1243129,1,1,,103163782,89594,Unspecified,,,,,Antinociceptive activity in intratracheally dosed mouse assessed as maximum latency after 5 mins by tail-flick assay,Other,26233800.0,
2710,1243130,1,1,,103163782,89594,Unspecified,,,,,Antinociceptive activity in sc dosed mouse assessed as jumping or licking of paw behavior after 5 mins by hot-plate test,Other,26233800.0,
2711,1243133,1,1,,103163782,89594,Unspecified,,,,,Antinociceptive activity in sc dosed mouse assessed as reduction of body rectal temperature,Other,26233800.0,
2712,1243135,1,1,,103163782,89594,Unspecified,,,,,Antinociceptive activity in sc dosed mouse assessed as spontaneous locomotor activity measured for 10 mins,Other,26233800.0,
2713,1243140,1,1,,103163782,89594,Unspecified,,,,,Agonist activity at rat alpha4beta2 nAChR expressed in Xenopus laevis oocytes assessed as mean current response at 100 uM by two-electrode voltage clamp electrophysiology assay relative to acetylcholine,Other,26233800.0,
2714,1243141,1,1,,103163782,89594,Unspecified,,,,,Agonist activity at rat alpha3beta4 nAChR expressed in Xenopus laevis oocytes assessed as mean current response at 100 uM by two-electrode voltage clamp electrophysiology assay relative to acetylcholine,Other,26233800.0,
2715,1243142,1,1,,103163782,89594,Unspecified,146345356.0,25302.0,,,Agonist activity at rat alpha7 nAChR expressed in Xenopus laevis oocytes assessed as mean current response at 100 uM by two-electrode voltage clamp electrophysiology assay relative to acetylcholine,Other,26233800.0,
2716,1243143,1,1,,103163782,89594,Inconclusive,,,,,Antagonist activity at rat alpha4beta2 nAChR expressed in Xenopus laevis oocytes assessed as inhibition of acetylcholine-induced mean current response by measuring remaining current at 100 uM by two-electrode voltage clamp electrophysiology assay relative to control,Other,26233800.0,
2717,1243144,1,1,,103163782,89594,Inconclusive,,,,,Antagonist activity at rat alpha3beta4 nAChR expressed in Xenopus laevis oocytes assessed as inhibition of acetylcholine-induced mean current response by measuring remaining current at 100 uM by two-electrode voltage clamp electrophysiology assay relative to control,Other,26233800.0,
2718,1243145,1,1,,103163782,89594,Inconclusive,146345356.0,25302.0,,,Antagonist activity at rat alpha7 nAChR expressed in Xenopus laevis oocytes assessed as inhibition of acetylcholine-induced mean current response by measuring remaining current at 100 uM by two-electrode voltage clamp electrophysiology assay relative to control,Other,26233800.0,
2719,1243904,1,1,,103163782,89594,Active,,,0.0021,Ki,Displacement of [3H]epibatidine from immunoimmobilized alpha4beta2 nAChR in Sprague-Dawley rat striatal membranes by liquid scintillation counting,Confirmatory,26164842.0,
2720,1243905,1,1,,103163782,89594,Active,,,0.0033,Ki,Displacement of [3H]epibatidine from immunoimmobilized alpha6beta2 nAChR in Sprague-Dawley rat striatal membranes by liquid scintillation counting,Confirmatory,26164842.0,
2721,1243906,1,1,,103163782,89594,Active,146345356.0,25302.0,0.25,Ki,Displacement of [125I]alpha-bungarotoxin from alpha7 nAChR in Sprague-Dawley rat hippocampus membrane homogenates by gamma counting,Confirmatory,26164842.0,
2722,1243922,1,1,,103163782,89594,Active,113105.0,1141.0,,,Agonist activity at alpha4beta2 nAChR (unknown origin) expressed in HEK293 cells assessed as increase of ERK1/2 phosphorylation at 10 uM after 5 mins by Western blotting,Other,26164842.0,
2723,1243922,1,1,,103163782,89594,Active,1351848.0,1137.0,,,Agonist activity at alpha4beta2 nAChR (unknown origin) expressed in HEK293 cells assessed as increase of ERK1/2 phosphorylation at 10 uM after 5 mins by Western blotting,Other,26164842.0,
2724,1247318,1,1,,103163782,89594,Active,14285341.0,,0.32,Kd,Binding affinity to Lymnaea stagnalis AChBP after 300 seconds by SPR biosensor analysis,Confirmatory,26301559.0,
2725,1247319,1,1,,103163782,89594,Active,,,3.16,Kd,Binding affinity to Aplysia californica AChBP after 300 seconds by SPR biosensor analysis,Confirmatory,26301559.0,
2726,1250208,1,1,,103163782,89594,Active,,,0.013000000000000001,Ki,Displacement of [3H]epibatidine from rat neuronal acetylcholine receptor subunit alpha4beta2 expressed in HEK293 cell membranes incubated for 4 hrs by scintillation counting method,Confirmatory,26298493.0,
2727,1250209,1,1,,103163782,89594,Active,,,0.07200000000000001,Ki,Displacement of [3H]epibatidine from rat neuronal acetylcholine receptor subunit alpha4beta4 expressed in HEK293 cell membranes incubated for 4 hrs by scintillation counting method,Confirmatory,26298493.0,
2728,1250210,1,1,,103163782,89594,Active,,,0.29,Ki,Displacement of [3H]epibatidine from rat neuronal acetylcholine receptor subunit alpha3beta4 expressed in HEK293 cell membranes incubated for 4 hrs by scintillation counting method,Confirmatory,26298493.0,
2729,1250212,1,1,,103163782,89594,Active,,,0.72,EC50,Agonist activity at mouse neuronal acetylcholine receptor subunit alpha4beta2 expressed in HEK293T cells by FMP assay,Confirmatory,26298493.0,
2730,1250214,1,1,,103163782,89594,Active,,,1.5,EC50,Agonist activity at rat neuronal acetylcholine receptor subunit alpha3beta4 expressed in HEK293 cells by FMP assay,Confirmatory,26298493.0,
2731,1252851,1,1,,103163782,89594,Active,,,0.21,EC50,Agonist activity at alpha4beta2 nAChR in Sprague-Dawley rat striatal slices assessed as increase in [3H]-Dopamine release after 5 mins by microbeta counting,Confirmatory,26383127.0,
2732,1257714,1,1,,103163782,89594,Unspecified,308153612.0,1548.0,400.0,IC50,"BindingDB_Patents: Inhibition Assay. The inhibition of human CYP2A6-mediated 7-hydroxy coumarin formation was evaluated in the presence of 95 selected test compounds in a standard assay (Greenlee et al., J Pharmacol Exp Ther, 1978). Our first studies were with highly purified human CYP2A6 that provided a convenient and relatively high-throughput measure of CYP2A6 inhibition.",Confirmatory,,
2733,1259241,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
2734,1259241,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
2735,1259242,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
2736,1259242,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
2737,1259243,1,1,,144209012,89594,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
2738,1259243,1,1,,144210494,89594,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
2739,1259244,1,1,,144209012,89594,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
2740,1259244,1,1,,144210494,89594,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
2741,1259247,1,1,,144209012,89594,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
2742,1259247,1,1,,144210494,89594,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
2743,1259248,1,1,,144209012,89594,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
2744,1259248,1,1,,144210494,89594,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
2745,1259310,1,1,,104170075,89594,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
2746,1259310,1,1,,321949287,89594,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
2747,1259313,1,1,,56314824,89594,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
2748,1259318,1,1,,56314824,89594,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
2749,1259325,1,2,,336956262,89594,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
2750,1259364,1,1,,144209012,89594,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
2751,1259364,1,1,,144210494,89594,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
2752,1259365,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
2753,1259365,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
2754,1259366,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
2755,1259366,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
2756,1259367,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
2757,1259367,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
2758,1259368,1,1,,144209012,89594,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
2759,1259368,1,1,,144210494,89594,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
2760,1259369,1,1,,144209012,89594,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
2761,1259369,1,1,,144210494,89594,Inactive,109731339.0,2737.0,76.9588,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
2762,1259377,1,1,,144209012,89594,Inconclusive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
2763,1259377,1,1,,144210494,89594,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
2764,1259378,1,1,,144209012,89594,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
2765,1259378,1,1,,144210494,89594,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
2766,1259379,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
2767,1259379,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
2768,1259380,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
2769,1259380,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
2770,1259381,1,1,,144209012,89594,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
2771,1259381,1,1,,144210494,89594,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
2772,1259382,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
2773,1259382,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
2774,1259383,1,1,,144209012,89594,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
2775,1259383,1,1,,144210494,89594,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
2776,1259384,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
2777,1259384,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
2778,1259385,1,1,,144209012,89594,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
2779,1259385,1,1,,144210494,89594,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
2780,1259386,1,1,,144209012,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
2781,1259386,1,1,,144210494,89594,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
2782,1259387,1,1,,144209012,89594,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
2783,1259387,1,1,,144210494,89594,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
2784,1259388,1,1,,144209012,89594,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
2785,1259388,1,1,,144210494,89594,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
2786,1259389,1,1,,124750017,89594,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
2787,1259390,1,1,,144209012,89594,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
2788,1259390,1,1,,144210494,89594,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
2789,1259391,1,1,,144209012,89594,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
2790,1259391,1,1,,144210494,89594,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
2791,1259392,1,1,,144209012,89594,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
2792,1259392,1,1,,144210494,89594,Inconclusive,109731339.0,2737.0,32.4533,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
2793,1259393,1,1,,144209012,89594,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
2794,1259393,1,1,,144210494,89594,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
2795,1259394,1,1,,144209012,89594,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
2796,1259394,1,1,,144210494,89594,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
2797,1259395,1,1,,144209012,89594,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
2798,1259395,1,1,,144210494,89594,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
2799,1259396,1,1,,144209012,89594,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
2800,1259396,1,1,,144210494,89594,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
2801,1259401,1,1,,144209012,89594,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
2802,1259401,1,1,,144210494,89594,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
2803,1259402,1,1,,144209012,89594,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
2804,1259402,1,1,,144210494,89594,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
2805,1259403,1,1,,144209012,89594,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
2806,1259403,1,1,,144210494,89594,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
2807,1259404,1,1,,144209012,89594,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
2808,1259404,1,1,,144210494,89594,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
2809,1259406,1,1,,363920279,89594,Unspecified,,,,,BK Channel Variant Modulator Selectivity Assay,Screening,,
2810,1259406,1,1,1.0,363920279,89594,Inactive,26638650.0,3778.0,0.027476,LogChange(F380Y),BK Channel Variant Modulator Selectivity Assay,Screening,,
2811,1259406,1,1,2.0,363920279,89594,Inactive,4758626.0,3779.0,0.0102279,LogChange(F380Y/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
2812,1259406,1,1,3.0,363920279,89594,Inactive,5031823.0,10242.0,0.0270355,LogChange(F380Y/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
2813,1259406,1,1,4.0,363920279,89594,Inactive,26051275.0,27345.0,0.0602936,LogChange(F380Y/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
2814,1259406,1,1,5.0,363920279,89594,Inactive,160410009.0,389816.0,-0.0144846,LogChange(F380Y/Slo1WT/gamma1),BK Channel Variant Modulator Selectivity Assay,Screening,,
2815,1259406,1,1,6.0,363920279,89594,Inactive,26638650.0,3778.0,0.0330295,LogChange(R275C),BK Channel Variant Modulator Selectivity Assay,Screening,,
2816,1259406,1,1,7.0,363920279,89594,Inactive,4758626.0,3779.0,0.00440307,LogChange(R275C/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
2817,1259406,1,1,8.0,363920279,89594,Inactive,5031823.0,10242.0,0.032949,LogChange(R275C/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
2818,1259406,1,1,9.0,363920279,89594,Inactive,26051275.0,27345.0,-0.0173498,LogChange(R275C/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
2819,1259406,1,1,10.0,363920279,89594,Inactive,5031823.0,10242.0,-0.00315048,LogChange(R275C/Slo1WT/beta2),BK Channel Variant Modulator Selectivity Assay,Screening,,
2820,1259407,1,1,,363899587,89594,Active,,,,,CCRIS mutagenicity studies,Other,,
2821,1259408,1,1,,363894812,89594,Inactive,,,,,GENE-TOX mutagenicity studies,Other,,
2822,1259411,1,1,,363899587,89594,Inactive,,,,,CCRIS carcinogenicity studies,Other,,
2823,1259413,1,2,,104170075,89594,Inactive,47605623.0,173990.0,,,Modulators of fzo-1,Other,,
2824,1259415,1,1,,56314824,89594,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
2825,1259416,1,2,,340081667,89594,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
2826,1259416,1,2,,375177861,89594,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
2827,1259421,1,1,,340081667,89594,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
2828,1259421,1,1,,375177861,89594,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
2829,1259423,1,2,,354795330,89594,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
2830,1259423,1,2,,354934037,89594,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
2831,1259423,1,2,,354957671,89594,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
2832,1259423,1,2,,355001096,89594,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
